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A B S T R A C T
Background
Migraine occurs in around 15% of adults and is ranked as the seventh most disabling disease amongst all diseases globally. Despite the
available treatments many people suffer prolonged and frequent attacks which have a major impact on their quality of life. Chronic
migraine is defined as 15 or more days of headache per month, at least eight of those days being migraine. People with episodic migraine
have fewer than 15 headache days per month. Botulinum toxin type A has been licensed in some countries for chronic migraine
treatment, due to the results of just two trials.
Objectives
To assess the effects of botulinum toxins versus placebo or active treatment for the prevention or reduction in frequency of chronic or
episodic migraine in adults.
Search methods
We searched CENTRAL, MEDLINE & MEDLINE in Process, Embase, ClinicalTrials.gov and World Health Organization Interna-
tional Clinical Trials Registry (to December 2017). We examined reference lists and carried out citation searches on key publications.
We sent correspondence to major manufacturers of botulinum toxin.
Selection criteria
Randomised, double-blind, controlled trials of botulinum toxin (any sero-type) injections into the head and neck for prophylaxis of
chronic or episodic migraine in adults. Eligible comparators were placebo, alternative prophylactic agent or different dose of botulinum
toxin.
Data collection and analysis
Two review authors independently selected trials and extracted data. For continuous outcomeswe usedmean change datawhen available.
For dichotomous data we calculated risk ratios (RRs). We used data from the 12-week post-treatment follow-up time point. We assessed
the evidence using GRADE and created two ’Summary of findings’ tables.
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Main results
Description of trials
We found 90 articles describing 28 trials (4190 participants), which were eligible for inclusion. The longest treatment duration was
three rounds of injections with three months between treatments, so we could not analyse long-term effects. For the primary analyses,
we pooled data from both chronic and episodic participant populations. Where possible, we also separated data into chronic migraine,
episodic migraine and ‘mixed group’ classification subgroups. Most trials (21 out of 28) were small (fewer than 50 participants per trial
arm). The risk of bias for included trials was low or unclear across most domains, with some trials reporting a high risk of bias for
incomplete outcome data and selective outcome reporting.
Botulinum toxin versus placebo
Twenty-three trials compared botulinum toxin with placebo. Botulinum toxin may reduce the number of migraine days per month
in the chronic migraine population by 3.1 days (95% confidence interval (CI) -4.7 to -1.4, 4 trials, 1497 participants, low-quality
evidence). This was reduced to -2 days (95% CI -2.8 to -1.1, 2 trials, 1384 participants; moderate-quality evidence) when we removed
small trials.
A single trial of people with episodic migraine (N = 418) showed no difference between groups for this outcome measure (P = 0.49).
In the chronic migraine population, botulinum toxin reduces the number of headache days per month by 1.9 days (95% CI -2.7 to -1.0,
2 trials, 1384 participants, high-quality evidence). We did not find evidence of a difference in the number of migraine attacks for both
chronic and episodic migraine participants (6 trials, N = 2004, P = 0.30, low-quality evidence). For the population of both chronic and
episodic migraine participants a reduction in severity of migraine rated during clinical visits, on a 10 cm visual analogue scale (VAS)
of 3.3 cm (95% CI -4.2 to -2.5, very low-quality evidence) in favour of botulinum toxin treatment came from four small trials (N =
209); better reporting of this outcome measure from the additional eight trials that recorded it may have improved our confidence in
the pooled estimate. Global assessment and quality-of-life measures were poorly reported and it was not possible to carry out statistical
analysis of these outcome measures. Analysis of adverse events showed an increase in the risk ratio with treatment with botulinum toxin
over placebo 30% (RR 1.28, 95% CI 1.12 to 1.47, moderate-quality evidence). For every 100 participants 60 experienced an adverse
event in the botulinum toxin group compared with 47 in the placebo group.
Botulinum toxin versus other prophylactic agent
Three trials studied comparisons with alternative oral prophylactic medications. Meta-analyses were not possible for number of migraine
days, number of headache days or number of migraine attacks due to insufficient data, but individually trials reported no differences
between groups for a variety of efficacy measures in the population of both chronic and episodic migraine participants. The global
impression of disease measured using Migraine Disability Assessment (MIDAS) scores were reported from two trials that showed no
difference between groups. Compared with oral treatments, botulinum toxin showed no between-group difference in the risk of adverse
events (2 trials, N = 114, very low-quality evidence). The relative risk reduction (RRR) for withdrawing from botulinum toxin due to
adverse events compared with the alternative prophylactic agent was 72% (P = 0.02, 2 trials, N = 119).
Dosing trials
There were insufficient data available for the comparison of different doses.
Quality of the evidence
The quality of the evidence assessed using GRADE methods was varied but mostly very low; the quality of the evidence for the placebo
and active control comparisons was low and very low, respectively for the primary outcome measure. Small trial size, high risk of bias
and unexplained heterogeneity were common reasons for downgrading the quality of the evidence.
Authors’ conclusions
In chronic migraine, botulinum toxin type A may reduce the number of migraine days per month by 2 days compared with placebo
treatment. Non-serious adverse events were probably experienced by 60/100 participants in the treated group compared with 47/100
in the placebo group. For people with episodic migraine, we remain uncertain whether or not this treatment is effective because the
quality of this limited evidence is very low. Better reporting of outcome measures in published trials would provide a more complete
evidence base on which to draw conclusions.
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P L A I N L A N G U A G E S U M M A R Y
Botulinum toxin injections for preventing migraine in adults
Bottom line
People with chronic (persisting) migraine treated with botulinum toxin injections had two fewer migraine days per month than people
treated with placebo (fake treatment). It is unclear if this improvement was large enough to make a meaningful difference to their lives.
More work is needed to show whether botulinum toxin is better than oral treatments (treatments that are swallowed), that prevent
migraine. The evidence for botulinum toxin for people with episodic (occasional) migraine was uncertain. Treatment with botulinum
toxin did not cause many side effects.
Background
Migraine occurs in three in 20 adults and three in every four sufferers are female. People who have 15 or more days of headache in
a month, with eight or more of those days being migraine, have chronic migraine. People with fewer than 15 days of headache in
a month have episodic migraine. We included trials that compared botulinum toxin treatment with placebo injections of salt water,
different doses of botulinum toxin, or other oral treatments to prevent migraine. We collected information for the following outcomes:
number of migraine days in a month (our preferred measure); migraine severity; use of medications for migraine symptoms; disease-
rating scales; quality-of-life scales; side effects; and cost effectiveness of treatment.
Trial characteristics
We found 28 clinical trials involving 4190 participants. Their average age was 42 years and eight in 10 were female. It is likely that
we found all relevant trials published before December 2017. Trials were short, the longest lasting nine months. Around half the
participants had chronic migraine symptoms and half episodic. Trial doses ranged from 6 to 300 units. The dose recommended for
chronic migraine in the UK and USA is 155-195 units. Sixteen trials, involving 8 in 10 participants, were funded by botulinum toxin
manufacturers.
Key results
Disappointingly, there was not enough detail in the trial reports about many important measures of disease for us to study them.
People with chronic migraine treated with the recommended dose of botulinum toxin had two fewer migraine days in a month than
people treated with placebo. Six trials in both chronic and episodic migraine also reported the number of migraine attacks per month.
Botulinum toxin was not proven to be better than placebo at reducing the number of attacks suffered per month. Botulinum toxin
may reduce the severity of migraines but we need larger trials to have confidence in this result.
Three trials also compared botulinum toxin (at least 100 units) with oral treatments (sodium valproate and topiramate). There was no
difference in the improvement in number of days with migraine; these data came from one trial. Botulinum toxin was no better or
worse than oral treatments at reducing the scores on a migraine disability questionnaire (Migraine Disability Assessment) for people
with chronic migraine. As all the results for comparison with oral treatments came from a few small trials it is likely that further large
trials would change these results and so we cannot be confident in them.
Of the participants treated with botulinum toxin, 60 in 100 reported side effects (most common was drooping eyelid or muscle
weakness), which was a little higher than the number receiving placebo (47 in 100). No difference was seen in the risk of side effects
between botulinum toxin and oral treatments. Participants from two small trials were nearly four times less likely to stop their treatment
if they were given botulinum toxin than if they had oral treatments. Information about side effects was reported for 8 in 10 trial
participants.
Quality of the evidence
We rated the quality of the evidence from trials using four levels: very low, low, moderate or high. Very low-quality evidence means
that we are very uncertain about the results. High-quality evidence means that we are very confident in the results. The results for the
change in migraine days for people with chronic migraine and the number of side effects experienced were based on moderate-quality
evidence. All other results discussed in this summary were low or very low-quality evidence, so the true effect is likely to be different
to these results.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Botulinum toxin type A compared to placebo for the prevention of migraine in adults
Patient or population: adults with migraine
Setting: outpat ient clinic
Intervention: botulinum toxin type A
Comparison: placebo
Outcomes Result with placebo Result with botulinum toxin
type A
Relative effect
(95% CI)
of participants
(trials)
Quality of the evidence
(GRADE)
Number of m igraine days
per month: chronic migraine
only
The mean number of m i-
graine days (chronic mi-
graine only) ranged f rom 12
to 20 days
MD 3.1 days lower
(4.7 lower to 1.4 lower)
- 1497
(4 RCTs)
⊕⊕©©
Lowa,b
Number of m igraine days
per month
The mean number of m i-
graine days ranged f rom 4
to 20 days
MD 2.4 days lower
(4.0 lower to 0.8 lower)
- 1915
(5 RCTs)
⊕©©©
Very lowa,b,c
Number of headache days
per month: chronic migraine
only
The mean number of
headache days (chronic mi-
graine only) ranged f rom 13
to 13.4 days
MD 1.9 days lower
(2.7 lower to 1.0 lower)
- 1384
(2 RCTs)
⊕⊕⊕⊕
High
Number of m igraine attacks The mean number of m i-
graine attacks ranged f rom
1.9 to 7.8 attacks
MD 0.5 attacks lower
(1.3 lower to 0.4 higher)
- 2004
(6 RCTs)
⊕⊕©©
Lowd,e
Headache intensity mea-
sure (Visual Analogue
Score 0-10)
The mean severity of m i-
graine (Visual Analogue
Score 0-10) ranged f rom 6.
2 to 9.2 cm
MD 3.3 cm lower
(4.2 lower to 2.5 lower)
- 209
(4 RCTs)
⊕©©©
Very lowf,g
Global impression scale
assessed with Headache
Impact Test-6
The mean global impres-
sion scale was 58.6 points
MD 1.6 points higher
(2.1 lower to 5.3 higher)
- 45
(1 RCT)
⊕©©©
Very lowf,g
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Total number of part ici-
pants experiencing an ad-
verse event
Trial populat ion RR 1.28
(1.12 to 1.47)
3325
(13 RCTs)
⊕⊕⊕©
Moderateh
471 per 1000 603 per 1000
(528 to 693)
CI: conf idence interval; MD: mean dif ference; RCT : randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded once due to inconsistency: stat ist ical heterogeneity observed despite sim ilarit ies in populat ions and doses.
bDowngraded once due to imprecision: sensit ivity analysis test ing robustness of result suggested small t rials may be
overest imating treatment ef fect. The result of this sensit ivity analysis for the chronic migraine group (MD 2 days lower, 95%
CI 2.8 days lower to 1.1 days lower, 2 RCTs, N = 1384, results with placebo 12-13 days) is not af fected by imprecision and so
we judged it to be moderate-quality evidence.
cDowngraded once due to indirectness: insuf f icient evidence to form subgroups represent ing our dist inct populat ions of
interest.
dDowngraded once due to indirectness: sensit ivity of this outcome measure at risk of being too low to detect clinically
meaningful dif f erences.
eDowngraded once due to publicat ion bias: evidence found of trials that have never been published that record this outcome.
fDowngraded once due to risk of bias: high or unclear risk of select ive report ing bias and poor report ing of this outcome
measure had a large ef fect on numbers analysed.
gDowngraded twice due to imprecision: trial size small, new trial evidence likely to change result .
hDowngraded once due to imprecision: trial size small, new trial evidence likely to change result .
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B A C K G R O U N D
Description of the condition
Migraine is a common headache disorder affecting around 15% of
adults (GBD 2016; Stovner 2010; Victor 2010), 75% of sufferers
are female (Lipton 2007). It is ranked as the seventh most dis-
abling disease amongst all diseases globally (GBD 2016), causing
significant morbidity and considerable negative impact on suffer-
ers’ quality of life (Bigal 2008). As a result, migraine has a major
economic impact through days lost fromwork and other activities
of daily living (Linde 2012). Table 1 illustrates the current descrip-
tions and diagnostic criteria for migraine and its two subtypes,
migraine without aura and migraine with aura. Migraine can be
categorised as chronic or episodic and these terms are commonly
used in eligibility criteria for clinical trials and systematic reviews.
Diagnostic criteria for chronic migraine do, however, remain con-
troversial. Chronicmigraine was not defined in the First Edition of
The International Headache Classification (ICHD-I) (IHS 1988)
and first appeared in the Second Edition (ICHD-II) (IHS 2004),
which described chronic migraine as migraine headache occurring
on at least 15 days per month for more than three months in the
absence of medication overuse headache. This definition was re-
vised in the recent Third Edition (ICHD-III) to state that indi-
viduals must have headache for at least 15 days per month with
migraine features on eight of those days (IHS 2013). Full defini-
tions and diagnostic criteria for the various editions are given in
Table 1. Episodic migraine is commonly used to describe people
with symptoms ofmigraine who have fewer than 15 headache days
per month. ICHD-III refers to episodic migraine as a term to be
used for migraine that is not covered by the definition of chronic
migraine (IHS 2013).
Medicationoveruse headache is an interactionbetween a therapeu-
tic agent used excessively and a susceptible person (IHS 2004; IHS
2013). Chronic migraine can often be the pre-existing disorder
in people with medication overuse headache, and the relationship
between the two diagnoses has also altered between publication of
ICHD-II where medication overuse headache first appeared, and
ICHD-III. For a diagnosis of medication overuse headache prior
to the publication of ICHD-III, the withdrawal of medications for
a period of two months was required and only then with a resul-
tant reduction in headache days could a diagnosis of medication
overuse headache be suggested. People at this time would not have
been given the dual diagnoses of medication overuse headache
and chronic migraine. With the publication of ICHD-III, it was
acknowledged that this was a somewhat artificial separation and
people with symptoms of both medication overuse headache and
chronicmigraine were given both diagnoses. Two large trials of bo-
tulinum toxin for chronic migraine, which have influenced licens-
ing of botulinum toxin for migraine, have included individuals
with medication overuse headache (Aurora 2010; Diener 2010).
As a result of these intricacies, exclusion of people withmedication
overuse headache from the migraine population under considera-
tion in this review is difficult and impractical.
For the purposes of this review, the terms chronic migraine and
medication overuse headache refer to the definitions that were in
use at the time of publication of the particular trial under discus-
sion.
Description of the intervention
Botulinum toxin is a natural product synthesised by an anaerobic
bacterium Clostridium botulinum. It is responsible for the food
poisoning disease botulism. Different strains of Clostridium bo-
tulinum produce seven distinct sero-types of botulinum neuro-
toxin that are labelled A through to G. These potent neurotoxins
are metalloproteases that block the release of acetylcholine at the
neuromuscular junction though the cleavage of different peptide
bonds that are crucial components in synaptic vesicle membrane
fusion. The resulting impairment of neuromuscular transmission
causes a flaccid paralysis (Brin 2002). As a result clinical use of
botulinum toxin, for conditions involving excessive muscle con-
tractions, began in the early 1980s. It has become the first line
therapy for many conditions including dystonia, spasticity, hyper-
hidrosis and some forms of bladder disturbance. Since then, bo-
tulinum toxin has been seen to have pain relieving properties in
excess of what might be expected due to the relief of muscle con-
tractions and its use for the treatment of migraine has developed
(Aoki 2005). For treating migraine, botulinum toxin is adminis-
tered by intramuscular injection to multiple sites around the head
and back of the neck with regular re-treatment required.
The United States Food and Drug Administration (FDA) assigns
official names to subsequent versions of biopharmaceutical prod-
ucts made by different manufacturers to reflect the sensitivity of
such drugs to changes in themanufacturing process (Table 2). Not
only will there be variation in the diffusion profiles and proper-
ties between the various sero-types of botulinum toxin but also
between the different preparations from numerous manufacturers
within sero-types.
One preparation of botulinum toxin, onabotulinum toxin A
(Botox), has recently been licensed in the USA and the UK as an
agent for the prevention of chronic migraine (at least 15 migraine
days per month) on the basis of two large randomised, placebo-
controlled trials (Aurora 2010; Diener 2010). The recommended
reconstituted dose is 155 to 195 units, administered intramuscu-
larly as 0.1 mL (5 units) injections to between 31 and 39 sites
around the head and back of the neck (NICE 2012a).
How the intervention might work
The mechanism by which pain in migraine is generated is not
fully understood. It is commonly thought that noxious stimuli
lead to the release of calcitonin gene-related peptide and sub-
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stance P by trigeminal peripheral nerve endings. Release of these
peptides causes meningeal vasodilation resulting in stimulation of
the meningeal sensory nerves and activation of trigeminovascular
pathways, which in turn lead to self-sustained central sensitisation
(Goadsby 2002; Pietrobon 2005).
Botulinum toxin has been reported to alleviate pain in a variety of
conditions, but the mechanism of action is not well understood.
It has been postulated that botulinum toxin acts to reduce pain by
inhibiting the release of neuropeptides such as calcitonin gene-re-
lated peptide and substance P, involved in the initiation ofmigraine
(Aoki 2005; Cui 2004). Soluble N-ethylmaleimide-sensitive fu-
sion protein attachment protein receptor (SNARE) complexes are
involved in mechanotransduction of noxious stimuli (Table 1).
It is thought that botulinum toxin may act to prevent migraine
through cleavage of synaptosomal-associated protein 25 (SNAP-
25), one of the SNARE-complex proteins, impairing synaptic vesi-
cle fusion and release of neurotransmitters involved in pain sensi-
tivity (Burstein 2014; Paterson 2014).
This inhibitory effect of botulinum toxin on pain sensation is sup-
ported by clinical observations in the treatment of peripheral neu-
ropathy (Ranoux 2008; Yuan 2009), cervical dystonia (Jankovic
1990), chronic tennis elbow (Hayton 2005; Keizer 2002; Wong
2005), and myofascial pain (Cherkin 1998; Porta 2000; Smith
2002). It is reported that the mechanism of action of the various
sero-types and preparations of botulinum toxin are similar and
they are all capable of blocking the release of neurotransmitters
(Aoki 2005).
Why it is important to do this review
Attempts to reduce the frequency and severity of migraine with
daily agents have had mixed results (Linde 2004; Linde 2013a;
Linde 2013b; Linde 2013c; Linde 2013d). Recently, two posi-
tive placebo-controlled trials of Botox in chronic migraine have
been published (Aurora 2010; Diener 2010). These results and
the subsequent licensing of Botox for the preventative treatment
of chronic migraine were in contrast with previous trials including
people with episodic migraine, which showed no effect (Aurora
2007; Cady 2008; Vo 2007). Cost of treatment and administra-
tion of botulinum toxin in the UK is around 25 times higher than
usual migraine doses of propranolol and 15 times that of topira-
mate, the two first line treatments for the prevention ofmigraine as
recommended by treatment guidelines (BMA/RPS 2014; NICE
2012a; NICE 2012b). Therefore, a systematic review and meta-
analysis of the full literature was needed to inform patient choice
and clinical practice.
An important consideration in assessing the literature surrounding
this question will be the effect of including evidence from small
trials. Small trials are prone to bias and random chance effects
due to small amounts of data, especially in pain (Dechartres 2013;
Nguyen 2017; Nüesch 2010). In this review we have addressed
these potential problems by including size as a parameter in our
assessment of bias, carrying out a sensitivity analysis of the effect
of small trials on the pooled estimate of effect for the primary
outcome measure and also by considering the extent to which
small trials have contributed to the final estimate when discussing
other outcome measures.
O B J E C T I V E S
To assess the effects of botulinum toxins versus placebo or active
treatment for the prevention or reduction in frequency of chronic
or episodic migraine in adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered all prospective, randomised and quasi-randomised,
double-blind, controlled trials of all sero-types of botulinum toxin.
We included all identified trials of this type irrespective of their
publication status.
Types of participants
Participants:
• 18 years of age and over;
• suffering from migraine as defined by any edition of the
International Headache Society criteria (IHS 1988; IHS 2004;
IHS 2013), or meeting reasonable criteria designed to distinguish
between migraine and tension-type headache. People with both
chronic and episodic migraine were included in this review.
Use of botulinum toxin is currently recommended by the Na-
tional Institute for Health and Care Excellence for chronic mi-
graine only, despite the fact that the definition of chronic migraine
remains controversial and is still evolving. In order to assess the
effectiveness of botulinum toxin in migraine sufferers, we did not
restrict our inclusion criteria to an arbitrary 15 migraine days per
month cut-off point, but we have acknowledged these clinically
useful definitions using subgroup analysis to determine levels of
effectiveness for the different diagnoses. We did not exclude medi-
cation overuse headache or those without two months’ withdrawal
of headache medications, as these types of participants have been
included in large and prominent trials in this area. To address
the inconsistent eligibility criteria for trial participants across the
available evidence, we attempted to assess the effectiveness of bo-
tulinum toxin on migraine participants with or without medica-
tion overuse headache as described in our data analysis.
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Types of interventions
Injections of botulinum toxin (any sero-type) into head and neck
muscles compared with placebo injections, active preventative
agent or the same drug treatment with a different dose. We also
included trials allowing the use of concomitant preventative or
rescue treatment.
We made a note of whether rescue medications for acute migraine
or concomitant medications for the prevention of migraine were
permitted.
Types of outcome measures
Primary outcomes
• Number of migraine days per month (frequency with
which exclusively migraine-type headaches are experienced).
Secondary outcomes
• Number of headache days per month (frequency with
which any type of headache inclusive of migraine headache are
experienced).
• Number of migraine attacks per month (frequency with
which exclusively migraine-type attacks are experienced).
• Headache intensity measures, usually reported as migraine
’severity’, measured on verbal or numerical scale.
• Headache index, measured using headache intensity score
multiplied by time spent with migraine.
• Duration of migraine (hours).
• Use of rescue medication (number of days on which rescue
medication is used per month or number of instances of taking
any type/dose of rescue medication per month).
• Patient and clinician global impression scales.
• Generic and disease-specific quality-of-life rating scales (e.g.
Headache Impact Test, Migraine Specific Quality of Life).
• Cost effectiveness measured using incremental cost
effectiveness ratio or cost per headache day avoided.
• Adverse events: we considered the following ways of
recording adverse events, listed in preferred order:
◦ total number of participants experiencing any type of
adverse event;
◦ total number of participants experiencing the specific
adverse event types; blepharoptosis, muscle weakness, neck pain
and injection site pain;
◦ total number of participants experiencing a treatment-
related adverse event, as determined by trial investigators;
◦ withdrawals due to adverse events.
Search methods for identification of studies
Electronic searches
To identify trials for inclusion in this review, we developed detailed
search strategies for each electronic database searched. These were
based on the search strategy developed forMEDLINE, but revised
appropriately for each database. The search strategies can be found
in Appendix 1.
Our search strategy combined the subject search with the appro-
priate trial design filter as described in the Cochrane Handbook of
Systematic Reviews of Interventions (Lefebvre 2011). The subject
search involved a combination of controlled vocabulary and free-
text terms. We did not add any language or date restrictions.
We carried out a systematic search of the literature to identify
publications or abstracts describing relevant trials. This included
searching the following databases:
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2017, Issue 12) via the Cochrane Register of
Studies Online (CRSO), 7 December 2017;
• MEDLINE and MEDLINE in Process (via OVID) 1946 to
7 December 2017;
• Embase (via OVID) 2017 week 49.
Searching other resources
We searched the following trials registers for ongoing trials:
• The World Health Organization’s International Clinical
Trials Registry Platform (ICTRP)(www.who.int/ictrp/en/);
• ClinicalTrials.gov (clinicaltrials.gov/).
In addition, we screened reference lists of relevant review articles
and included trial reports for additional trials; and we performed
citation searches on key articles.
We contacted relevant manufacturers for unpublished trial data
and additional information. Initial contact was made by email
to research and development contact addresses available online;
if no response was received within two weeks, we sent a follow-
up letter by post requesting information. Our final contact was
made by email, after a further four weeks without response, stat-
ing parties will have the opportunity to contribute to the review
before a given date two weeks from the time of the email. If no
information or communication indicating an intention to provide
trial data was received by the stated date, we listed manufacturers
as ’contacted without response’. Correspondence contained full
contact details, email, postal address and telephone numbers for
two authors (CPH and CEC), as well as details of the scope of the
review and a data extraction form. We listed the types of informa-
tion and data needed in the letter/email and referred to the data
extraction form to be used as an aid or filled in directly as desired.
We contacted trial authors in a similar manner where necessary
for additional information. We made this contact twice by email
stating a final date for contributing to the review in the second
attempt: if no response was received by this date we listed trial
authors as ’contacted without response’; where no contact details
were available we listed trial authors as ’uncontactable’.
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Data collection and analysis
Selection of studies
One author (CPH) considered all abstracts identified by the search,
and three other authors (CLT,CR andAS) independently repeated
this initial screening process in sections. We retrieved trial reports
that appeared to qualify for inclusion in the review or for which
insufficient information had been given in the abstract to allow
proper assessment of eligibility. Two authors (CPH and CEC)
independently assessed the trial reports for inclusion and these two
authors decided separately whether each trial met the inclusion
criteria. Wemade contact with trial authors for clarification where
necessary. When information pertaining to the eligibility criteria
was not provided in the available full-text articles and could not
be obtained from trial authors, we excluded the trials from this
review.
If the search strategy identified abstracts for which no full report
could be obtained, we assessed these for inclusion. If they included
only partial results of ongoing trials or contained insufficient in-
formation on the trial design or results, we listed these under trials
awaiting classification.
We completed a PRISMA study flow diagram (Moher 2009) to
document the screening process as recommended in the Cochrane
Handbook for Systematic Reviews of Interventions (Schünemann
2011).
Data extraction and management
Six review authors (CH, CLT, CR, WS, CEC and AS) were in-
volved in independently extracting data in duplicate from all in-
cluded trials. If disagreements occurred, a third review author con-
sidered the available information or if necessary we contacted the
trial authors for clarification. We also attempted to contact trial
authors where information required for data analysis or quality as-
sessment of a trial was not reported. We collated multiple reports
of the same trial into single trials. We extracted data onto elec-
tronic forms based on the template provided by Cochrane Pain,
Palliative and Supportive Care, which we customised for this re-
view according to the guidelines stated in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011a).
Trial length and time points for recording of outcome measures
were likely to be variable. We standardised the unit over which
headache diary data were measured at 28 days (four weeks) when
possible.We used data from the 12week time point following final
treatment to maximise the likelihood of observing a real treatment
effect.
For continuous outcomes, we used change in groupmeans, as these
adjust for imbalances in the baseline scores. We used these values if
they were given in the trial paper or we calculated them frommean
pre-treatment and mean post-treatment scores. If change scores
were not available, we used post-treatment (endpoint) means, as-
suming that baseline data would be balanced due to randomisa-
tion. We checked this assumption by sensitivity analysis for the
primary outcome measure.
For the dichotomous outcome, proportion of responders, we con-
sidered a participant with a reduction in number of headaches of
at least 50% to be a responder and a participant with less than 50%
reduction in headache to be a non-responder. We intended to set
out clinically significant thresholds for other outcome measures as
the collected data required it; this was not required in the current
version of the review but we will consider this approach for future
updates.
For each trial, we recorded the proportion of participants report-
ing any adverse events in each arm, as well as numbers report-
ing blepharoptosis, muscle weakness, neck pain and injection site
pain.
Assessment of risk of bias in included studies
All review authors were involved in independently assessing risk of
bias in the included trials in duplicate using the criteria outlined
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011b) and guidelines from Cochrane Pain, Palliative
and Supportive Care. We resolved any disagreements through dis-
cussion.
We assessed the following domains for each trial.
• Random sequence generation (checking for possible
selection bias):
◦ we assessed the method used to generate the allocation
sequence as: low risk of bias (any truly random process, e.g.
random number table; computer random number generator);
unclear risk of bias (method used to generate sequence not clearly
stated); high risk of bias (trials using a non-random process (e.g.
odd or even date of birth; hospital or clinic record number).
• Allocation concealment (checking for possible selection
bias):
◦ the method used to conceal allocation to interventions
prior to assignment determines whether intervention allocation
could have been foreseen in advance of, or during recruitment,
or changed after assignment. We assessed the methods as: low
risk of bias (e.g. telephone or central randomisation;
consecutively numbered, sealed, opaque envelopes); unclear risk
of bias (method not clearly stated); high risk of bias (trials that
do not conceal allocation (e.g. open list).
• Blinding of participants and personnel (checking for
possible performance bias):
◦ we assessed the methods used to blind trial
participants and personnel from knowledge of which
intervention they received. We assessed the methods as: low risk
of bias (trial states that it was blinded and describes the method
used to achieve blinding, such as identical tablets matched in
appearance and smell or a double dummy technique); unclear
risk of bias (trial states that it was blinded but does not provide
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an adequate description of how blinding was achieved). We
excluded trials that were not double-blind.
• Blinding of outcome assessment (checking for possible
detection bias):
◦ we assessed the methods used to blind trial
participants and outcome assessors from knowledge of which
intervention a participant received. We assessed the methods as:
low risk of bias (trial has a clear statement that outcome assessors
were unaware of treatment allocation, and ideally describes how
this was achieved); unclear risk of bias (trial states that outcome
assessors were unaware of treatment allocation but does not
provide an adequate description of how blinding was achieved).
We excluded trials that were not double-blind.
• Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data):
◦ we assessed the methods used to deal with incomplete
data as: low risk (< 10% of participants did not complete the
trial and/or used ‘baseline observation carried forward’ analysis);
unclear risk of bias (used ’last observation carried forward’
analysis); high risk of bias (used ’completer’ analysis).
• Selective reporting (checking for possible reporting bias)
◦ we assessed the likelihood that a subset of original
variables had been selected for publication, based on results, as:
low risk (protocol available and all outcomes reported or all
reasonable expected outcomes reported); unclear risk
(insufficient information available to make a judgement); high
risk (protocol available and some outcomes not reported or
obvious expected outcomes missing).
• Size of trial (checking for possible biases confounded by
small size):
◦ we assessed trials as being at low risk of bias (≥ 200
participants per treatment arm); unclear risk of bias (50 to 199
participants per treatment arm); high risk of bias (< 50
participants per treatment arm).
Measures of treatment effect
We used risk ratios (RRs) as the preferred statistical output for
dichotomous outcomes, with 95% confidence intervals (CIs).
Where possible, we also provided number needed to treat for an
additional beneficial outcome (NNTB) and the number needed
to treat for an additional harmful outcome (NNTH), also with
95% CIs.
For continuous data, we used mean differences (MDs) with 95%
CIs. We considered results with P values lower than 0.05 to be
statistically significant.
Unit of analysis issues
Cluster-randomised trials
Where trials employed ’cluster randomisation’ techniques, we in-
tended to carry out analysis at the allocation level as described
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011c). By this method, the number randomised would
be reduced to the number of centres rather than the number of
individuals included in the trial and consequently there would be
a reduction in power for any trials that had adopted a cluster de-
sign. We did not identify any cluster-randomised trials but will
consider these methods for future updates.
Cross-over trials
As a carry-over effect from treatment with botulinum toxin cannot
be ruled out, we sought data from the first phase for any cross-
over trials identified.
Trials with multiple treatment group
We included relevant trials with multiple treatment arms, but we
extracted and included only data from those arms that fulfilled the
criteria for this review.
Dealing with missing data
When data were found to be missing or inadequate, we attempted
to contact trial authors and obtain these data.
Assessment of heterogeneity
Four review authors (CH, CR, CEC and AS) assessed trial baseline
characteristics to identify clinical heterogeneity during the extrac-
tion of trial information. If we confirmed clinical homogeneity
and the review authors considered trials eligible for a certain com-
parison to be methodologically similar, we carried out meta-anal-
ysis of the data. We tested for statistical homogeneity of pooled
estimates of effectiveness using the Chi2 test and the I2 statistic
(Higgins 2003), for which a statistically significant (P value≤ 0.1)
value of the Chi2 test together with I2 value of at least 50% in-
dicates heterogeneity. In cases where statistical heterogeneity ex-
isted, we investigated possible causes and we have listed them in
the Discussion section of this review.
Assessment of reporting biases
We considered the use of funnel plots to assess the risk of pub-
lication bias but did not carry them out. We made this decision
because of the small number of trials included in the individual
meta-analyses and the true heterogeneity in the trial design (dose,
injection paradigm) and populations studied (migraine subclassi-
fications), which would make it impossible to draw useful conclu-
sions from the plots.
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Data synthesis
We intended to use a fixed-effect model as our preferred model
for meta-analyses, but the clinical heterogeneity present in doses,
injection sites and participant populations meant that a random-
effects model was more appropriate. Our primary analysis was
grouped according to the type of treatment arms used and for each
outcome, and a separate forest plot was planned for the following
comparisons:
• botulinum toxin versus placebo;
• botulinum toxin versus botulinum toxin with clinically
relevant different dose;
• botulinum toxin versus other agent for the prevention of
migraine;
• botulinum toxin with other agent for the prevention of
migraine versus other agent for the prevention of migraine.
Within these comparisons, we split data into migraine classifi-
cation subgroups in order to show results for chronic migraine,
episodic migraine and a mixed group, for which the diagnosis
could not be split. When a multi-arm trial contributed several
comparisons to a meta-analysis, we divided the shared control or
intervention group evenly among the comparisons. For dichoto-
mous outcomes we split both the number of events and the to-
tal number of participants and rounded them up to the nearest
integer value. For continuous outcomes, we split the number of
participants in the same way but entered the mean and standard
deviation unchanged in both comparisons.
’Summary of findings’ table
We created two ’Summary of findings’ tables to give an overview of
the outcomes of interest for all included trials with data available.
In order to help the readers to understand the review’s primary
outcomes, we discuss the clinical relevance of any statistically sig-
nificant outcomes using published minimally clinically important
change data where available.
We assessed the validity of our findings as well as the level of
confidence suitable to any estimates of effect generated by our
analyses using theGRADE approach (Guyatt 2008).We imported
data from Review Manager 5 (RevMan 5) (RevMan 2014) into
GRADE profiler (GRADEpro GDT 2015) to create ’Summary
of findings’ tables, which comprise outcome-specific information
on the overall quality of the evidence and representations of the
anticipated absolute effects of the intervention. We included the
following outcomes:
• number of migraine days;
• number of headache days;
• number of migraine attacks;
• migraine severity measured on 10 cm VAS;
• global impression scales measured using Headache Impact
Test-6 question version (HIT-6) or MIDAS;
• total number of participants experiencing an adverse event.
The evidence level for all outcomes was high quality to start with,
as all included trials were randomised controlled trials. We down-
graded the evidence by one level for serious (or by two for very
serious) trial limitations (risk of bias), unexplained inconsistency
of results, indirectness (population, outcome or intervention), im-
precision of data or risk of publication bias. We planned to up-
grade outcomes by one level if there had been evidence of a large
effect or a dose-response relationship.
Subgroup analysis and investigation of heterogeneity
A number of differences in trial designs were likely to cause hetero-
geneity in our meta-analyses and we planned the following sub-
group analyses to test for variation in effect:
• trials including medication overuse headache versus trials
excluding people with this diagnosis;
• different sero-types of botulinum toxin (e.g. A versus B)
and within sero-types (Dysport versus Botox);
• different types of agents for the prevention of migraine
versus botulinum toxin;
• accepted and licensed 31 injection pattern versus other
injection patterns used.
At least two trials and 200 participants per group were required
for any particular subgroup analysis to be carried out.
Sensitivity analysis
We carried out sensitivity analyses for our primary outcome only.
We planned to test the effect of the changing definitions used for
classification of migraine as chronic or episodic by reclassifying
participants, if possible, using current guidelines and re-analysing
the data. We planned to test the use of post-treatment means, for
which the assumption is made that baselines are balanced by ran-
domisation, if this type of data are identified and used in any meta-
analyses. Some issues can only be identified as decisions are made
throughout the review process and we had planned additional sen-
sitivity analyses, as required, as a result of the individual peculiari-
ties of the trials under investigation (Deeks 2011). Prevailing evi-
dence suggests that smaller trials are more likely to report stronger
effect estimates than large trials (Dechartres 2013; Nüesch 2010).
To assess whether these stronger effect estimates reflected the true
treatment effect we carried out a sensitivity analysis in which we
examined the effect of removing trials at high risk of bias from
trial size.
R E S U L T S
Description of studies
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Results of the search
See Figure 1: PRISMA flow chart.
Figure 1. Study flow diagram
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In December 2017, we searched electronic databases and trials
registers and identified 1481 records. In addition, we obtained
140 records from other sources. After removal of duplicates, 1153
records remained and we screened these for inclusion. We con-
sidered full-text articles for 109 records to determine eligibility.
From these we found 28 trials, from 90 associated articles, eligible
for inclusion in this review and an additional three ongoing trials,
which we believe will qualify for inclusion in this review once the
trials are completed.
Included studies
The main features of the 28 trials included in this review are
presented in the Characteristics of included studies tables.
Full publications for three of these trials are still pending and
therefore only limited information was available (Allergan 2015;
Jabbari 2014;Mazza 2016). Of the remaining 25 trials, all but one
cited the International Headache Society (IHS) criteria for diag-
nosing migraine (Lauretti 2014). Pregnancy or unwillingness to
prevent pregnancy during the trial period was stated by 21 of these
trials as an exclusion criteria (Anand 2006; Aurora 2007; Aurora
2010; Barrientos 2003; Blumenfeld 2008; Blumenkron 2006;
Cady 2008; Cady 2011; Cady 2014; Diener 2010 (PREEMPT
2); Elkind I 2006; Elkind II 2006; Freitag 2008; Hou 2015;
Jabbari 2014; Jost 2011; Mathew 2009; Millán-Guerrero 2009;
Relja 2007; Saper 2007; Silberstein 2000), and pregnancy in the
remaining trials was not reported.
There was a small amount of variation between trials in the diary
period over which number of migraines and duration outcomes
were recorded. This ranged from28days to 30 days and some trials
stated that they used a period of onemonthwith no clarification on
the exact number of days this represented. We considered making
attempts to convert all diary outcomes to a period of 28 days
but this was not possible without individual participant data. The
diary periods stated by each trial are given in the notes sections of
the Characteristics of included studies table.
Adverse events were reported over the full follow-up period of the
trials, which ranged from four weeks to nine months with some
using a single treatment and some giving multiple treatments at
12-week intervals. Adverse events that would be captured by the
follow-up periods used in our included trials would likely occur
shortly after treatment had takenplace andwe therefore aggregated
all available data for each of these outcomes on to single forest
plots.
Funding for 16of the trials (involving 85%of the trial participants)
was provided by themanufacturer of the botulinum toxin product
under investigation (Allergan 2015; Aurora 2007; Aurora 2010
(PREEMPT 1); Barrientos 2003; Blumenfeld 2008; Cady 2008;
Chankrachang 2011; Diener 2010 (PREEMPT 2); Elkind I 2006;
Elkind II 2006; Freitag 2008; Mathew 2009; Petri 2009; Relja
2007; Saper 2007; Silberstein 2000). Eight trials did not declare
the source of their trial funding (Anand 2006; Blumenkron 2006;
Cady 2011; Cady 2014; Jabbari 2014; Lauretti 2014; Mazza
2016;Millán-Guerrero 2009). The remaining four stated that they
received funding from alternative sources.
Participants
Trials investigating botulinum toxin thatwere eligible for inclusion
in this review randomised a total of 4190 participants. The average
age of participants was 42 years, excluding three trials that failed to
provide this information (Anand 2006; Blumenkron 2006;Mazza
2016). Only one trial did not provide information about the gen-
der of its 94 participants (Mazza 2016). All trials that reported
male to female ratios were dominated by female participants with
the single exception of Jabbari 2014, which had 12 female and
13 male participants. Overall 85% (3491) of the trial participants
werewomen. Baseline disease characteristicswere notwell reported
and were given in varying formats. The ratio of chronic to episodic
migraine sufferers was not reported by six trials involving 390 par-
ticipants (Blumenkron 2006; Cady 2008; Chankrachang 2011;
Jost 2011; Millán-Guerrero 2009; Vo 2007); for the remaining
trials, the overall ratio was 1872/1928. Due to the inclusion of
chronic and episodic migraine populations in this review, the fre-
quency and severity of migraines in the trial populations, when
reported, showed a wide variation between trials. Such variation
makes reporting of a meaningful point estimate or range sum-
marising all trials impossible. Disease characteristics for individual
trials are given in the ’Characteristics of included studies’ tables and
are discussed within individual outcome sections when relevant.
People with medication overuse headache were excluded from 13
trials (Anand 2006; Aurora 2007; Barrientos 2003; Blumenfeld
2008; Cady 2011; Elkind I 2006; Elkind II 2006; Freitag 2008;
Hollanda 2014; Petri 2009; Relja 2007; Saper 2007; Silberstein
2000). Three trials did not exclude peoplewithmedicationoveruse
headache (Allergan 2015; Aurora 2010 (PREEMPT 1); Diener
2010 (PREEMPT 2)); the two PREEMPT trials gave the ratio of
participants with andwithout this additional diagnosis; totals were
906/478, but subgroup data were not available from these groups
for re-analysis in this review. One trial included only participants
who were overusing acute medications (Millán-Guerrero 2009).
The remaining 11 trials did not consider medication overuse in
their eligibility criteria. The available evidence was therefore not
sufficient for investigation of the effect of botulinum toxin on the
medication overuse headache subgroup.
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Interventions and controls
See Table 2 for details of the botulinum toxin products. Botox
is the only licensed botulinum toxin product for use in chronic
migraine.
Twenty-eight trials compared botulinum toxin with matched
placebo injections or active control; of these, 21 had at least one
arm treated with the Botox formulation (Allergan 2015; Anand
2006; Aurora 2007; Aurora 2010 (PREEMPT 1); Barrientos
2003; Blumenfeld 2008; Blumenkron 2006; Cady 2008; Cady
2011;Diener 2010 (PREEMPT2); Elkind I 2006; Elkind II 2006;
Freitag 2008; Jabbari 2014; Jost 2011; Lauretti 2014; Mathew
2009; Millán-Guerrero 2009; Relja 2007; Saper 2007; Silberstein
2000), two used Dysport (Chankrachang 2011; Petri 2009), two
used Prosigne (Hollanda 2014; Lauretti 2014) and one, HengLi
(Hou 2015). Three trials did not state the brand used, but de-
scribed the toxin as type A (Cady 2014; Mazza 2016; Vo 2007).
The range of doses administered in trials of Botox was 6 units to
300 units, with eight trials using doses lower than 75 units in all
treated arms (Anand 2006; Barrientos 2003; Elkind I 2006; Elkind
II 2006; Jost 2011; Lauretti 2014; Millán-Guerrero 2009; Saper
2007). The Chankrachang 2011 and Petri 2009 trial publications
reported Dysport dose equivalency to be between 2 to 3 units:
1 units Botox, with doses of 80 units up to 240 units in treated
arms. HengLi and Prosigne are two botulinum toxin preparations
produced by Lanzhou Institute of Biological Products which were
studied in three trials with doses ranging from25 units to 96 units;
the trial publications reported a dose equivalency to Botox of ap-
proximately 1:1 (Hollanda 2014; Hou 2015; Lauretti 2014).
Injection profiles varied with trials using between 2 and 58 in-
jection sites in varying locations in the head and neck. Four tri-
als used a ’follow the pain’ method for injection sites and doses
(Blumenfeld 2008; Hollanda 2014; Jost 2011; Mazza 2016), and
six used some fixed sites and some optional ’follow the pain’ sites/
doses (Aurora 2007; Aurora 2010 (PREEMPT 1); Cady 2011;
Cady 2014; Diener 2010 (PREEMPT 2); Mathew 2009). The re-
maining 18 trials adhered to fixed doses and locations of injections
for all participants.
Nineteen trials gave a single treatment and the majority followed
up participants for three months; exceptions to this were Jabbari
2014, which followed up participants for four weeks only, and
Elkind I 2006, Freitag 2008 and Hou 2015, which carried out
four-month follow-up to treatment. Seven trials (Allergan 2015;
Aurora 2010 (PREEMPT 1); Blumenfeld 2008; Diener 2010
(PREEMPT 2); Elkind II 2006;Mathew 2009;Mazza 2016) gave
two rounds of treatment, all with threemonths between treatments
and at least three months’ follow-up, with the single exception of
Elkind II 2006, which had four months between treatments. Two
further trials provided three rounds of treatment at months zero,
three and six and with assessments carried out to nine months
(Aurora 2007; Relja 2007).
Concomitant prophylactic medications at stable doses were per-
mitted during 11 of the included trials (Anand 2006; Aurora 2007;
Cady 2014; Chankrachang 2011; Elkind I 2006; Elkind II 2006;
Freitag 2008; Lauretti 2014; Saper 2007; Silberstein 2000; Vo
2007), seven trials did not report on this (Blumenkron 2006; Cady
2008; Cady 2011; Hou 2015; Jabbari 2014; Jost 2011; Mazza
2016), and the remaining ten trials did not allow their use dur-
ing the trial period. Rescue medications were more commonly al-
lowed. Five trials did not discuss the use of rescue medications
during their trial periods (Allergan 2015; Blumenkron 2006; Hou
2015; Jabbari 2014; Jost 2011) but all remaining trials stated that
their use was permissible or included use of rescue medications as
a trial outcome.
Country and language of publication
Sixteen trials were conducted in the USA, two each in Brazil
(Hollanda 2014; Lauretti 2014), Germany (Jost 2011; Petri 2009)
and Mexico (Blumenkron 2006; Millán-Guerrero 2009), and one
each inChile (Barrientos 2003), China (Hou 2015), Europe (Relja
2007), India (Anand 2006), Italy (Mazza 2016) and Thailand
(Chankrachang 2011). We identified only one non-English lan-
guage publication (Blumenkron 2006), which was translated from
Spanish to English for inclusion in the review.
Excluded studies
We excluded seven trials, which are listed in the Characteristics of
excluded studies tables. Two trials did not report a relevant com-
parison (Cady 2012; Schwedt 2007), two trials did not report rel-
evant outcomes (De Tommaso 2016; Guyuron 2005), two trials
randomised people with non-migraine headache and investigators
were not able or not willing to provide data for migraine-only par-
ticipants (Evers 2004; Ondo 2004), one health economics paper
reported on data taken from published material from a non-asso-
ciated trial (Ruggeri 2013).
Trials awaiting classification
We identified five trials awaiting classification, which are listed in
the Characteristics of studies awaiting classification tables. One
trial was published as an abstract only, no further information
could be gained from the trial authors and there was insufficient in-
formation in the abstract to determine eligibility (Brin 2000). Two
trials were reported only as protocol/methods papers and we could
not locate any reports of trial results (Ipsen 2006; Kuper 2007).
Two trials included non-migraine participants and we could not
contact the trial authors or they did not respond to requests for
migraine-only data (Mathew 2005; Silberstein 2005).
Ongoing trials
We identified three ongoing trials, which are listed in the
Characteristics of ongoing studies tables (NCT02074163;
NTR3440; NCT02291380). All three can reasonably be expected
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to publish in the next one to three years and will be eligible for
inclusion in updates of this review.
Risk of bias in included studies
The overall risk of bias for all 28 included trials is presented graph-
ically in Figure 2. Summary details for each trial are given in the
’Risk of bias’ sections of the Characteristics of included studies
tables and are illustrated in Figure 3. Of the 28 included trials, 21
had at least one source of bias rated as high risk.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included trials
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
trial.
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Allocation
All trials clearly stated that they were randomised, but only 13
gave details, in either published or unpublished materials, of a
low-risk method used to generate the sequence (Aurora 2007;
Aurora 2010 (PREEMPT 1); Blumenkron 2006; Cady 2014;
Chankrachang 2011; Diener 2010 (PREEMPT 2); Freitag 2008;
Hollanda 2014;Hou 2015; Lauretti 2014;Millán-Guerrero 2009;
Petri 2009; Vo 2007). The remaining trials did not provide any
information from which we could evaluate the method used to
randomise participants into their trials and so we judged they were
at unclear risk of selection bias.
Eight trials provided adequate details to enable a judgement of a
low risk of bias for the concealment of allocation (Aurora 2007;
Aurora 2010 (PREEMPT 1); Cady 2008; Cady 2011; Cady 2014;
Chankrachang 2011; Diener 2010 (PREEMPT 2); Petri 2009).
The remaining 20 gave insufficient or no information and so we
judged them to be at unclear risk of bias.
Blinding
All trials were double-blind. Fourteen trials published information
on low-risk methods of blinding participants and personnel, and
we judged these to be at low risk of performance bias (Aurora 2007;
Aurora 2010 (PREEMPT 1); Cady 2008; Cady 2011; Cady 2014;
Chankrachang 2011; Diener 2010 (PREEMPT 2); Freitag 2008;
Hollanda 2014; Lauretti 2014; Mazza 2016; Millán-Guerrero
2009; Petri 2009; Relja 2007). The remaining 14 trials gave no
details of how they had achieved blinding and we rated them
unclear for risk of performance bias.
Fourteen trials gave details of methods used to blind personnel and
assessors and we judged these to be at low risk of detection bias
(Aurora 2007; Aurora 2010 (PREEMPT 1); Cady 2008; Cady
2011; Cady 2014; Chankrachang 2011;Diener 2010 (PREEMPT
2); Freitag 2008;Hollanda 2014;Hou 2015;Mazza 2016;Millán-
Guerrero 2009; Petri 2009; Relja 2007). The remaining fourteen
trials gave insufficient details of theirmethods and we judged them
to be unclear for risk of detection bias.
Incomplete outcome data
Due to large numbers of participants dropping out, we judged four
trials to be at high risk of attrition bias (Allergan 2015; Blumenfeld
2008; Jabbari 2014; Mathew 2009). Twelve trials gave sufficient
information about dropout rates and imputation methods to be at
low risk of attrition bias (Anand 2006; Aurora 2010 (PREEMPT
1); Barrientos 2003; Cady 2014; Diener 2010 (PREEMPT 2);
Elkind I 2006; Elkind II 2006; Freitag 2008;Hollanda 2014;Hou
2015; Lauretti 2014; Silberstein 2000). The remaining 12 trials
gave insufficient information for conclusions to be drawn and so
we judged them to be at unclear risk of attrition bias.
Selective reporting
Three trials had at least one outcome mentioned in the methods
section missing from the reported results and so we judged them
to be at high risk of reporting bias (Cady 2011; Hou 2015; Jost
2011). Seven trials clearly reported all recorded outcomes as listed
in the protocol or full methods sections and so we judged them to
be at low risk of reporting bias (Aurora 2010 (PREEMPT1); Cady
2014; Diener 2010 (PREEMPT 2); Freitag 2008; Hollanda 2014;
Mathew 2009; Millán-Guerrero 2009). We found an unclear risk
of reporting bias in the remaining 18 trials due to incomplete or
unclear reporting of data or the absence of expected outcomes.
We made attempts to contact all trial authors if we could identify
contact information. We contacted trial authors twice by email
requesting further data if needed. Only two trials provided ad-
ditional, unpublished data (Lauretti 2014; Mazza 2016). These
remained at unclear risk of selective reporting bias as not all of
the required information was provided to allow us to make this
judgement.
Other potential sources of bias
Trial size
Most trials (21 out of 28) included in this review had fewer than 50
participants per trial arm, sowe considered these trials to be at high
risk of bias. Five trials had between50 and199 participants per arm
and we gave a rating of unclear risk of bias (Aurora 2007; Elkind I
2006; Elkind II 2006; Millán-Guerrero 2009; Relja 2007). Only
two trials included more than 200 participants in each arm and
could be considered to have a low risk of bias from trial size (Aurora
2010 (PREEMPT 1); Diener 2010 (PREEMPT 2)).
Effects of interventions
See: Summary of findings for the main comparison Botulinum
toxin type A compared to placebo for the prevention ofmigraine in
adults; Summary of findings 2Botulinum toxin type A compared
to other established prophylactic agent for the prevention of
migraine in adults
We focused upon the 12-week, post-treatment time point using
data from the final treatment cycle unless otherwise stated. For
continuous outcomes, five trials provided endpoint data (Anand
2006; Hollanda 2014; Hou 2015; Lauretti 2014; Mazza 2016).
All remaining trials included in the meta-analysis provided change
data.
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Botulinum toxin versus placebo
See: Summary of findings for the main comparison
Twenty-three of the trials eligible for the review included a placebo
arm (N = 3912). All used injections of saline or vehicle in matched
sites and volumes to those used in the botulinum toxin treatment
arm.
Primary outcome: number of migraine days per month
See: Figure 4
Figure 4. Forest plot of comparison 1. Botulinum toxin type A versus placebo, outcome: 1.1 Number of
migraine days. Mazza 2016 and Cady 2014 removed for sensitivity analysis of small trial effect. Data for Mazza
2016 is endpoint data.
Only five trials contributed data to the meta-analysis of the pri-
mary outcome (Aurora 2010 (PREEMPT 1); Cady 2014; Diener
2010 (PREEMPT 2); Elkind I 2006; Mazza 2016); 17 did not
report this outcome, and one trial reported the outcome in an un-
usable format (Relja 2007). Four trials of 1497 participants were
in chronic migraine participants only; there were also nine chronic
migraine participants inadvertently included in the Elkind I 2006
trial of episodic migraine, meaning 1506 of 1915 participants in-
cluded in this meta-analysis were chronic migraine sufferers with
an average baseline of more than 19 days migraine per month.
At 12 weeks post-treatment using a random-effects model, the
pooled estimate for the improvement in the number of migraine
days per month for the chronic migraine subgroup was -3.1 (95%
CI -4.7 to -1.4, I2 = 76%) above that seen for the placebo group.
Contributing to this pooled estimate were two trials at high risk
of bias due to small size (Cady 2014; Mazza 2016); in addition
to this, one of these trials provided only endpoint data (Mazza
2016). Due to these concerns we carried out a sensitivity analysis
and removed these trials leaving just two larger phase III trials
with 1384participants (Aurora 2010 (PREEMPT1);Diener 2010
(PREEMPT 2)), for which the pooled estimate for this outcome is
-2.0 days (95%CI -2.8 to -1.1, I2 = 37%). This sensitivity analysis
raises concerns about the original estimate. We therefore focused
the conclusions of this review on themore conservative estimate of
a 2-day improvement in the chronic-migraine group treated with
botulinum toxin, above that seen in the placebo-treated group, for
this outcome.
The episodic-migraine subgroup in this analysis contained only
a single trial (Elkind I 2006; N = 418), the results of which
showed no between-group difference in number of migraine days
per month between those treated with botulinum toxin and those
treated with placebo (P = 0.49). The test for subgroup difference
showed a statistically significant heterogeneity between the results
of this population and the chronic migraine subgroup for both
the original and the sensitivity analyses (P = 0.001 for both, I2 =
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90 and 91% respectively).
We judged the quality of the evidence for the change in number
of migraine days for the chronic migraine population to be low.
We downgraded by one level for inconsistency due to unexplained
statistical heterogeneity and one further level for imprecision due
to the lack of robustness to sensitivity analysis. We judged the
quality of the results of the sensitivity analysis to be moderate, as
the heterogeneity was removed and so this could be upgraded by
one level.
For the whole migraine population, we downgraded the evidence
one further level, to give a rating of very lowquality, for indirectness
due to insufficient evidence to form subgroups representing our
distinct populations of interest.
Secondary outcomes
Number of headache days per month
Only the two PREEMPT trials contributed data for analysis of
number of headache days per month with a pooled estimate of
-1.9 days (95% CI -2.7 to -1.0; I2 = 37%) in favour of treat-
ment (Aurora 2010 (PREEMPT 1); Diener 2010 (PREEMPT
2)). All 1384 participants included in this analysis were chronic
migraineurs (Analysis 1.2). Five other trials recorded this outcome:
three did not clearly state their results (Anand 2006; Petri 2009;
Relja 2007), one reported a reduction of two headache days in the
treated group above that in the placebo group (P = 0.018; Freitag
2008), and the final trial stated that the difference between the two
groups was not statistically significant (Cady 2008). The partici-
pants involved in Freitag 2008 were all chronic migraine sufferers,
but the eligibility criteria for Cady 2008 were inclusive of chronic
and episodic migraine and the ratio was not given; the differing
populations may be the cause of disparity in the trial results.
We judged the quality of the evidence for the change in number
of headache days to be high.
Number of migraine attacks per month
Data from six trials were available for the analysis of number of mi-
graine attacks per month (Aurora 2007; Aurora 2010 (PREEMPT
1); Chankrachang 2011; Hou 2015; Relja 2007; Saper 2007).
There was no statistically significant difference for the number of
migraine attacks between botulinum toxin and placebo injections
with a pooled estimate of -0.5 attacks (95% CI -1.3 to 0.4, I2 =
89%, P = 0.30; Analysis 1.3). This analysis included both chronic
and episodic migraineurs, with a total of 2004 participants in-
cluded.
Seven further trials, with a total of 380 participants, recorded this
outcome. Three of these trials reported the result as not significant
(Jost 2011; Petri 2009; Vo 2007), one reported a between-group
difference in favour of treatment of approximately 2.5 attacks (P <
0.05; Barrientos 2003) and three trials reported unclear or partial
data (Anand 2006; Freitag 2008; Silberstein 2000).
The proportion of responders, defined as participants with 50% or
greater reduction in number of migraine attacks or migraine days,
was reported fully by only one trial and no significant difference
between the active and placebo armwas observed (P = 0.27; Freitag
2008). Two further trials recorded this outcome and commented
that there were no significant between-group differences, but did
not provide analysable data.
We judged the quality of the evidence for the change in number
of migraine attacks to be low. We downgraded by one level for
indirectness, due to our concern that the sensitivity of this outcome
measure was too low to detect clinically meaningful difference,
and one additional level for publication bias, due to evidence of
trials that recorded this outcome but have never been published.
Headache intensity measures
Only four trials contributed data for just 209 participants to
the analysis of severity of migraine, measured on a 10 cm visual
analogue scale (VAS) (Anand 2006; Hollanda 2014; Hou 2015;
Lauretti 2014). It should be noted that all of the data included
in this analysis were endpoint data as no mean change data were
available from these trials. An improvement in the severity of mi-
graines, measured in centimetres, in favour of treatment of -3.3
(95% CI -4.2 to -2.5, I2 = 55%; Analysis 1.4; Figure 5) was ob-
served from this small data set. Episodic and chronic migraine
populations contributed to this outcome measure, the trial and
participant numbers were too low to compare these subgroups or
to have confidence in the overall pooled estimate. The other trials
that recorded this outcome stated that the result was not signifi-
cant (Chankrachang 2011; Petri 2009; Saper 2007), or ’favouring
placebo’ (Aurora 2007), or gave only partial, ineligible or unclear
data (Cady 2014; Jost 2011; Silberstein 2000; Vo 2007). Four tri-
als provided data on intensity outcomes, which were not suitable
for aggregation with the VAS data. Blumenkron 2006 used an al-
ternative migraine severity scale, MIGSEV, but did not provide
statistical analysis for their data. Three trials reported some other
form of category data with Anand 2006 reporting that 75% of par-
ticipants experienced a marked improvement in the treated group
compared with 0% in the placebo arm (P < 0.05), and pooled data
for Aurora 2010 (PREEMPT 1), and Diener 2010 (PREEMPT
2), showed that significantly more participants treated with bo-
tulinum toxin had at least one grade improvement of average daily
headache severity score than in the placebo group (P < 0.001).
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Figure 5. Forest plot of comparison 1. Botulinum toxin type A versus placebo, outcome: 1.4 Severity of
migraine (Visual Analogue Score 0-10)
We judged the quality of the evidence for the change in VAS score
to be very low. We downgraded by one level for risk of bias, due to
poor reporting of the outcome, which had a large effect on number
of participants included in the analysis, and two additional levels
for imprecision, as all included trials were all small and new trial
evidence would be very likely to change the result.
Headache index
None of the included trials reported data for this outcome. It was
recorded in a single trial that reported that there was no statistically
significant difference between placebo and treatment for the 12-
week time point (Freitag 2008).
Duration of migraine
Only one trial reported duration of migraine in a format we could
use in our analysis (Hou 2015). Their results showed an improve-
ment in duration of migraine of -5.1 hours (95% CI -6.2 to -
4.0) in favour of botulinum toxin for a mixed population of 66
episodic migraine participants and 36 chronic migraine partici-
pants. Four other trials, with a total of 420 participants, reported
that they found no significant difference between groups for this
outcome, but provided no analysable data (Jost 2011; Petri 2009;
Saper 2007; Vo 2007).
Three trials reported reduction in timewith severe (ormore severe)
migraine: Chankrachang 2011 reported only that there was no
significant between-group difference; Diener 2010 (PREEMPT
2) reported a difference of -2.5 days per month (95% CI -3.4
to -1.5, P < 0.001) in favour of botulinum treatment; Jabbari
2014 reported an improvement of 7.5 days per month in favour of
treatment with botulinum toxin, but gave no confidence intervals
for these data, only providing a P value (P = 0.03).
We judged the quality of the evidence for this outcome to be very
low. We downgraded by two levels due to imprecision as the single
included trial was small and new trial evidence would be very likely
to change the result; we downgraded by one additional level for
risk of bias, due to selective reporting bias which had a large effect
on number of participants included in the analysis.
Use of rescue medication
Data were provided by only two trials, with a total of 717 par-
ticipants, on the use of rescue medication in chronic migraineurs
(Aurora 2010 (PREEMPT 1); Hollanda 2014; Analysis 1.5).
There was no statistically significant difference between groups in
the reduction innumber of times a participant took acute headache
pain medication regardless of dose or type/number of medications
taken at the same time (P = 0.16). Six additional trials reported
that there were no significant between-group differences for this
outcome (Diener 2010 (PREEMPT 2); Freitag 2008; Jost 2011;
Petri 2009; Saper 2007; Vo 2007); one reported that their re-
sults favoured placebo (Aurora 2007), and one that their results
favoured botulinum toxin (Barrientos 2003), but all eight failed
to provide analysable data.
We judged the quality of the evidence for this outcome to be
moderate. We downgraded by one level for risk of bias, due to
selective reporting bias, which had a large effect on number of
participants included in the analysis.
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Patient and clinician global impression scales
The only trial to report analysable data for any global impression
scale was Allergan 2015, which reported a small between-group
difference in patient-rated Headache Impact Test-6 question ver-
sion (HIT-6) scores of 1.6 points (N = 45) without statistical sig-
nificance (P = 0.40). Eight trials did not list any global impres-
sion scales in their recorded outcomes (Anand 2006; Cady 2014;
Hollanda 2014; Hou 2015; Jabbari 2014; Lauretti 2014; Mazza
2016; Vo 2007). The remaining trials either did not provide data
or reported data in a format not suitable for meta-analysis.
We judged the quality of the evidence for the change in HIT-6
score to be very low. We downgraded by one level for risk of bias,
due to selective reporting bias, which had a large effect on number
of participants included in the analysis, and two additional levels
for imprecision, as the single trial was small and new trial evidence
would be very likely to change the result.
Generic and disease specific quality of life rating scales
None of the trials included in this review provided data on quality-
of-lifemeasures in a format suitable for analysis. Eleven trial reports
did not list quality-of-life scales as a trial outcome (Allergan 2015;
Aurora 2007; Barrientos 2003; Cady 2014; Chankrachang 2011;
Hollanda 2014;Hou 2015; Jost 2011; Lauretti 2014;Mazza 2016;
Silberstein 2000). All remaining trials reported data in a format
that could not be meta-analysed.
We could not assess the quality of the evidence due to the lack of
reporting of this outcome.
Cost effectiveness
Only two trials carried out economic analysis of the intervention
(Aurora 2010 (PREEMPT 1); Diener 2010 (PREEMPT 2)). A
single economic analysis was conducted to support these two trials
that were run by the same investigators and had the same design,
with the exception of their designated primary outcome (Batty
2013). As the efficacy data were taken from these two trials, the
relevance of the analysis was limited to the chronicmigraine popu-
lation. The incremental cost-effectiveness ratio (ICER) generated
using data from the two PREEMPT trials was GBP 15,028 per
quality adjusted life year gained. The trial authors calculated that
the cost of treatment per headache day avoided was GBP 18. Lim-
itations cited by the authors of this paper were the use of a placebo
comparator, which does not represent real alternative treatments,
and the use of extrapolation beyond the 56-week trial treatment
period for modelling. Both trials included in this health economic
analysis were funded by the manufacturers of the intervention.
We judged the quality of the evidence for this outcome to be high.
Adverse events
Meta-analysable data on adverse events were available from 15
trials (Allergan 2015; Anand 2006; Aurora 2007; Aurora 2010
(PREEMPT 1); Blumenkron 2006; Chankrachang 2011; Diener
2010 (PREEMPT 2); Elkind I 2006; Hollanda 2014; Hou 2015;
Jabbari 2014; Petri 2009; Relja 2007; Saper 2007; Silberstein
2000). Two of these trials stated that no adverse events occurred
(Anand 2006; Blumenkron 2006). Of the remaining trials five had
unclear or inadequate reporting (Cady 2008; Cady 2014; Freitag
2008; Jost 2011;Mazza 2016), and three did not list adverse events
as an outcome in theirmethods sections (Barrientos 2003; Lauretti
2014; Vo 2007).
The risk ratio of any adverse event reported by 13 trials involving
3325 participants was 1.28 (95% CI 1.12 to 1.47, I2 = 63%;
Analysis 1.6; Figure 6). For ease of interpretation we converted
this into a relative risk reduction (RRR) of treatment with placebo
over treatment with botulinum toxin of 30%. The number needed
to treat for an additional harmful outcome (NNTH), calculated
using the total adverse event data, was 7 (95% CI 6 to 9). In
the placebo group 47 in every 100 people experienced an adverse
event, and in the treatment group 60 in every 100 treated people
experienced an adverse event.
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Figure 6. Forest plot of comparison 1. Botulinum toxin type A versus placebo, outcome: 1.6 Total adverse
events
We extracted all subtypes of event to ensure any important unfore-
seen safety issues could be analysed in this review. We identified
no such issues. We analysed four pre-specified adverse event types.
Seven trials involving 1867 participants reported data for ble-
pharoptosis with the higher risk in the botulinum toxin arm (RR
7.29, 95% CI 3.18 to 16.73, I2 = 0%; Analysis 1.7).
Six trials involving 2602 participants reported muscle weakness
and showed an increased risk in the botulinum treated arm with
a RR of 13.67 (95% CI 6.73 to 27.75, I2 = 0%; Analysis 1.8).
For neck pain, participants in the treatment arm were around
three times more likely to experience the event than participants
receiving placebo (RR 2.98, 95% CI 2.06 to 4.32, I2 = 0%;
Analysis 1.9), with six trials in 2424 participants reporting this
outcome.
Injection site pain was twice as likely to occur in the treated group
than the placebo group (RR 2.10, 95% CI 1.02 to 4.32, I2 = 0%;
Analysis 1.10). Eight trials involving 1332 participants reported
this final adverse event type.
The RR of adverse events considered by trialists to be treatment-
related in six trials with 2893 participants was 2.18 (95% CI 1.73
to 2.75, I2 = 56%; Analysis 1.11).
Four trials (N = 2248) administered more than one cycle of
injections and provided data on withdrawals due to adverse
events (Aurora 2007; Aurora 2010 (PREEMPT 1); Diener 2010
(PREEMPT 2); Relja 2007). Participants were three times more
likely to withdraw due to adverse events in the treated group than
in the placebo group (RR 3.28, 95% CI 1.52 to 7.07, I2 = 0%;
Analysis 1.12). The overall proportion withdrawn due to adverse
events in the treated groups was 2%.
We judged the quality of the evidence for the total adverse events
outcome to be moderate. We downgraded by one level for im-
precision, as many of the included trials were small and new trial
evidence would be likely to change the result.
Planned subgroup analyses
Insufficient data were available to carry out any of the planned
subgroup analyses on the primary outcome measure.
Botulinum toxin versus other agent: established
prophylactic agents
See: Summary of findings 2
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Three trials with 178 participants made comparisons with other
established agents for migraine prophylaxis. Two trials compared
100 units fixed dose plus an optional 100 units or less of Botox
with topiramate, using maximum dose of 200 mg per day in both
cases (Cady 2011; Mathew 2009). Blumenfeld 2008 compared
100 units or less of Botox with sodium valproate 250 mg twice
daily. Fourteen of the 59 participants involved in Cady 2011 had
episodic migraine; all other participants across all three trials had
chronic migraine.
Primary outcome: number of migraine days per month
Only one trial recorded the primary outcome for this review.
Mathew 2009 stated that the number of migraine days decreased
for both groups with no statistically significant difference between
the Botox-treated group and the topiramate-treated group. All
participants in this trial had a diagnosis of chronic migraine.
We judged the quality of the evidence for the change in number
of migraine days to be very low. We downgraded the quality of
the evidence by one level for risk of bias due to unclear or high
risk for selection, performance, detection and attrition bias. We
downgraded by two further levels for imprecision due to small trial
size, meaning that new trial evidence would be likely to change
the result, and a fourth level for imprecision, as only a narrative
description of the outcome results was provided.
Secondary outcomes
Number of headache days per month
Twoof the included trials (Blumenfeld 2008;Cady 2011) recorded
number of headache days per month for participants. Only
Blumenfeld 2008 reported meta-analysable data (P = 0.55), but
both reported a decrease in number of headache days with no sta-
tistically significant between-group difference.
We judged the quality of the evidence for the change in number
of headache days to be very low. We downgraded the quality of
the evidence by one level for risk of bias due to unclear or high
risk for selection, performance, detection and attrition bias. We
downgraded by two further levels for imprecision due to small
trial size, meaning that new trial evidence would be very likely to
change the result.
Number of migraine attacks per month
Number of migraine attacks were not recorded by any of the trials
included in this comparison.
Headache intensity measures
Two trials reported headache intensity measures (Blumenfeld
2008; Mathew 2009). Neither used the VAS discussed for other
comparisons in this review. Both trials used a five-point scale for
migraine severity. Blumenfeld 2008 reported that no differences
between the groups were found, but did not report any statistical
analysis for this finding, nor did they provide sufficient data to do
this. Mathew 2009 showed a small difference in favour of topira-
mate of 0.40 (95% CI 0.79 to 0.01) points, though participant
numbers had to be used from other diary outcome measures as
they were not clear for this outcome.
We judged the quality of the evidence for the five-point migraine
severity scale scores to be very low. We downgraded the quality of
the evidence by one level for risk of bias due to unclear or high
risk for selection, performance, detection and attrition bias. We
downgraded by two further levels for imprecision due to small
trial size, meaning that new trial evidence would be very likely to
change the result.
Headache index
A single trial recorded headache index scores and reported no sig-
nificant between-group differences for this outcome (Blumenfeld
2008).
Duration of migraine
None of the trials included in this comparison recorded duration
of migraine.
Use of rescue medication
Only one trial recorded data for this outcome measure, and their
data showed no significant between-group difference (P = 0.2;
Mathew 2009).
Patient and clinician global impression scales
Two small trials reported analysable data for the MIDAS (
Blumenfeld 2008; Mathew 2009; Analysis 2.1), but they showed
no significant difference in change scores between the established
drug treatments and injection with Botox (P = 0.80, N = 101).
Physician global assessment, HIT-6 and MIDAS scores were all
reported for the participants in Cady 2011, but statistical analysis
was limited to statements that the differences between the groups
were not statistically significant for any of these measures.
We judged the quality of the evidence for the global impression of
disease measured using MIDAS scores to be very low. We down-
graded the quality of the evidence by one level for risk of bias due
to unclear or high risk for selection, performance, detection and
attrition bias. We downgraded by two further levels for impreci-
sion due to small trial sizes meaning that new trial evidence would
be very likely to change the result.
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Generic and disease-specific quality-of-life rating scales
Blumenfeld 2008 was the only trial to record a quality-of-life out-
come measure. They used the 24-Hour Migraine QoL question-
naire. They did not report full data nor discuss between-group
comparisons in the published material.
Cost effectiveness
We did not identify any cost-effectiveness analyses for this com-
parison.
Adverse events
Two trials reported adverse event data for 114 participants and
analysis of the risk ratio of experiencing any adverse event
(Blumenfeld 2008; Mathew 2009) and of experiencing a treat-
ment-related adverse event was possible. In the botulinum toxin
group 73 in every 100 people experienced any adverse event, and
in the alternative oral treatment group 86 in every 100 treated
people experienced an adverse event; the difference in risk between
groups of any adverse event was not statistically significant (P =
0.67, Analysis 2.2). The RR for the number of treatment-related
adverse events was 0.76 (95% CI 0.59 to 0.98; I2 = 0%, Analysis
2.3) in favour of Botox. This translates to a RRR of 24% in the bo-
tulinum toxin arm. There was also a difference in favour of Botox
in the RR of withdrawing due to adverse events of 0.28 (95% CI
0.10 to 0.79; I2 = 0%), which is a RRR of 72% (Analysis 2.4).
The proportion dropping out from the botulinum toxin-treated
armwas low at 7%. These results suggest that injection with Botox
is more tolerable than treatment with the two established agents,
topiramate and sodium valproate.
We judged the quality of the evidence for the total adverse events
outcome tobe very low.Wedowngraded the quality of the evidence
by one level for risk of bias due to unclear or high risk for selection,
performance, detection and attrition bias. We downgraded by two
further levels for imprecision due to small trial sizes, meaning that
new trial evidence would be very likely to change the result.
Botulinum toxin versus other agent: histamine
Insufficient informationwas available tomake sensible judgements
about the relative safety and effectiveness of botulinum toxin versus
histamine for prophylactic treatment of migraine. For a summary
of the existing evidence for this comparison see Appendix 2.
Botulinum toxin versus clinically relevant different
dose of botulinum toxin
Insufficient informationwas available tomake sensible judgements
about the dose-response relationship of botulinum toxin treat-
ment to migraine. For a summary of the existing evidence for this
comparison see Appendix 3.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Botulinum toxin type A compared to other established prophylactic agent for the prevention of migraine in adults
Patient or population: adults with migraine
Setting: outpat ient clinic
Intervention: botulinum toxin type A
Comparison: other established prophylact ic agent
Outcomes Result with other estab-
lished prophylactic agent
Result with botulinum toxin
type A
Relative effect
(95% CI)
of participants
(trials)
Quality of the evidence
(GRADE)
Number of m igraine days
per month: chronic migraine
only
One trial using topiramate in its comparison arm reported
narrat ively on this outcome stat ing that there was no
signif icant dif f erence between groups
- 43
(1 RCT)
⊕©©©
Very lowa,b,c
Number of headache days
per month
The mean number of
headache days was 6.6
days
MD 1 day lower
(4.3 lower to 2.3 higher)
- 59
(1 RCT)
⊕©©©
Very lowa,b
Number of m igraine attacks
per month
- - - - -
Headache intensity mea-
sure
assessed with 5-point
scale, 5 being severe, 1 be-
ing mild: chronic migraine
only
The mean severity of m i-
graine was 2.3 points
MD 0.4 points lower
(0.79 lower to 0.01 lower)
- 46
(1 RCT)
⊕©©©
Very lowa,b
Global impression of dis-
ease
assessed with Migraine im-
pact and disability assess-
ment scores
The mean global impres-
sion of disease ranged f rom
9.8 to 16.5 points
MD 4.3 points higher
(28 lower to 37 higher)
- 101
(2 RCTs)
⊕©©©
Very lowa,b
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Total number of part ici-
pants experiencing an ad-
verse event
Trial populat ion RR 0.76
(0.59 to 0.98)
114
(2 RCTs)
⊕©©©
Very lowa,b
862 per 1000 724 per 1000
(319 to 1000)
CI: conf idence interval; MD: mean dif ference; RCT : randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded once due to risk of bias: unclear or high risk for select ion, performance, detect ion and attrit ion bias.
bDowngraded twice due to imprecision: trial sizes small, new trial evidence likely to change result .
cDowngraded once due to imprecision: narrat ive descript ion only.
2
6
B
o
tu
lin
u
m
to
x
in
s
fo
r
th
e
p
re
v
e
n
tio
n
o
f
m
ig
ra
in
e
in
a
d
u
lts
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
D I S C U S S I O N
Summary of main results
Efficacy
Uncertainty remains around the estimate of effect of botulinum
toxin on our primary outcome, the number of migraine days ex-
perienced per month for people with chronic migraine. The data
showed a reduction of 3 days (-3.1, 95% CI -4.7 to -1.4, low-
quality evidence) for this outcome measure over and above the
placebo effect. This result did not prove to be reliable when tested
using sensitivity analysis for effects of small trial bias. We had
greater confidence in the more conservative estimate of a 2-day
improvement (-2.0, 95% CI -2.8 to -1.1, moderate-quality evi-
dence). This came only from trials at low risk of bias from trial
size (Aurora 2010 (PREEMPT 1); Diener 2010 (PREEMPT 2)).
All participants included in this analysis had chronic migraine
with a high baseline frequency of around 20 days per month. The
data showed a large placebo effect on their symptoms of improve-
ment of over 6 days. Just how clinically meaningful this result is
remains difficult to determine. It does approach reductions ob-
served in topiramate versus placebo trials of 3.7 (Diener 2007)
and 1.5 migraine days per month (Silberstein 2007). Recent trials
of the novel anti-calcitonin gene-related peptide (CGRP) mono-
clonal antibody treatment option found a reduction of around 2
headache days permonth (Giamberardino 2016; Silberstein 2017)
and up to 2 migraine days, depending on dose, when compared
with placebo (Goadsby 2017). This is in keeping with previous
trials with prophylactic agents. Insufficient data were available to
draw conclusions for the episodic migraine population from this
outcome measure as we identified only a single trial experimenting
with doses well below those recommended by the UK national
guidelines (Elkind I 2006). We had hoped to use subgroup analy-
sis to investigate the effect of including people with the additional
medication overuse headache diagnosis but we could not carry out
this analysis as we did not identify sufficient data to create the
subgroups.
Secondary outcomemeasures were inconsistent in showing a treat-
ment effect. Botulinum toxin was better than placebo in reduc-
ing the number of days with any type of headache by two days
per month, based on evidence judged to be high-quality. We did
not observe any significant difference from placebo for number of
migraine attacks per month in those with episodic migraine (low-
quality evidence); this may be as a result of variable parameters in
this outcome measure, which was generally poorly defined in trial
reports. There was a reduction in favour of botulinum treatment
of migraine severity on a visual analogue scale of 3 cm on a 10
cm scale (very low-quality evidence), compared with placebo. This
difference is in excess of the minimal clinically important differ-
ence of between 1.0 cm and 1.4 cm reported for other chronic
pain conditions (Hawker 2011). The migraine severity analysis
included trials with episodic migraine populations and the effect
size was shown to be similar to that seen for chronic migraineurs.
There was no significant heterogeneity between the two popula-
tion subgroups. All trials contributing to the analysis of migraine
severity were small and so the quality of this evidence is very low
and likely to change with the emergence of new evidence from
larger, higher-quality trials. If all trials had used a uniform out-
come measure for severity of migraine, we could have included
an additional 2298 participants in our analyses for this outcome,
giving much greater confidence in the results.
None of the included trials provided headache index, duration of
migraine, or use of rescue medication data from which we could
carry out meta-analyses. Patient and clinician-reported global as-
sessment scales and quality-of-life scales were underused. When
they were incorporated into trials, they were poorly reported so
no meta-analyses could be performed.
It was not possible to carry out any analysis on migraine or
headache frequency outcomes, severity of migraine, headache in-
dex, duration of migraine or the use of rescue medication outcome
measures for head-to-head comparisons between botulinum toxin
and other established agents due to lack of available data. MIDAS
scores for 101 participants from two small trials, one comparing
Botox with topiramate and one with sodium valproate were avail-
able and these showed no significant between-group difference (P
= 0.8, very low-quality evidence). Because of the small number
of trials and participants contributing towards this estimate, the
apparent comparable prophylactic effect of botulinum toxin with
established oral agents must be treated with caution. No data were
available to assess the effects of the treatments on quality of life.
Very few data were available to analyse the effectiveness of one
dose of Botox over another. Further evidence is required to explore
possible non-inferiority of lower doses of Botox than the 155 units
recommended in the guidance (NICE 2012a). We were unable to
make comparisons between different doses of the other botulinum
toxin preparations under investigation in trials included in this
review due to a lack of meta-analysable data.
Safety and tolerability
Data from 23 trials included in this review reported few adverse
events as a result of treatment with botulinum toxin. There was
an increased risk of adverse events in the botulinum toxin group
compared with placebo (moderate-quality evidence), but these
events were not serious and were transient.
Our analysis showed no statistically significant difference between
total number of participants experiencing any adverse event from
treatment with botulinum toxin compared with topiramate (100
mg/day to 200mg/day) and sodium valproate (250mg twice daily)
but we judged this evidence to be of very low-quality. We analysed
the relative tolerability of common side effects using withdrawal
due to adverse event data from Mathew 2009 and Blumenfeld
2008 and this showed a relative risk reduction in favour of Botox
of 72%.
27Botulinum toxins for the prevention of migraine in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
The withdrawal rate due to adverse events for all six trials (N
= 1312) administering more than one round of Botox, irrespec-
tive of the comparison arm type, was only 3%. The data sets
for comparisons with other prophylactic agents were small. How-
ever, published withdrawal rates from other prophylactic agents
were higher at 20% for topiramate and 12% for sodium valproate
(Linde 2013c; Linde 2013d). Adherence to oral migraine preven-
tative medications is known to be poor (Hepp 2015). The low
withdrawal rate from botulinum toxin suggests that participants
are either more able or more willing to tolerate this treatment than
the oral alternatives.
Insufficient evidence was available to allow full analysis of any
dose-response relationship for adverse events.
Cost
The cost-effectiveness analysis for Botox carried out using data
from the two large PREEMPT trials estimated a treatment cost
of GBP 18 per headache day avoided. Other oral preventative
strategies are currently much cheaper (BMA/RPS 2014; Rothrock
2014).
Overall completeness and applicability of
evidence
Reporting was generally poor, with only six of 28 trials reporting
data on the primary outcome measure in a usable format and
an additional five providing data for number of migraine attacks.
These twomeasures are recommended as primary outcomes in the
guidelines produced by the International Headache Society (Tfelt-
Hansen 2012) and should be fully reported to allow individual
trials to be placed in the context of the totality of the evidence.
A large proportion of the recorded data was missing from the
published reports of the included trials. When an outcome had
shownno significant between-group difference, data and statistical
analysis were frequently omitted from articles and in its place trial
authors gave a narrative description of the results.
Number of migraine attacks was commonly used as the primary
outcome, particularly in trials run before the publication of the
PREEMPT trials. Use of this measure may mask a change in du-
ration and severity of migraine attacks, which may represent a
more important outcome for people with migraines. More sensi-
tive measures would be number of days or hours spent with mi-
graine per month coupled with a measure of intensity. Another
problem with focusing on migraine attacks is the common failure
to define what is meant by the term, leading to variation depend-
ing on the definition used. The definition of an attack should in-
clude the required interval to separate one attack from the next,
any maximum attack length or sleep interval that causes a second
attack count to be started, and the baseline duration of migraine
for the population under consideration. It is these variables that
lead to difficulty in interpreting the data describing migraine at-
tacks.
Neither efficacy nor safety data were available for long-term treat-
ment with botulinum toxin. The longest treatment period in any
of the trials included in this review was three treatments with three
months between treatments. Therefore, we cannot evaluate the
efficacy and safety of botulinum toxin over a period longer than
nine months.
Evidence concerning the efficacy implications of the inclusion
of people with medication overuse headache was not available.
Half of the trials in this review did not report whether or
not they had included these types of participants. Of those
that did describe medication overuse headache in their eligibil-
ity criteria, 11 trials excluded it (Anand 2006; Aurora 2007;
Barrientos 2003; Blumenfeld 2008; Cady 2011; Freitag 2008;
Hollanda 2014; Petri 2009; Relja 2007; Saper 2007; Silberstein
2000), one included only people with this additional diagno-
sis (Millán-Guerrero 2009), and two randomised both people
with and without it (Aurora 2010 (PREEMPT 1); Diener 2010
(PREEMPT 2)). Pooled data for the two PREEMPT trials for the
chronic migraine plus medication overuse subgroup (N = 904)
showed that the difference between groups for both migraine and
headache day frequencies was 2 days (P < 0.001) in favour of treat-
ment with Botox (Silberstein 2013). These results match that gen-
erated in this review for combined populations with and without
medication overuse headache. It would appear from these data that
the inclusion of people with medication overuse does not change
the effectiveness of Botox for prophylactic treatment of migraine.
The changing definitions of chronic migraine and medication
overuse headache will have caused a small shift over time in the
populations included in the various trials. Given that adequate
descriptions of the populations were commonly not provided and
that the trial numbers in the primary outcome analyses were low,
we were unable to carry out subgroup analyses for these variables.
The shift may have contributed to the significant heterogeneity
seen in many of the analyses.
No randomised evidence was available for botulinum toxin sero-
types other than type A, so no comparisons were possible.
Quality of the evidence
See: Characteristics of included studies tables, ’Risk of bias’ sum-
mary tables, Figure 2, Figure 3, Summary of findings for the main
comparison and Summary of findings 2.
The quality of the trials included in this review was mixed. We
considered only the two PREEMPT trials to be at low risk of bias
for trial size. More than 50% of trials, including all of those with
sample sizes not considered to be high risk, were commercially
sponsored. All trials were double-blind, as stated in our inclusion
criteria, but only half provided adequate details of the methods
used to ensure blinding of participants or assessors, or both. Selec-
tive reporting of outcomes was also a major flaw, which could have
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a significant impact on our results. Most data that were omitted
from reports were for outcomes for which the results were often
described in a narrative fashion as showing no significant differ-
ence between groups. It could be that addition of all of these miss-
ing data would alter the significance of the results.
In the placebo comparison, we rated the quality of the evidence
for the primary outcome as low for chronic migraine and very
low for the pooled population estimate. We downgraded once due
to unexplained heterogeneity and once due to imprecision caused
by small trials in both cases. We also downgraded the primary
outcome for the pooled population due to indirectness, as the
episodic migraine subgroup had insufficient data to allow distinct
analysis of the two groups and combining the data would have
clouded the clinical relevance of the result.We upgraded the results
of the sensitivity analysis carried out for the chronic migraine
population only for the primary outcome measure to moderate-
quality, as we excluded the small trials. We considered number
of headache days and risk of treatment-related adverse events to
be of high and moderate quality respectively, but we judged all
other outcomes for the placebo comparison and all outcomes for
the comparison with established agents to be of low or very low-
quality. Most commonly, we downgraded these outcomes due to
the small size of the data set, significant unexplained heterogeneity,
unclear or high risk of bias, and poor reporting of non-significant
data.
Potential biases in the review process
We included trials of all preparations and sero-types of botulinum
toxin, which led to the inclusion of two preparations, HengLi and
Prosigne, for which we could find little information. In particular
we would have liked details of relative potency and whether they
are the same preparation sold under two different brandings (as
they are manufactured at the same site). The uncertainty about
the identity of the toxins places a question over the validity of
the resulting trial data and whether or not it was appropriate to
include such preparations.
Agreements and disagreements with other
studies or reviews
The most recently published guidance from the American
Academy ofNeurology bases its recommendation for treating peo-
ple with chronic migraine upon the two large PREEMPT trials
(Simpson 2016). While we agree with the findings that these large
scale phase III trials provide evidence supporting the use of bo-
tulinum toxin type A in chronic migraine, their results must be
placed within the context of the totality of evidence for this treat-
ment.
Botulinum toxin type A is recommended as an option for the
prophylaxis of chronic migraine only. On conversion to episodic
migraine, UK guidelines state that people are no longer eligible for
treatment (NICE 2012a). It seems biologically implausible that
botulinum toxin would be efficacious in chronic migraine but not
in high-frequency, episodic migraine. But, we were unable to find
sufficient evidence to contradict this guidance.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
For people with migraine
Botulinum toxin type A reduces migraine days per month by two
days more than placebo in chronic migraine, based on moderate-
quality evidence from two large trials. We also saw a reduction of
30%more in the severity of migraines in the treated group than in
the placebo group but this was based on very low-quality evidence
from four small trials in chronic and episodic migraine, so our
confidence in this estimate is low. There is inadequate evidence to
support its use in episodic migraine. The results of this review are
applicable up to the first nine months of treatment, after which no
evidence was available to determine long-term treatment effects
or safety.
For clinicians
Our conclusions are in line with current clinical guidelines. We
could not draw conclusions about the order in which botulinum
toxin and other prophylactic agents should be used to treat mi-
graine as there was insufficient evidence on comparative efficacy
and safety.
For policy makers
We did not identify sufficient data to assess whether botulinum
toxin treatment should cease on reduction of headache days below
the current 15-day chronic migraine cut off (NICE 2012a). There
are not enough data to support or refute the use of botulinum
toxin injections for episodic migraine.
For funders of the intervention
Cost effectiveness of this treatment is unclear. Data were avail-
able to show the price per quality adjusted life year gained (GBP
15,028) from treatment with botulinum toxin compared with
placebo. Treatment costs are high relative to other treatments and
no direct comparisons have been made to evaluate the cost effec-
tiveness of the small degree of efficacy shown by the botulinum
toxin treatment relative to oral prophylactic alternatives or to lower
dose treatments with botulinum toxin.
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Implications for research
General
Large trials with distinct and well-defined subgroups are required
to determine the effects of botulinum toxin in migraine overuse
headache and episodic migraine, and to investigate dose response,
and efficacy compared to other active treatments. Testing of the
validity of the requirement for 15ormoremigraine days permonth
for treatment with botulinum toxin was not possible, as we failed
to identify enough evidence for people with episodic migraine.
Design
The design and reporting of future trials should be carried out
in accordance with the guidance of the International Headache
Society (Tfelt-Hansen 2012). trials must be randomised, double-
blind and placebo-controlled to determine effects and dose re-
sponse, and ideally comparisons with other treatments should also
include a placebo arm. Trials should use and fully report standard
outcomes including quality-of-life measures, and consider the use
of reduction in number of migraine days as their primary outcome
measure (Silberstein 2008). Longer-term trials (longer than nine
months) are needed for evidence of long-term safety and tolera-
bility.
Measurement
Use of more sensitive outcome measures would enable trials to
pick up reduction in migraine days and duration. Trials with bo-
tulinum toxin should be performed over longer than nine months
to determine the efficacy and safety of treatment over extended pe-
riods. Longer trials would also allow analysis of the time to discon-
tinuation, which is known to be short for first-line, oral prophy-
lactic medication and decreases further as people with migraine
cycle through multiple prophylactics (Hepp 2016).
Other
All trials should be reported using CONSORT guidelines (Schulz
2010).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Allergan 2015
Methods Randomised, double-blind, placebo-controlled, parallel-group, sites unclear
2 treatments, 12 weeks FU per treatment
Fixed injections of Botox vs placebo
Assessments carried out at baseline and at week 12, week 22, week 24
Participants Inclusion criteria: history of CM for at least 6 months prior to the screening visit; ≥ 15
headache d during the 4-week screening period; ≥ 4 headache episodes lasting ≥ 4 h
and ≥ 50% of headache days were migraine
Exclusion criteria: conditions causing chronic facial pain such as temporomandibular
disorder and fibromyalgia; use of headache prophylaxis medication within 4 weeks of the
screening visit; diagnosis of myasthenia gravis, Eaton-Lambert Syndrome, amyotrophic
lateral sclerosis; previous use of any BTX of any sero-type for any reason; skin infections
or acne that would interfere with the injection sites; acupuncture, TENS, cranial trac-
tion, dental splints for headache, nociceptive trigeminal inhibition, occipital nerve block
treatments, or injection of anaesthetics/steroids within 4 weeks of screening
N = 52, mean age 43, M 13/F 39
CM only eligible, MOH eligible Y/N not reported
Baseline disease characteristics not stated
Interventions Intervention: Botox 155 U, number and location of injection sites not reported
Control: matched placebo injections
Outcomes Assessment of CM impacts questionnaire
Assessment of CM symptoms questionnaire
HIT-6
Migraine-specific questionnaire
Notes Protocol NCT01833130
Funder: Allergan, Inc., Irvine, California (manufacturer of Botox)
No diary data recorded
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not stated
Allocation concealment (selection bias) Unclear risk Method not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind: subject, caregiver and in-
vestigator blind, participant blinded with
matched placebo injections; no methods
given for blinding of personnel
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Allergan 2015 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind: no methods given for blind-
ing of personnel
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropouts at 56%
Selective reporting (reporting bias) Unclear risk Not yet published, information and data
from trial registry only
Study size High risk < 50 participants per treatment arm
Anand 2006
Methods Randomised, double-blind, placebo-controlled, parallel-group, multi-site
Single treatment, 3 months FU
Fixed injections of Botox vs placebo injections
Assessments at baseline and 1 month and 3 months post-treatment
Participants Inclusion criteria: aged 18-50 years; history of severe or moderately severe migraine
with/without aura (criteria used IHS 1988); 4-8 attacks per month or stable headache
frequency and severity for the past 1 year; users of prophylactic medication such as beta-
blockers and flunarizine were not excluded
Exclusion criteria: cardiovascular disease, peripheral venous disease and seizures; preg-
nancy or lactation; abused drugs or alcohol in the preceding 2 years; > 15 days headache
per month or history of complicated migraine
N = 32, mean age not stated, M 8/F 24
CM excluded, MOH excluded
Baseline disease characteristics not stated
Interventions Intervention: Botox 50 U, 10 injections (3 pericranial muscle regions)
Comparator: matched placebo injections
Outcomes Number of headache days
Number of migraine days
Number of migraine attacks
Proportion of responders
Use of rescue medication
Severity of migraine
Overall treatment effect
Quality-of-life questionnaire
Adverse events
Notes Funding source unclear
Diary period 28 days
Risk of bias
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Anand 2006 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not stated
Allocation concealment (selection bias) Unclear risk Method not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind: participant blinded with
matched placebo injections no methods
given for blinding of personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind: no methods given for blind-
ing of personnel
Incomplete outcome data (attrition bias)
All outcomes
Low risk Appears to be no dropouts
Selective reporting (reporting bias) Unclear risk Data reported in unusual format
Study size High risk < 50 participants per treatment arm
Aurora 2007
Methods Randomised, double-blind, placebo-controlled, parallel-group, multi-site
3 treatments, 90 days FU per treatment
’Follow the pain’ (fixed for occipitalis) injections of Botox vs placebo injections
Assessments carried out at baseline and 30 days, 60 days and 90 days post-treatment for
each treatment
Participants Inclusion criteria: aged 18-65 years; average of at least 4 moderate-to-severe migraine
episodes but ≤ 15 headache d/month (criteria used ICHD-I); migraine episodes for at
least 1 year prior to enrolment and first diagnosed before age 50 years; stable medical
condition; chronic medication regimens, if any, stable including migraine prophylactic
medications ≥ 3 months prior to baseline period; willing and able to stay on current
medications during the course of the study
Exclusion criteria: any medical condition or used any agent that may have put them at
risk with exposure to this formulation of Botox; infection or skin problem at any of the
injection sites or a known allergy or sensitivity to the trial medication or its components;
history of “complicated” migraine; inadequate response (in the investigator’s opinion) to
≥ 2 prophylactic treatments after an adequate trial; psychiatric problems severe enough
to interfere with trial implementation; previous therapy with BTX of any sero-type,
or injection of anaesthetics or steroids into the trial-targeted muscles during the 30
d immediately prior to initiation baseline period; overusing or abusing symptomatic
medication, alcohol, or drugs; concurrent chronic use or chronic use in the 3 months
prior to the screening period of muscle relaxants; concurrently participating in another
investigational trial or participated in such a trial in the 30 d immediately prior to
baseline; condition that in the investigator’s opinion might have put person at significant
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Aurora 2007 (Continued)
risk, might have confounded the trial or might have interfered with participation in
the trial; pregnancy, breastfeeding, or planning a pregnancy during the trial; unable or
unwilling to use a reliable form of contraception during the trial
N = 369, mean age 45 years, M 40/F 329
CM excluded, MOH excluded
Years since diagnosis of migraine 23 years, number migraine attacks during baseline diary
period 6.5
Interventions Intervention: Botox 110-260 U, 23-58 injections (frontal/glabellar 25-40 U, occipitalis
20 U, temporalis 20-50 U, masseter optional; 0-50 U, trapezius 20-60 U, semispinalis
10-20 U, splenius capitis 10-20 U)
Comparator: matched placebo injections
Outcomes Number of headache days
Number of migraine attacks
Proportion of responders
Use of rescue medication
Severity of migraine
Patient global assessment
Adverse events
Notes Trial includes 30-day, single-blind, placebo run-in phase to identify placebo responders
and placebo non-responders
Funder: Allergan, Inc., Irvine, California (manufacturer of Botox)
Diary period 30 days
Contacted without response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation used
Allocation concealment (selection bias) Low risk Neither the investigator nor the participant
knew the treatment stratum or random
block size. An individual with no other trial
involvement reconstituted 3 vials of trial
medication and drew the trial drug into the
syringes for administration. The syringes
were then given to the investigator for in-
jection
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind: participant blinded with
matched placebo injections, an individual
with no other trial involvement reconsti-
tuted 3 vials of trial medication and drew
the trial drug into the syringes for admin-
istration. The syringes were then given to
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Aurora 2007 (Continued)
the investigator for injection
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind: an individual with no other
trial involvement reconstituted 3 vials of
trial medication and drew the trial drug
into the syringes for administration. The
syringes were then given to the investigator
for injection
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Dropout rate per group not given
Selective reporting (reporting bias) Unclear risk Data not provided for secondary outcomes
- narrative description of results only
Study size Unclear risk 50-199 participants per arm
Aurora 2010 (PREEMPT 1)
Methods Randomised, double-blind, placebo-controlled, parallel-group, multi-site
2 treatments, 12 weeks FU per treatment
Fixed plus optional ’follow the pain’ injections of Botox vs placebo
Assessments carried out at baseline and 4 weeks, 8 weeks and 12 weeks after each treat-
ment out to 24 weeks, (further 3 treatments and 32 weeks of assessments in OL phase)
Participants Inclusion criteria: aged 18-65 years; migraine meeting the diagnostic criteria listed in
ICHD-II (2004), migraine, with the exception of “complicated migraine” (i.e. hemi-
plegic migraine, basilar-type migraine, ophthalmoplegic migraine, migrainous infarc-
tion); provided diary data on ≥ 20 of 28 days during baseline; ≥15 headache days with
each day consisting of≥ 4 h of continuous headache and with ≥ 50% of days being mi-
graine or probable migraine days during baseline period;≥ 4 distinct headache episodes,
each lasting ≥ 4 h
Exclusion criteria: any medical condition that might put participants at increased risk
if exposed to onabotulinumtoxinA (e.g. neuromuscular diseases); other primary or sec-
ondary headache disorders; use of any headache prophylactic medication within 28 days
before start of baseline; Beck Depression Inventory score of > 24 at baseline; fibromyal-
gia; psychiatric disorders that could have interfered with trial participation; previous
exposure to any botulinum neurotoxin sero-type; women of childbearing potential must
have had a negative urine pregnancy test prior to each injection and have been using a
reliable means of contraception; investigators were trained not to enrol participants who
frequently used opioids as acute pain medication
N = 679, mean age 42 years, M 85/F 594
CM only eligible, MOH eligible Y/N 462/217
Years since onset of CM 20, number of migraine days during baseline diary period 19
Interventions Intervention: Botox 31 fixed injections, total 155 U, followed by 8 optional follow the
pain injections, total 40 U. PREEMPT paradigm: frontalis 20 U in 4 sites; corrugator
10 U in 2 sites; procerus 5 U in 1 site; occipitalis 30 U in 6 sites up to 40 U in 8 sites;
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Aurora 2010 (PREEMPT 1) (Continued)
temporalis 40 U in 8 sites up to 50 U in 10 sites; trapezius 30 U in 6 sites; cervical
paraspinal 20 U in 4 sites
Control: matched placebo injections
Outcomes Number of headache days
Number of migraine days
Number of migraine attacks
Proportion of responders (≥ 50% reduction in migraine)
Use of rescue medication
HIT-6
Headache impact score
Migraine specific quality of life questionnaire
HRQoL
Adverse events
QALYs
Incremental cost-effectiveness ratio
Notes Protocol NCT00156910
Funder: Allergan, Inc., Irvine, California (manufacturer of Botox)
Diary period 28 days
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation se-
quence
Allocation concealment (selection bias) Low risk Upon randomisation subject number was
linked to next randomisation number
grouped within strata for that site, site was
then notified of medication kit assigned to
that number
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind: placebo arm, prepacked
medication kits with number for assign-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind: placebo arm, prepacked
medication kits with number for assign-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawals balanced across groups and
adjusted LOCF method used
Selective reporting (reporting bias) Low risk All expected outcomes reported
Study size Low risk ≥ 200 participants per treatment arm
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Barrientos 2003
Methods Randomised, double-blind, placebo-controlled, parallel-group, sites unclear
Single treatment , 90-day FU
Fixed injections of Botox vs placebo injections
Assessments carried out at baseline and 30, 60 and 90 days post-treatment
Participants Inclusion criteria: history ≥ 1 year of EM, with/without aura (criteria used ICHD-I),
aged between 19 and 65 years
Exclusion criteria: > 15 headaches per month; a history of complicated migraine (with
aura); previous treatment with BTX of any sero-type; substance abuse, including overuse
of analgesics and migraine treatments; current prophylactic treatment for migraine, and
caffeine. Pregnancy or breastfeeding; any condition, which, in the opinion of the inves-
tigator, could compromise the results of the trial
N = 30, mean age 41, M 6/F 24
CM excluded, MOH excluded
Years since diagnosis of migraine 16 years, number of migraine attacks 5 during baseline
diary period
Interventions Intervention: Botox 50 U, 15 injections (temporalis, 10 U total at 2 sites; frontalis, 10
U total at 4 sites; glabellar, 8 U total at 4 sites; procerus, 2 U at 1 site; trapezius, 10 U
total at 2 sites; splenius capitis, 10 U total at 2 sites)
Comparator: matched placebo injections
Outcomes Number of migraine attacks
Duration of migraine
Use of rescue medication
Participant- and investigator-related 6-point global effectiveness evaluation scale
Adverse events
Notes Funder: Allergan, Inc., Irvine, California (manufacturer of Botox)
Diary period 30 days
Uncontactable
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not stated
Allocation concealment (selection bias) Unclear risk Method not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind: participant blinded with
matched placebo injections no methods
given for blinding of personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind: no methods given for blind-
ing of assessors
48Botulinum toxins for the prevention of migraine in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed
Selective reporting (reporting bias) Unclear risk Group means reported without standard
errors or standard deviations
Study size High risk < 50 participants per treatment arm
Blumenfeld 2008
Methods Randomised, double-blind, active control, parallel-group, single-site
2 rounds of treatment, 3 months FU for first treatment and 6 months for second
Follow the pain injections of Botox plus placebo vs sodium valproate tablets plus placebo
injections
Assessments carried out at baseline and 1 month, 3 months, 6 months and 9 months
post-treatment
Participants Inclusion criteria: EM or CM (criteria used for diagnosis not clear, ICHD-II cited in
Background); aged between 18-65 years with EM (defined for this trial as≥ 3migrainous
headaches but < 15 d/month) or CM (defined for this trial as migrainous headaches on
≥ 15 d/month); stable headache severity and pattern
Exclusion Criteria: any medical condition or use of any agent that might expose them
to risk if they received Botox; prior exposure, allergy, or sensitivity to any component
of BTX of any sero-type or to divalproex; skin problems, infections, profound atrophy,
or excessive weakness in the target areas of the injection sites; concomitant prophylactic
migraine therapy or a history of overusing symptomatic medication; headache disorders
outside of the classification strata outlined; pregnancy, breastfeeding, or planning a preg-
nancy during the trial
N = 59, mean age 42, M 9/F 50
EM/CM 45/14, MOH excluded
Number of headache days 11.7 during baseline diary period, headache severity 3.5 on
5-point scale where 5 is most severe
Interventions Intervention: Botox ≤ 100 U, number of injections unclear (procerus 2.5-5 U, corruga-
tors 2.5-5U, frontalis 25 U, temporalis 7.5-20 U, splenius capitis 2.5-10 U, sternoclei-
domastoid 7.5-15 U, trapezius 2.5-5 U, occipitalis 2.5-5 U, cervical paraspinalis 7.5-15
U, semispinalis capitis 5-10 U, masseter 5-15 U
Comparator: sodium valproate tablets, 250 mg twice daily
Outcomes Number of headache days
Proportion of responders (≥ 50% reduction in migraine)
Headache severity
Headache index
MIDAS
HIT-6
24 hr migraine QoL
Adverse events
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Notes Funder: Allergan, Inc., Irvine, California (manufacturer of Botox)
Diary period 1 month
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not stated
Allocation concealment (selection bias) Unclear risk Method not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind: double dummy, participant
blinded with matched placebo injections
or placebo tablets, no methods given for
blinding of personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind: double dummy, nomethods
given for blinding of personnel
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropouts at 44%
Selective reporting (reporting bias) Unclear risk Some time points not reported for some
outcomes
Study size High risk < 50 participants per treatment arm
Blumenkron 2006
Methods Randomised, double-blind, placebo-controlled, parallel-group, unclear sites
Single treatment, appears to be 3 months FU
Fixed injections of Botox 100 U vs matched placebo injections
Assessments carried out at baseline and 1month, 2months and 3months post-treatment
Participants Inclusion criteria: age > 18 years; migraine (IHS 1988); previous history of conventional
treatment failure and functional disability
Exclusion criteria: non adherence to the protocol and non-acceptance by participant;
pregnancy; lactation; treatment with aminoglycosides; acne conglobata; Lambert-Eaton
myasthenic syndrome; history of hypersensitivity to the components of the BTX and
secondary headache
N = 30, mean age not stated, M 5/F 25
EM/CM unclear, MOH eligibility unclear
Baseline disease characteristics not stated
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Blumenkron 2006 (Continued)
Interventions Intervention: Botox 100 U from 25 injections (4 front points total 10 U, 1 application
in procerus muscle and 1 application in each corrugator muscle total 10 U, 3 points each
temporalis muscle total 30 U, 5 points in each trapezius muscle total 50 U)
Comparator: matched placebo injections
Outcomes MIDAS
MIGSEV
Quality-of-life measure
Adverse events
Notes Funding source unclear
No diary data
Contacted without response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation se-
quence
Allocation concealment (selection bias) Unclear risk Method not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind: participant blinded with
matched placebo injections no methods
given for blinding of personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind: no methods given for blind-
ing of personnel
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Dropouts not mentioned
Selective reporting (reporting bias) Unclear risk No protocol and no migraine frequency
data
Study size High risk < 50 participants per treatment arm
Cady 2008
Methods Randomised, double-blind, placebo-controlled, parallel-group, single-site
Single treatment, 3-month FU (optional OL treatment at end of trial for placebo arm)
Fixed injections of Botox versus placebo injections
Assessments carried out at baseline and 1month, 2months and 3months post-treatment
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Cady 2008 (Continued)
Participants Inclusion criteria: age > 18 years; history (≥ 6 months) of headache (ICHD-II diagnosis
1.1 (migraine without aura), 1.2 (migraine with aura), 1.7 (migrainous disorder not
fulfilling above criteria), or 2.2 (chronic tension-type headache)); onset before the age
of 50 years; HIT-6 score > 56; episodic chronic headache; stable headache severity and
pattern; failed at least 1 attempt with preventive medications because of compliance,
adherence, or AE issues; women of childbearing potential taking approved birth control
measures and having a negative urine pregnancy test prior to administration of trial
medications
Exclusion criteria: any medical condition that might put them at risk with Botox expo-
sure (e.g. myasthenia gravis, Eaton-Lambert Syndrome, amyotrophic lateral sclerosis);
any disease that might interfere with neuromuscular function; uncontrolled systemic dis-
ease; abnormal pathology contributing to headaches; concurrent infection at proposed
injection sites; pregnant or breast-feeding; currently using aminoglycoside antibiotics,
curare-like agents, or other agents that might interfere with neuromuscular function;
undergone injection of anaesthetics or steroids, within 1 month immediately prior to
enrolment, into the muscles to be injected in the trial; previous BTX treatment with any
sero-type; currently participating in another drug or device trial or had done so within
the 30 days before the baseline period; suspected hypersensitivity to Botox or any of the
ingredients in the proprietary formulation; known or suspected drug or alcohol abuse
N = 61, mean age 42 years, M 9/F 52
EM/CM unclear, MOH eligibility unclear
Number of headache days 8 during baseline diary period, severity of migraine (max
recorded during baseline period) 2.2 (scale unclear)
Interventions Intervention: Botox 139 U, 17 injections (corrugator 2 applications of 6 U, splenius
capitis 2 applications of 10 U, trapezius 4 applications of 10 U, temporalis 4 applications
of 10 U, procerus 1 application of 3 U, frontalis 4 applications of 6 U)
Comparator: matched placebo injections
Outcomes Number of headache episodes
Number of headache days
Number of headache-free days
Percentage of headache episodes with aura
Severity of headaches
HIT-6 (mean in 30 days compared to baseline)
MIQ (MIDAS & QoL)
Notes The trial received enrolment of subjects with diagnostic criteria 1.1 and 1.2 only
Funder: Allergan, Inc., Irvine, California (manufacturer of Botox)
Diary period 30 days
Contacted without response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not stated
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Allocation concealment (selection bias) Low risk Randomisation of participants was per-
formed by a supervisory individual not as-
sociated with the trial
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind: participant blinded with
matched placebo injections, research co-or-
dinator, whowas not involvedwith the par-
ticipants prepared the injections
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind: research co-ordinator, who
was not involved with the participants pre-
pared the injections
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Treatment of missing data not described
Selective reporting (reporting bias) Unclear risk Full data not given (P values only, no AE
data given)
Study size High risk < 50 participants per treatment arm
Cady 2011
Methods Randomised, double-blind, active controlled, parallel-group multi-site
Single treatment, 12-week FU (additional treatment for all participants in OL phase)
Fixed plus follow the pain injections of Botox plus placebo tablets vs placebo injections
and topiramate tablets
Assessments carried out at baseline and 4 weeks and 12 weeks post-treatment
Participants Inclusion criteria: CM (criteria used ICHD-II); aged 18-65 years; female participants
of child-bearing potential with a negative urine pregnancy test who practiced reliable
contraception throughout the trial period
Exclusion criteria: pregnancy, breastfeeding, or planning pregnancy during the time
frame of the trial; headache disorders other than CM;medical disorders that increase risk
with exposure to Botox; significant liver or renal impairment including kidney stones;
ketogenic diets; previous use of BTX or topiramate; recent alcohol/drug abuse or overuse
of acute medication
N = 59, mean age 40 years, M 5/F 54
CM only eligible, MOH excluded
Years since diagnosis of migraine 16 years, severity of migraine 2.8 on 3-point scale
Interventions Intervention: Botox up to 200 U, number and location of injections not reported (100
U fixed locations + up to 100 U in follow the pain), average dose 109 U
Comparator: topiramate 25 mg escalated to max 200 mg (average 136 mg)
Outcomes Number headache days
Number migraine attacks
Proportion of responders (≥ 50% reduction in migraine)
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Money spent on rescue medication
Physician’s global assessment
HIT-6
MIDAS
MIQ
Severity of migraine
Notes Funding source unclear
Diary period 28 days
Contacted without response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not stated
Allocation concealment (selection bias) Low risk A sealed cardmarkedwith participant’s trial
number was delivered via FedEx to the trial
site. A research co-ordinator, not involved
with the trial, would open the card, note the
treatment assignment, prepare treatment,
and hand to trial co-ordinator, who assisted
the investigator with the injections
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind: participant blinded with
matched placebo injections, research co-
ordinator, who was not involved with the
trial, prepared the injections
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind: research co-ordinator, who
was not involved with the trial, prepared
the injections
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear reporting of attrition
Selective reporting (reporting bias) High risk Some outcomesmissing from results (sever-
ity/MIQ/AEs)
Study size High risk < 50 participants per treatment arm
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Cady 2014
Methods Randomised, double-blind, placebo-controlled, cross-over, multi-site
Single treatment, 3-month FU (additional treatment given post cross-over)
Fixed plus follow the pain injections of OnabotulinumtoxinA vs placebo injections
Assessments carried out at baseline and 1month, 2months, and 3months post-treatment
Participants Inclusion criteria: CM (criteria used ICHD-II); aged 18-65; history of CM according
to the criteria proposed as an appendix diagnosis in 2006 by the Headache Classifica-
tion Committee; preventive medications were of a stable dose for at least 6 weeks prior
to screening and maintained throughout trial period; women of childbearing potential
agreed to urine pregnancy test at screening and a medically acceptable form of contra-
ception
Exclusion criteria: pregnancy, planning pregnancy during the trial period, breastfeeding,
or of childbearing potential and not practicing a reliable form of birth control (see
inclusion criteria); headache disorders outside IHS-defined CM; evidence of underlying
pathology contributing to headaches; pathology of the salivary glands such as sialadenitis
(e.g. Sjorgen’s syndrome, viral or bacterial sialadenitis) or condition or symptom that
would alter the content of saliva; any medical condition that may increase their risk with
exposure to BTX-A including diagnosed myasthenia gravis, Eaton-Lambert syndrome,
amyotrophic lateral sclerosis, or any other significant disease that might interfere with
neuromuscular function; profound atrophy or weakness of muscles in the target areas of
injection; skin conditions or infections at any of the injection sites; allergy or sensitivities
to any component of test medications; active major psychiatric or depressive disorders
including alcohol/drug abuse; met IHS criteria for Medication Overuse with opioid- or
butalbital-containing products; planning or requiring surgery during the trial; history
of poor compliance with medical treatment as determined by the investigator; currently
participating in an investigational drug trial or had participated in an investigational
drug trial within the previous 30 days of the screening visit
N = 20, mean age 49, M 5/F 15
CM only eligible, MOH eligibility unclear
Baseline disease characteristics not stated
Interventions Intervention: Botox ≥ 155 U, 31 injections following PREEMPT paradigm with op-
tional follow the pain injections in occipitalis, temporalis, and trapezius
Comparator: matched placebo injections
Outcomes Number of headache days
Notes Protocol NCT01071096
Funding source unclear
Diary period 1 month
Contacted without response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation se-
quence
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Allocation concealment (selection bias) Low risk Third party responsible for generation of
number and preparation of medications
Quote: “Randomisation of subjects was
performed by a supervisory individual not
associated with the trial, who numbered
trial medications in a manner which was
blinded to subject, coordinator, and inves-
tigator”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind: participant blinded with
matched placebo injections, trial medica-
tions were numbered by a supervisory in-
dividual not associated with the trial in a
manner which was blind to subject, co-or-
dinator and investigator
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind: trial medications were num-
bered by a supervisory individual not asso-
ciated with the trial in a manner which was
blind to subject, co-ordinator and investi-
gator
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 1 participant dropped out
Selective reporting (reporting bias) Low risk All protocol outcomes reported
Study size High risk < 50 participants per treatment arm
Chankrachang 2011
Methods Randomised, double-blind, placebo-controlled, parallel-group, multi-site
Single treatment, 3-month FU
Fixed injections with Dysport vs placebo
Assessments carried out at baseline and 4 weeks, 8 weeks and 12 weeks post-treatment
Participants Inclusion criteria: aged 18-65 years; experienced an average of 2-8 migraine attacks per
month over the 3 months prior to a screening period; 2-8 migraine attacks occurred
during the 4-week screening period; medication for acute migraine and prophylactic
treatment was permitted if doses were stable
Exclusion criteria: pure migraine with aura as defined by ICHD-II; history of compli-
cated migraine; pregnancy; lactation; not using adequate contraception; history of drug
abuse; treatment with Botox within the past 6months; previously experienced an adverse
reaction to Botox; history of botulism or other neuromuscular disorders; current treat-
ment with aminoglycoside antibiotics or other agents that could affect neuromuscular
transmission; received unlicensed medication or investigational drugs within 6 months
of the screening visit; any other clinically significant medical conditions that could in-
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fluence trial results; liver transaminase levels had to be less than twice the upper normal
values
N=128,mean age 39,M7/F120 (ITTpopulation (127) used for baseline characteristics)
EM/CM unclear, MOH eligibility unclear
Years since diagnosis migraine 5, number of migraine attacks during baseline diary period
5
Interventions Intervention (arm 1): Dysport 120U, 6 injections - 2 x frontal, 2 x temporal, 2 x occipital
Intervention (arm 2): Dysport 240U, 6 injections - 2 x frontal, 2 x temporal, 2 x occipital
Control: matched placebo injections
Outcomes Number of migraine attacks
Total intensity score
MIDAS
Duration of migraine
Number of hours per month with moderate-to-severe headache
Global assessment score
Adverse events
Notes Protocol NCT00258609
Funder: IPSEN Group (manufacturer of Dysport)
Diary period 28 days
Contacted without response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation se-
quence
Allocation concealment (selection bias) Low risk Sealed envelopes with allocation, nurse per-
formed reconstitution and had no further
involvement with participants
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind: participants and all other
personnel, apart from nurse who per-
formed reconstitution of drug, were blind
to allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind: participants and all other
personnel, apart from nurse who per-
formed reconstitution of drug, were blind
to allocation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk ITT with no description of method of im-
putation, stated dropouts 1/3/5
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Selective reporting (reporting bias) Unclear risk All expected outcomes discussed but data
not always provided
Study size High risk < 50 participants per treatment arm
Diener 2010 (PREEMPT 2)
Methods Randomised, double-blind, placebo-controlled, parallel-group, multi-site
2 treatments, 12 weeks FU per treatment
Fixed plus optional follow the pain injections of Botox vs placebo
Assessments carried out at baseline and 4 weeks, 8 weeks and 12 weeks after each treat-
ment out to 24 weeks, (further 3 treatments and 32 weeks of assessments in OL phase)
Participants Inclusion criteria: aged 18-65 years; migraine meeting the diagnostic criteria listed in
ICHD-II (2004) section 1, migraine (1), with the exception of “complicated migraine”
(i.e., hemiplegic migraine, basilar-type migraine, ophthalmoplegic migraine, migrainous
infarction); provided diary data on ≥ 20 of 28 days during baseline; ≥ 15 headache
days with each day consisting of ≥ 4 h of continuous headache and with ≥ 50% of days
being migraine or probable migraine days during baseline period; ≥ 4 distinct headache
episodes, each lasting ≥ 4 h
Exclusion criteria: any medical condition that might put participants at increased risk
if exposed to Botox (e.g. neuromuscular diseases); other primary or secondary headache
disorders; use of any headache prophylactic medication within 28 days before start of
baseline; Beck Depression Inventory score of > 24 at baseline; fibromyalgia; psychiatric
disorders that could have interfered with trial participation; previous exposure to any
botulinum neurotoxin sero-type; Women of childbearing potential must have had a
negative urine pregnancy test prior to each injection and have been using a reliable means
of contraception; investigators were trained not to enrol participants who frequently
used opioids as acute pain medication
N = 705, mean age 41 years, M 103/F 602
CM only eligible, MOH eligible Y/N 444/261
Years since onset of CM 18, number of migraine days during baseline diary period 19
Interventions Intervention: Botox 31 fixed injections (total 155 U) followed by 8 optional follow the
pain injections (total 40 U). PREEMPT paradigm: frontalis 20 U in 4 sites; corrugator
10 U in 2 sites; procerus 5 U in 1 site; occipitalis 30 U in 6 sites up to 40 U in 8 sites;
temporalis 40 U in 8 sites up to 50 U in 10 sites; trapezius 30 U in 6 sites; cervical
paraspinal 20 U in 4 sites
Control: matched placebo injections
Outcomes Number of headache days
Number of migraine days
Number of headache episodes
Monthly cumulation of headache hours
Proportion of responders (≥ 50% reduction in migraine)
Use of rescue medication
HIT-6
Headache impact score
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Diener 2010 (PREEMPT 2) (Continued)
Migraine specific quality of life questionnaire
HRQoL
Adverse events
QALYs
Incremental cost-effectiveness ratio
Notes Protocol NCT00156910
Funder: Allergan, Inc., Irvine, California (manufacturer of Botox)
Diary period 28 days
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation se-
quence
Allocation concealment (selection bias) Low risk Upon randomisation subject number was
linked to next randomisation number
grouped within strata for that site, site was
then notified of medication kit assigned to
that number
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind: placebo arm, prepacked
medication kits with number for assign-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind: placebo arm, prepacked
medication kits with number for assign-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawals balanced across groups and
adjusted LOCF method used
Selective reporting (reporting bias) Low risk All expected outcomes reported
Study size Low risk ≥ 200 participants per treatment arm
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Elkind I 2006
Methods Randomised, double-blind, placebo-controlled, parallel-group, multi-site
4-arm trial.
2 arms received 1 treatment before being re-randomised, 2 arms received 3 treatments
before being re-randomised, 120 days FU per treatment
This paper comprised 3 trials of which this is the first. (Elkind II 2006 - included, Elkind
Study III 2006 (Elkind 2006)- excluded)
3 arms with varying doses of fixed injections of Botox vs placebo injections
Assessments carried out at baseline and 30 days, 60 days, 90 days and 120 days post-
treatment for each treatment cycle
Participants Inclusion criteria: aged 18-65 years; IHS-definedmigraines with or without aura; average
of 4-8 moderate-severe migraines per month that occurred with a stable frequency and
severity and had begun at least 1 year prior to the trial; first diagnosed with migraine
before age 50 years; able to distinguish between migraine and non migraine headaches;
stable medical condition; if taking chronicmedications (including prophylactic migraine
medications), on stable doses and regimens for at least 3 months prior to enrolment, to
be continued throughout the trial
Exclusion criteria: > 15 headache d/month; history of complicated migraine or typical
migraine pain localised predominantly to the occipital or suboccipital region; consistently
refractory to multiple acute therapies or had never tried any acute therapies; overuse
of symptomatic medications; excessive use of caffeine; alcohol/drug abuse; any medical
condition or use of any agent that might have put the participant at increased risk
with exposure to Botox or interfered with trial participation or the results; pregnancy,
breastfeeding, or planning a pregnancy during the trial period; previous injection with
any BTX or allergy to any of the components of the trial medication; prior injection of
anaesthetic or steroid into the muscles to be injected in the month immediately prior
to enrolment; participation in another investigational drug or device clinical trial either
concurrently or in themonth immediately prior to enrolment; infection or skin problems
at the injection site
Participants withmigraine headache at the time of treatmentmay have been randomised/
injected at a later date within 2 weeks of the scheduled visit
N = 418, mean age 44 years, M 64/F 354
Some CM inadvertently included against protocol EM/CM 409/9, MOH excluded
Years since onset of migraine 21, number of migraine attacks in baseline diary period 6
Interventions Intervention (arm 1): 50 U Botox total of 11 injections - frontal 4 sites, temporal 2 sites,
glabellar 5 sites
Intervention (arm 2): 25 U Botox total of 11 injections - frontal 4 sites, temporal 2 sites,
glabellar 5 sites
Intervention (arm 3): 7.5 U Botox total of 11 injections - frontal 4 sites, temporal 2 sites,
glabellar 5 sites
Control: matched placebo injections
Outcomes Number of migraine attacks
Secondary endpoint:
Proportion of responders (≥ 50% reduction in migraine)
Maximum migraine headache severity
Use of rescue medication
Severity of migraine
Maximum migraine duration
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Elkind I 2006 (Continued)
Number of days with aura
Number of days with migraine-associated symptoms
Patient global assessment score
SF-36
Migraine-Specific Measure of Quality of Life
Migraine Impact Questionnaire
Headache Pain Specific Quality of Life Questionnaire
Adverse events
Notes Funder: Allergan, Inc., Irvine, California (manufacturer of Botox)
Diary period 30 days
Contacted without response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not stated
Allocation concealment (selection bias) Unclear risk Method not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind: participant blinded with
matched placebo injections no methods
given for blinding of personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind: no methods given for blind-
ing of personnel
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data low and balanced across
groups
Selective reporting (reporting bias) Unclear risk All expected outcomes discussed but data
not always provided
Study size Unclear risk 50-199 participants per arm
Elkind II 2006
Methods Randomised, double-blind, placebo-controlled, parallel-group, multi-site
2 treatment cycles, 120 days FU per treatment. Follows on from Elkind I 2006
Fixed injections of Botox dosing trial
Assessments carried out at baseline and 30 days, 60 days, 90 days and 120 days post-
treatment for each treatment cycle
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Participants Inclusion criteria: aged 18-65 years; IHS-definedmigraines with or without aura; average
of 4-8 moderate-severe migraines per month that occurred with a stable frequency and
severity and had begun at least 1 year prior to the trial; first diagnosed with migraine
before age 50 years; able to distinguish between migraine and non migraine headaches;
stable medical condition; if taking chronicmedications (including prophylactic migraine
medications), on stable doses and regimens for at least 3 months prior to enrolment, to
be continued throughout the trial
Exclusion criteria: > 15 headache d/month; history of complicated migraine or typical
migraine pain localised predominantly to the occipital or suboccipital region; consistently
refractory to multiple acute therapies or had never tried any acute therapies; overuse of
symptomatic medications; excessive use of caffeine; alcohol/drugs abuse; any medical
condition or use of any agent that might have put the participant at increased risk
with exposure to Botox or interfered with trial participation or the results; pregnancy,
breastfeeding, or planning a pregnancy during the trial period; previous injection with
any BTX or allergy to any of the components of the trial medication; prior injection of
anaesthetic or steroid into the muscles to be injected in the month immediately prior
to enrolment; participation in another investigational drug or device clinical trial either
concurrently or in themonth immediately prior to enrolment; infection or skin problems
at the injection site
participants withmigraine headache at the time of treatmentmay have been randomised/
injected at a later date within 2 weeks of the scheduled visit
N = 183, baseline data given for Elkind I 2006 participant set only. Some attrition of
participants between end of study I and start of study II not described in detail
Some CM inadvertently included against protocol EM/CM unclear, MOH excluded
Interventions Intervention (arm 1): 50 U Botox total of 11 injections - frontal 4 sites, temporal 2 sites,
glabellar 5 sites
Intervention (arm 2): 25 U Botox total of 11 injections - frontal 4 sites, temporal 2 sites,
glabellar 5 sites
Outcomes Number of migraine attacks
Secondary endpoint:
Proportion of responders (≥ 50% reduction in migraine)
Maximum migraine headache severity
Use of rescue medication
Severity of migraine
Maximum migraine duration
Number of days with aura
Number of days with migraine-associated symptoms
Patient global assessment score
SF-36
Migraine-Specific Measure of Quality of Life
Migraine Impact Questionnaire
Headache Pain Specific Quality of Life Questionnaire
Adverse events
Notes Funder: Allergan, Inc., Irvine, California (manufacturer of Botox)
Diary period 30 days
Contacted without response
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not stated
Allocation concealment (selection bias) Unclear risk Method not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind: participant blinded with
matched placebo injections no methods
given for blinding of personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind: no methods given for blind-
ing of personnel
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data at 22% vs 16% of total par-
ticipant numbers balanced across groups
Selective reporting (reporting bias) Unclear risk All expected outcomes discussed but data
not always provided
Study size Unclear risk 50-199 participants per arm
Freitag 2008
Methods Randomised, double-blind, placebo-controlled, parallel-group, multi-site
Single treatment, 16-week FU
Fixed injections of Botox vs placebo
Assessments carried out at baseline and at 4 weeks, 8 weeks, 12 weeks and 16 weeks post-
treatment
Participants Inclusion criteria: 6-month history, prior to baseline, of CM; migraine episodes meeting
the criteria 1.1 or 1.2 of the ICHD-I; 15 headache days during the prospective baseline
phase; anyone taking preventive medications must have been on stable dosages for 60
days prior to trial entry and willing to remain at same doses for the duration of the trial;
women were required to be practicing an acceptable method of contraception and have
a pregnancy test or to be incapable of pregnancy
Exclusion criteria: previous treatment with BTX of any sero-type for any therapeutic
reason; history of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral scle-
rosis or other disorder of neuromuscular function; concomitant use of aminoglycoside
antibiotics, curare-like agents or other agents that might interfere with neuromuscular
function; diagnoses of migraine beginning for the first time after age 50 years; cluster
headaches or basilar, ophthalmoplegic, hemiplegic migraine, or exclusively having mi-
graine aura without headache; more painful condition than their migraine pain, pro-
gressive neurological disorders, or a structural disorder of the brain from birth, trauma,
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Freitag 2008 (Continued)
or past infection; received injections or oral corticosteroids within 30 days prior to the
baseline diary initiation visit; significant major psychiatric disorder; receiving antipsy-
chotic medication; Beck Inventory of Depression Scores > 24; received an investigational
drug or used an investigational device within 30 days of trial entry; taking triptans > 3
days per week, ergotamine > 2 days per week, or dihydroergotamine > 2 days per week
or any combination of the above medications > 3 days per week; consuming caffeine
from dietary and medicinal sources > 500 mg/d on a daily basis > 28 days prior to trial
enrolment; taking opioids > 2 days per week; taking simple analgesics on average > 2
tablets/d≥ 5 days per week for at least 28 days; taking combination analgesics on average
> 3 tablets per day and ≥ 3 days per week for at least 28 days; using a combination of
any of the previous on ≥ 4 days per week for at least 28 days
N = 41, mean age 42 years, M 11/F 30
CM only eligible, MOH excluded
Baseline disease characteristics not stated
Interventions Intervention: Botox 100 U, 22 injections (glabella 20 U, 4 sites; temporal 20 U, 4 sites;
frontal 10 U, 4 sites; suboccipital 30 U, 6 sites; trapezius 20 U, 4 sites)
Control: matched placebo injections
Outcomes Number of migraine episodes
Number of headache days
Headache index (HAI)
Proportion of 50% responders
Use of rescue medication
MIDAS
Headache Pain Specific Quality of Life measure
Adverse events
Notes Funder: Allergan, Inc., Irvine, California (manufacturer of Botox)
Diary period 28 days
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation se-
quence
Allocation concealment (selection bias) Unclear risk Method not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind: participant blinded, with
matched placebo injections, research nurse
who was not involved with the trial partici-
pants prepared the injections, trial medica-
tion was delivered to treating physician in
identical looking syringes
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind: research nurse, who was not
involved with the trial participants pre-
pared the injections, trial medication was
delivered to treating physician in identical
looking syringes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data low and balanced across
groups at 10% vs 14% of total participant
numbers
Selective reporting (reporting bias) Low risk All expected outcomes reported but stan-
dard errors or equivalent not reported and
some interim time points missing
Study size High risk < 50 participants per treatment arm
Hollanda 2014
Methods Randomised, double-blind, placebo-controlled, parallel-group, single-site
3 cycles of treatment at 4-week intervals (some uncertainty as to whether participants
were treated at each visit or just at first visit), trial length 12 weeks in total
Follow the pain injections of Prosigne vs placebo
Assessments carried out at baseline, 4 weeks, 8 weeks and 12 weeks
Participants Inclusion criteria: aged 18-85 years; diagnosis ofCMassociatedwith cutaneous allodynia,
according to the ICHD (edition revised, 2006)
Exclusion criteria: diagnosis of neuromuscular diseases (myasthenia gravis, Eaton-Lam-
bert syndrome and amyotrophic lateral sclerosis); conditions that could affect pericranial
muscles; other primary or secondary headaches; complicated migraine; CM associated
with analgesic overuse; severe systemic diseases; other neurologic or psychiatric disorders;
fibromyalgia; myofascial syndrome; temporomandibular disorder
N = 38, mean age 45, M 9/F 29
CM only eligible, MOH excluded
Severity of migraine 7.3 cm on 10 cm VAS
Interventions Intervention: Prosigne 12-24 injections, maximum dose 96 U (frontal 2-4 sites on each
side 3 U per site; temporal 2-4 sites on each side 4 U per site; occipital 2-4 sites on each
side 5 U per site)
Control: matched placebo injections
Outcomes Number of migraine episodes with cutaneous allodynia
Severity of headache pain (VAS)
Use of rescue medication
Adverse events
Notes Funder: Brazilian National Institutes of Science
Diary period 30 days
Protocol NCT01357798
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Hollanda 2014 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation se-
quence
Allocation concealment (selection bias) Unclear risk Method not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind: participant blinded, with
matched placebo injections, 1 designated
investigator who had access to randomisa-
tion sequence provided the trial medication
to the principal investigator according to
the allocation list generated
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind: 1 designated investigator
who had access to randomisation sequence
provided the trial medication to the princi-
pal investigator according to the allocation
list generated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Appear to be no dropouts
Selective reporting (reporting bias) Low risk All outcomes in protocol and methods re-
ported
Study size High risk < 50 participants per treatment arm
Hou 2015
Methods Randomised, double-blind, placebo-controlled, parallel-group, single-site
Single treatment with 4-month FU
3-arm trial, HengLi fixed muscle site injections vs HengLi acupoint site injections vs
placebo
Assessments carried out at baseline and 1 month, 2 months, 3 months and 4 months
postbaseline
Participants Inclusion criteria: EM and CM, criteria used ICHD-I; aged 18-57 years; history of
migraines with or without aura for 1-16 years; experienced headache ≥ 15 d/month
were diagnosed as CM; women of childbearing potential were required to be taking
approved birth control measures and to have a negative urine pregnancy test prior to
administration of trial medications
Exclusion criteria: any medical or neurological conditions that might put them at risk
with Botox exposure, such as amyotrophic lateral sclerosis, myasthenia gravis, Eaton-
Lambert Syndrome; any disease that might interfere with neuromuscular function; ab-
normal pathology contributing to migraine; uncontrolled systemic disease; concurrent
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Hou 2015 (Continued)
infection at proposed injection sites; pregnant or breast-feeding; currently using amino-
glycoside antibiotics, curare-like agents, or other agents that might interfere with neu-
romuscular function; undergone injection of anaesthetics or steroids, within 1 month
immediately prior to enrolment, into the muscles to be injected in the trial; previously
received Botox treatment with any sero-type; currently participating in another drug or
device trial or had done so within the 30 days before the baseline period; suspected hy-
persensitivity to Botox or any of the ingredients in the proprietary formulation; known
or suspected drug or alcohol abuse
N = 102, mean age 41, M 21/F 81
EM/CM 66/36, MOH eligibility unclear
Years since diagnosis of migraine 6, number of migraine attacks during baseline diary
period 7, severity of migraine 7.4 cm on 10 cm VAS
Interventions Intervention (arm 1): HengLi fixedmuscle site, 10 injections of 2.5 U each, total dose 25
U (1 on each side for frontal and occipital belly of occipitofrontalis, corrugator supercilii,
temporalis and superior part of trapeziuem)
Intervention (arm 2): HengLi acupoint site, 10 injections of 2.5 U each, total dose 25 U
(Yintang EX-HN3, at themidpoint of the line connecting the 2medial ends of eyebrows;
Taiyang EX-HN5, at the point of intersection of the continuations of the eyebrow and
the lower eyelid in the lateral direction, on the lateral border of the orbit; Baihui GV20,
at the middle of the vertex, on the line connecting the apexes of the 2 ears; Shuaigu
GB8, directly above the ear apex, 1.5 inches above the hairline; Fengchi GB20, at the
posterior lateral aspect of the neck, in the fossa between the superior margins of the
trapezius and sternocleidomastoid muscles; and Tianzhu BL10, 1.3 inches lateral to the
point 0.5 inches directly above the midpoint of the posterior hairline, in the depression
lateral to the border of the trapezius muscle
Control: placebo injections matched to fixed muscle site arm
Outcomes Number of migraine attacks
Duration of migraine
Severity of migraine
Frequency of migraine symptoms
Adverse events
Notes Funder: Scientific and Technique Support Project of Gansu Province (090NKCA112),
China
Diary period 1 month
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation se-
quence
Allocation concealment (selection bias) Unclear risk Method not stated
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind
Quote: “participant blind with matched
placebo injections, a research coordinator
who was not directly involved with the
subjects managed the randomisation and
preparation of injections.”
Since dummy injections are not mentioned
it cannot be the case that personnel carry-
ing out injections are blind to active assign-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind: a research co-ordinator who
was not directly involved with the par-
ticipants managed the randomisation and
preparation of injections, analysis of the
diary data was conducted by investigators
who did not know the exact group of each
participant
Incomplete outcome data (attrition bias)
All outcomes
Low risk Appear to be no dropouts
Selective reporting (reporting bias) High risk Use of rescue medications recorded but not
reported
Study size High risk < 50 participants per treatment arm
Jabbari 2014
Methods Randomised, double-blind, placebo-controlled, parallel-group unclear sites
Single treatment 4 weeks FU
Fixed injections of Botox vs placebo
Assessments carried out at baseline and 4 weeks post-treatment
Participants Inclusion criteria: aged ≥ 18 years; migraine for > 3 months that fail to respond to ≥ 2
major anti-migraine drugs; meeting criteria of CM
Exclusion criteria: pregnant or may become pregnant; disease of neuromuscular junction
or drugs that affect neuromuscular junction; allergy to Botox; previous use of Botox for
migraine by similar methodology
N = 25, mean age 60, M 13/F 12
CM only eligible, MOH eligibility unclear
Severity of migraine 8.2 on 10 cm VAS
Interventions Intervention: Botox 200-300 U depending on neck and body size, 22-24 injections
(frontalis 20 U, 5 sites/side; temporalis 30 U, 2 sites/side; occipitalis 5 U, 1 site/side)
; cervical region: splenius cervicis, semispinalis capitis, trapezius muscles 45-60 U 3-5
sites/side)
Control: matched placebo injections
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Outcomes Severity of migraine
Global assessment score
Pain impact questionnaire
HIT-6
Migraine-specific quality of life
Adverse events
Notes Protocol NCT00660192
Funding source unclear
Diary period 28 days
Contacted without response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not stated
Allocation concealment (selection bias) Unclear risk Method not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind: participant and investigator
blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind: participant and investigator
blind
Incomplete outcome data (attrition bias)
All outcomes
High risk 20% dropped out N = 5
Selective reporting (reporting bias) Unclear risk Not yet published, information and data
from trial registry only
Study size High risk < 50 participants per treatment arm
Jost 2011
Methods Randomised, double-blind, placebo-controlled, cross-over, unclear sites
Single treatment with 4 months FU precross-over
Unclear method of injections of Botox vs placebo
Assessments carried out at baseline and 6 weeks and 4 months post-treatment
Participants Inclusion criteria: aged 18-70 years; clinically confirmed diagnosis of migraine without
aura, criteria used ICHD, edition not stated; duration of illness, so far refractory to con-
servative treatment (physiotherapy, massages, stretching exercises, peroral medication)
at least 2 years
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Jost 2011 (Continued)
Exclusion criteria: participation in another clinical trial within the past 3 months; spe-
cific pain in neck/shoulder region in need of different specific treatment (i.e. acute nerve
irritation with disc prolapse, manifest inflammatory processes etc.); contraindication of
treatment with BTX (ascertained sensitivity to clostridial toxin or to 1 of the other in-
gredients and generalised disorders of muscular activity, e.g. myasthenia gravis or Lam-
bert-Eaton syndrome); pregnancy or breastfeeding or inadequate or no contraception in
women of childbearing age; serious concomitant illnesses involving the internal organs
in particular; systemic diseases; serious neurologic disorders; abuse of alcohol, drugs and
narcotics; medication with anticoagulants and heparin preparation (topically applied
heparin unguents excluded), thrombocyte aggregation inhibitors, amino-glycoside an-
tibiotics, spectinomycin or muscle relaxants of the tubocurarine type
N = 22, mean age 45, M 5/F 17
EM/CM unclear, MOH eligibility unclear
Baseline disease characteristics not stated
Interventions Intervention: Botox 10 U 2 injections in total into corrugator muscle and occipitalis
muscle of the side affected
Control: matched placebo injections
Outcomes Pain intensity (severity) VAS
Number of headache attacks
Duration of headache attacks
Use of rescue medication
Short form-McGill Pain Questionnaire
Northwick Park Neck Pain Questionnaire
International quality of life assessment
SF 36
Scale of attitudes toward disabled persons
Oswestry low back pain disability questionnaire
Adverse events
Notes Funder: German society of Neurology (statistical analysis only). States no funds came
from manufacturers of BTX
Diary period unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not stated
Allocation concealment (selection bias) Unclear risk Method not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind: participant blinded with
matched placebo injections no methods
given for blinding of personnel
70Botulinum toxins for the prevention of migraine in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Jost 2011 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind: no methods given for blind-
ing of personnel
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated from which group dropouts (3)
occurred. Participants lost to FU not anal-
ysed
Selective reporting (reporting bias) High risk AEs recorded but not reported or com-
mented upon
Study size High risk < 50 participants per treatment arm
Lauretti 2014
Methods Randomised, double-blind, placebo-controlled, parallel-group, single-site
Single treatment with 12 weeks FU
4-arm trial fixed injections Botox vs Prosigne (2 dosing arms) vs saline
Assessments carried out at baseline and 4 weeks, 8 weeks and 12 weeks post-treatment
Participants Inclusion criteria: aged 21-60 years; chronic daily unilateral headache characterised as
CM > 12 months’ duration and not responding to standard treatment with antidepres-
sants, nonsteroidal anti-inflammatory agents or anticonvulsants or beta-blockers
Exclusion criteria: presence of an infectious process at the site of application; associated
immunological diseases; previous history of allergy to Botox; application of Botox during
the last year; diabetes mellitus
N = 40, mean age 46 years, M 14/F 26
CM only eligible, MOH eligibility unclear
Years since diagnosis of CM 16, severity of migraine 10.0 on 10 cm VAS
Interventions Intervention (arm 1): Botox 10 injections, total dose 25 U (8 different sites in the frontal
region and 2 sites in the temporal region, 1 site on each side)
Intervention (arm 2): Prosigne 10 injections, total dose 25 U (8 different sites in the
frontal region and 2 sites in the temporal region, 1 site on each side)
Intervention (arm 3): Prosigne 10 injections, total dose 33.3 U (8 different sites in the
frontal region and 2 sites in the temporal region, 1 site on each side)
Control: matched placebo injections
Outcomes Number of headache attacks
Severity of headache
Time to 50% pain relief
Notes Funding source unclear
Diary period 4 weeks
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation se-
quence
Allocation concealment (selection bias) Unclear risk Method not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind: participant blind with
matched placebo injections, 1 of the trial
authors prepared injections and a second
trial author, who was unaware of the con-
tent of the previously prepared syringes de-
livered the treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind: 1 of the trial authors pre-
pared injections and a second trial author,
who was unaware of the content of the
previously prepared syringes delivered the
treatment, data were evaluated by a third
trial author
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data balanced across groups (1/1/
0/1)
Selective reporting (reporting bias) Unclear risk AEs not mentioned at all in report
Study size High risk < 50 participants per treatment arm
Mathew 2009
Methods Randomised, double-blind, active control, parallel-group, single site
2 treatments with 3months between treatments and 6months FU after second treatment
Fixed plus follow the pain injections of Botox 200 U plus placebo tablets vs TOPAMAX
(topiramate) tablets plus placebo injections
Assessments carried out at baseline and 1 month, 3 months, 6 months and 9 months
after first treatment
Participants Inclusion criteria: outpatient; aged 18-65 years; diagnosed CM not attributable to an-
other cause; CMheadache was defined as migraine headache with or without aura occur-
ring on≥ 15 d/month for > 3months in the absence of medication overuse with at least 2
of the following characteristics: unilateral location, pulsating quality, moderate or severe
pain intensity, and/or aggravation by or causing avoidance of routine physical activity
(e.g. walking or climbing stairs); at least 1 of the following occurred during headache:
nausea and/or vomiting or photophobia and/or phonophobia; stable headache severity
and pattern; headache data for at least 6 months prior to trial drug administration
Exclusion criteria: pregnancy or planning to become pregnant during the trial period;
breastfeeding; of childbearing potential and not practicing a reliable method of birth
control; people with chronic tension-type headaches based on recognised criteria; evi-
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dence of underlying conditions judged to preclude treatment with either test medica-
tion; previously used trial medications for any reason; unable to discontinue any prohib-
ited medication(s), including carbonic anhydrase inhibitors (e.g. acetazolamide, dichlor-
phenamide), digoxin, metformin, central nervous system depressants (including alcohol)
, non-trial migraine prophylaxis medications (e.g. propranolol, amitriptyline, sodium
valproate), non-trial anticonvulsant or antiepileptic medications, agents that might in-
terfere with neuromuscular function (e.g. aminoglycoside antibiotics, curare-like agents)
,or hormonal contraceptives; evidence of recent alcohol/drug abuse or acute medication
overuse
N = 60, mean age 37, M 6/F 54
CM only eligible, MOH eligibility unclear
Number of headache/migraine days during baseline period 16, migraine severity 2.9 on
5-point scale
Interventions Intervention: Botox 200 U, 100 U fixed site and 100 U follow the pain, number and
location of injection sites not reported plus placebo tablets
Control: TOPAMAX (topiramate) 100-200 mg/d, plus matched placebo injections
Outcomes Number of migraine attacks
Proportion of 50% responders
Severity of migraine
Use of rescue medication
MIDAS
MIQ
Adverse events
Notes Funder: Allergan, Inc., Irvine, California (manufacturer of Botox)
Diary period 1 month
Uncontactable
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not stated
Allocation concealment (selection bias) Unclear risk Method not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind: double dummy, participant
blinded with matched placebo injections
or placebo tablets, no methods given for
blinding of personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind: double dummy, nomethods
given for blinding of personnel
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Incomplete outcome data (attrition bias)
All outcomes
High risk Numbers analysed and numbers imputed
unclear. Dropouts excluded from analysis
higher than 10% for all outcomes
Selective reporting (reporting bias) Low risk All expected outcomes reported
Study size High risk < 50 participants per treatment arm
Mazza 2016
Methods Randomised, double-blind, placebo-controlled,parallel-group, unclear sites
2 treatments, 90-day FU, unclear at what point second treatment occurred
Follow the pain injections of BTX-A vs placebo
Assessments carried out at baseline, 30 days, 60 days and 90 days
Participants Inclusion criteria: CM with no response to intramuscular injections of BTX-A
Exclusion criteria not stated
N = 94, mean age and M/F ratio not stated
Duration of disease 18 years
Interventions Intervention: subcutaneous injection of BTX-A, up to 200 U into trigeminal or occipital
area
Control: matched placebo injections
Outcomes Number of migraine days
Proportion of 50% responders
Other outcomes not yet reported
Notes Publication due in 2017, only skeletal information available. Unpublished information
provided through correspondence with trial author
Funding source unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not stated
Allocation concealment (selection bias) Unclear risk Method not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind: the research assistant, who
had access to the randomisation list, de-
livered verum or placebo injections to the
investigator. The investigator who injected
the headache sufferers, the participants,
and the investigator who assessed outcome
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were all blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind: the research assistant, who
had access to the randomisation list, de-
livered verum or placebo injections to the
investigator. The investigator who injected
the headache sufferers, the participants,
and the investigator who assessed outcome
were all blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number of dropouts not stated
Selective reporting (reporting bias) Unclear risk Not yet published, information and data
from abstract and brief trial author corre-
spondence only
Study size High risk < 50 participants per treatment arm
Millán-Guerrero 2009
Methods Randomised, double-blind, active-control, parallel-group, multi-site
Single treatment, 12-week FU
Fixed injections of Botox vs histamine. Double dummy
Assessments carried out at baseline and every 30 days out to 12 weeks post-treatment
Participants Inclusion criteria: aged 18-65 years; history of migraine for several years; diagnosed
migrainous using criteria ICHD-II; unresponsive to available abortive (acetaminophen
(paracetamol), ergotamine, dexamethasone, sumatriptan) and/or prophylactic agents
(beta blocker, amitriptyline, sodium valproate, topiramate) without sustained pain-free
response; attack frequency of 4-6 per month; severity of 2-3; overuse of acute pharma-
cotherapy
Exclusion criteria: pregnant women; daily headaches; radiological tests revealing any
pathology, including computer-assisted tomography
N = 100, mean age 35, M 9/F 92
EM/CM unclear, MOH Y only eligible
Years since diagnosis of migraine 15, number of headache attacks during baseline diary
period 4, severity of migraine 2.9 on 3-point scale
Interventions Intervention: Botox, 50 U, 10 injections into fixed sites including procerus, corrugator,
frontalis, temporalis and occipitalis plus placebo injections into upper arm
Control: histamine, 1-10 µg injected into upper arm twice a week for 12 weeks plus
placebo injections into head and neck sites
Outcomes Number of migraine attacks
Duration of migraine
Severity of migraine
se of rescue medication
MIDAS
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Adverse events
Notes Funding source unclear
Diary period 4 weeks
Contacted without response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation
Allocation concealment (selection bias) Unclear risk Method not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, double dummy, research
collaborator prepared injections and place-
bos for both histamine and BTX in num-
bered matching vials so that neither partic-
ipants nor physicians were able to identify
drug
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind, double dummy, research
collaborator prepared injections and place-
bos for both histamine and BTX in num-
bered matching vials so that neither partic-
ipants nor physicians were able to identify
drug
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Dropouts uneven 10% vs 20% of total par-
ticipant numbers and imputation method
not stated
Selective reporting (reporting bias) Low risk All expected outcomes reported
Study size Unclear risk 50-199 participants per arm
Petri 2009
Methods Randomised, double-blind, placebo-controlled, parallel-group, multi-site
Single treatment, 12-week FU
Fixed injections of Dysport (2 dosing arms) vs placebo
Assessments carried out at baseline and 4 weeks, 8 weeks and 12 weeks post-treatment
Participants Inclusion criteria: aged 18-65 years; at least a 1-year history of migraine with or with-
out aura; first manifestation under 50 years of age; stable frequency of 3-6 attacks per
month ICHD-I; not previously received Botox; no concomitant prophylactic migraine
treatment was allowed during the trial; acute medication for migraine allowed for a max-
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imum of 10 d/month; participants restricted to only 1 type of escape medication that
they preferably used (either analgesic or triptan)
Exclusion criteria: non-migraine headaches for > 10 d/month before, but not after, injec-
tion; women who were pregnant or not using adequate contraception; history of alcohol
or other drug abuse; previously experienced an adverse reaction to Botox; treated with
aminoglycoside antibiotics (or other medication affecting neuromuscular transmission),
antidepressants, neuroleptics, antiepileptics or anticoagulants; severe psychiatric distur-
bance, a skin disorder at the injection site, a predisposition to bleeding, or an anticipated
lack of compliance and cooperation
N = 127, mean age 46, M 20/F 102 (characteristics given for analysed population - 122)
CM excluded, MOH excluded
Years since onset of migraine 27, number of migraine attacks during baseline diary period
5
Interventions Intervention (arm 1): Dysport 210 U from 18 injections, trapezius 45 U, splenius capitis
20 U, temporalis 20 U, frontalis 10 U, corrugator 10 U
Intervention (arm 2): Dysport 80 U from 18 injections, trapezius 45 U, splenius capitis
20 U, temporalis 20 U, frontalis 10 U, corrugator 10 U
Control: matched placebo injections
Outcomes Number of headache days
Number of migraine attacks
Duration of migraine
Severity of migraine
Use of rescue medication
Migraine related disability
Becks depression inventory
Total tenderness score
Patient global evaluation of treatment efficacy
Adverse events
Notes Funder: Ipsen Pharma, Ettlingen, Germany (manufacturer of Dysport)
Diary period 28 days
Contacted without response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation se-
quence
Allocation concealment (selection bias) Low risk Sealed envelopes, drug prepared by third
person
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind: participant blinded with
matched placebo injections, third person,
who was not involved with the trial pre-
pared the injections in a separate room
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind: third person, who was not
involved with the trial prepared the injec-
tions in a separate room
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk LOCF but unclear how often this had to
be used
Selective reporting (reporting bias) Unclear risk Secondary outcomes analysed descriptively
Study size High risk < 50 participants per treatment arm
Relja 2007
Methods Randomised, double-blind, placebo-controlled, parallel-group, multi-site
3 treatment cycles, 3 months FU per treatment
Fixed injections of Botox (3 dosing arms) vs placebo
Assessments carried out at baseline and 30 days, 60 days, 90 days post-treatment per
cycle
Participants Inclusion criteria: aged 18-65 years; average of at least 3 moderate-severe untreated
migraine episodes per month (ICHD-I); or at least 3 treated migraine episodes of any
severity per month; ≤ 15 headache d/month as confirmed by a headache diary during
the baseline period; migraine episodes must have occurred for at least 1 year prior to
enrolment and be first diagnosed before age 50 years; stable medical condition and
acceptable blood haematology and chemistry results; willing to discontinue headache
prophylactic medications for at least 3 months immediately prior to the initiation of the
baseline period and had to be willing and able to stay on current medications (other than
headache prophylaxis) during the course of the trial
Exclusion criteria: any medical condition or used any agent that may have put them at
risk with exposure to Botox; an infection or skin problem at any of the injection sites or
a known allergy or sensitivity to the trial medication or its components; inadequate re-
sponse to≥ 3 prophylactic treatments after an adequate trial; BeckDepression Inventory
score of > 24; psychiatric problems severe enough to interfere with trial participation or
results; previous therapy with BTX of any sero-type; been injected with anaesthetics or
steroids into the trial-targeted muscles during the 30 days immediately prior to initiation
of the baseline period; overusing or abusing symptomatic medication, alcohol or drugs;
concurrent chronic use or chronic use in the 3 months prior to the screening period of
muscle relaxants; concurrently participating in another investigational trial or who had
participated in such a trial in the 30 days immediately prior to baseline period; uncon-
trolled systemic disease or any condition that might have put the participant at signif-
icant risk, might have confounded the trial, or might have interfered significantly with
participation in the trial; women who were pregnant, nursing, or planning a pregnancy
during the trial or who were unable or unwilling to use a reliable form of contraception
during the trial
N = 495, mean age 43, M 60/F 435
CM excluded, MOH excluded
Years since onset of migraine 23
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Interventions Intervention (arm 1): Botox 255 U, 20 injections, frontalis 30 U, 4 sites; corrugator 15
U, 2 sites; temporalis 30 U, 4 sites; splenius capitis 30 U, 2 sites; trapezius 60 U, 4 sites;
semispinalis capitis 30 U, 2 sites; suboccipital region 30 U, 2 sites
Intervention (arm 2): Botox 150 U, 20 injections, frontalis 20 U, 4 sites; corrugator 10
U, 2 sites; temporalis 20 U, 4 sites; splenius capitis 20 U, 2 sites; trapezius 40 U, 4 sites;
semispinalis capitis 20 U, 2 sites; suboccipital region 20 U, 2 sites
Intervention (arm 3): Botox 75 U, 20 injections, frontalis 10 U, 4 sites; corrugator 5 U,
2 sites; temporalis 10 U, 4 sites; splenius capitis 10 U, 2 sites; trapezius 20 U, 4 sites;
semispinalis capitis 10 U, 2 sites; suboccipital region 10 U, 2 sites
Control: matched placebo injections
Outcomes Number of headache days
Number of migraine days
Number of migraine attacks
Proportion of 50% responders
Severity of migraine
Use of rescue medication
MIDAS
Headache pain specific quality of life measure
Adverse events
Notes Funder: Allergan, Inc., Irvine, California (manufacturer of Botox)
Diary period 30 days
Contacted without response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not stated
Allocation concealment (selection bias) Unclear risk Method not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind: participant blinded, with
matched placebo injections, an individual
with no other trial involvement reconsti-
tuted vials of trial medication with all di-
lutions carried out so that total volume
in each vial was the same, vials numbered
according to randomisation and reconsti-
tuted according to volume of diluent as-
signed to each randomisation number
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind: an individual with no other
trial involvement reconstituted vials of trial
medication with all dilutions carried out so
that total volume in each vial was the same,
79Botulinum toxins for the prevention of migraine in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Relja 2007 (Continued)
vials numbered according to randomisa-
tion and reconstituted according to volume
of diluent assigned to each randomisation
number
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Method of imputation not stated and
group split of dropouts not given
Selective reporting (reporting bias) Unclear risk All expected outcomes reported, primary
outcome data given but secondary data
showing no significant between-group dif-
ferences not fully reported
Study size Unclear risk 50-199 participants per arm
Saper 2007
Methods Randomised, double-blind, placebo-controlled, parallel-group, multi-site
Single treatment, 90-day FU
Fixed injections of Botox, 4 arms with different doses and sites vs placebo in all 3 muscle
sites
Assessment at baseline and at 30 days, 60 days and 90 days post-treatment
Participants Inclusion criteria: stable medical condition with migraine headaches as defined by the
ICHD- editionnot stated;with or without aura; average of 4-8moderate-severemigraine
headaches per month; aged 18-65 years; first diagnosed before age 50; able to distinguish
migraine from non migraine headaches; acute migraine therapy must have typically
relieved their migraines to an acceptable level; headache frequency/severity must have
been stable; chronic medications (if needed) must have been stable for≥ 3 months prior
to enrolment; prophylactic medications had been discontinued must have been at least
3 months before enrolment; previous medications, including any migraine prophylaxis
treatments, stay on the same dose and regimen during the course of the trial
Exclusion criteria: typical migraine pain was localised predominantly to the occipital or
suboccipital regions; > 15headache d/month (any type); history of complicatedmigraine;
migraine at the time of treatment were ineligible to be treated that day but could return
to be enrolled on a subsequent day; infection or skin problem at the injection site; other
medical condition that might have put a person at increased risk with exposure to Botox
or that was severe enough to interfere with trial participation or results; using agents that
interfered with neuromuscular function; overusing symptomatic medications; abusing
alcohol or drugs; previously receivedBTX therapy; known allergy or sensitivity to the trial
medication or its components; women who were pregnant, breastfeeding, or planning
a pregnancy during the trial period; received an injection of anaesthetic or steroid into
the muscles to be injected in the month prior to enrolment; participated in another
investigational drug or device clinical trial within the past month
N = 232, mean age 44, M 33/F 199
CM excluded, MOH excluded
Years since onset of migraine 24, number of migraine attacks during baseline diary period
6
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Interventions Intervention (arm 1): Botox 25 U in all 3 muscle areas, 11 sites
Intervention (arm 2): Botox 10 U in frontal muscle area, 4 sites, plus matched placebo
injections into temporal and glabellar muscles
Intervention (arm 3): Botox 6 U in temporal muscle area, 2 sites, plus matched placebo
injections into frontal and glabellar muscles
Intervention (arm 4): Botox 9 U in glabellar muscle, 5 sites, plus matched placebo
injections into frontal and temporal muscles
Control: placebo in all 3 muscle sites
Outcomes Number of migraine attacks
Severity of migraine
Duration of migraine
Number of nonmigraine headaches
Use of rescue medications
Presence or absence of aura
Presence or absence of associated symptoms
Patient global assessment of response to treatment
Headache pain-specific quality-of-life questionnaire
Migraine-specific measure of quality of life
Migraine impact questionnaire
SF-36
Treatment assessment questionnaire
Adverse events
Notes Funder: Allergan, Inc., Irvine, California (manufacturer of Botox)
Diary period 30 days
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not stated
Allocation concealment (selection bias) Unclear risk Method not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind: participant blinded with
matched placebo injections, no methods
given for blinding of personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind: no methods given for blind-
ing of personnel
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated from which group dropouts (7)
occurred. ITT analysis stated
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Selective reporting (reporting bias) Unclear risk All expected outcomes reported, primary
outcome data given but secondary data
with none statistically significant results
were reported narratively only
Study size High risk < 50 participants per treatment arm
Silberstein 2000
Methods Randomised, double-blind, placebo-controlled, parallel-group, multi-site
Single treatment, 3-month FU
Fixed injections of Botox (2 dosing arms) vs placebo
Assessments carried out at baseline and at 1 month, 2 months and 3 months post-
treatment
Participants Inclusion criteria: aged 18-65 years; history of ICHD-1definedmigraine, with orwithout
aura; average of 2-8 moderate-severe migraines per month over the previous 3 months;
2-8 such migraines during the 1-month baseline period; first diagnosis of migraine
before the age of 50 years; able to distinguish migraine from non-migraine headaches;
stable frequency and severity of migraines; no unstable medical conditions; migraines
relieved to an acceptable level by acutemigraine therapy; doses of concurrent prophylactic
medications for migraine stable for at least 3 months immediately prior to enrolment
Exclusion criteria: any medical condition or the use of any agent that may have put
the participant at risk with exposure to Botox; history of complicated migraine; typical
migraine pain localised predominantly to the occipital or suboccipital region of the
cranium; planned or actual pregnancy or lactation; known allergy or sensitivity to the
trial medication or its components; injection of anaesthetic or steroid into the muscles
to be injected in the month immediately prior to enrolment; > 15 headache d/month;
symptomatic medication overuse
N = 123, mean age 44, M 18/F 105
CM excluded, MOH excluded
Years since onset of migraine 23, number of migraine attacks during baseline diary period
4
Interventions Intervention (arm 1): Botox 75 U in 11 injection sites (frontalis 30 U, 4 sites; temporalis
18 U, 2 sites; glabellar 27 U, 5 sites)
Intervention (arm 2): Botox 25 U in 11 injection sites (frontalis 10 U, 4 sites; temporalis
6 U, 2 sites; glabellar 9 U, 5 sites)
Control: matched placebo injections
Outcomes Number of migraine attacks
Proportion of 50% responders
Severity of migraine
Use of rescue medication
Patient global assessment of response to treatment
Adverse events
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Notes Funder: Allergan, Inc., Irvine, California (manufacturer of Botox)
Diary period 30 days
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not stated
Allocation concealment (selection bias) Unclear risk Method not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind: participant blinded with
matched placebo injections no methods
given for blinding of personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind: no methods given for blind-
ing of personnel
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 1 participant dropped out
Selective reporting (reporting bias) Unclear risk Incomplete reporting of outcomes
Study size High risk < 50 participants per treatment arm
Vo 2007
Methods Randomised, double-blind, placebo-controlled, parallel-group, single-site
Single treatment, 3-month FU
Fixed injections of BTX-A (brand not reported) vs placebo
Assessments carried out at baseline and 1 month, 2 months and 3 months postbaseline
Participants Inclusion criteria: aged 18-65; migraine headaches occurring > 5 times/month and meet-
ing ICHD-I criteria for migraine headache with or without aura
Exclusion criteria: none stated
N = 49, (analysed population used for baseline characteristics N = 32) mean age 42, M
5/F 27
EM/CM unclear, MOH eligibility unclear
Years withmigraine 20, number ofmigraine days during baseline diary period 19, severity
of migraine 5.2 on 10 cm VAS
Interventions Intervention: BTX-A (brand not reported), weight-based dosing, < 65 kg: 135 U, ≥ 65
kg: 210 U, 22 injection sites (corrugator 2 sites 5 U/5 U, frontalis 4 sites 20 U/20 U,
temporalis 4 sites 20 U/40 U, posterior neck 6 sites 60 U/90 U, occipitalis 2 sites 10 U/
10 U, sternocleidomastoid 4 sites 20 U/40 U)
Control: matched placebo injections
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Outcomes Number of migraine attacks
Severity of migraine
Duration of migraine
Use of rescue medication
Migraine-specific questionnaire
Notes Funder: Comprehensive Neuroscience Program and the Uniformed Services University
of the Health Sciences award
Diary period 30 days
Contacted without response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation se-
quence
Allocation concealment (selection bias) Unclear risk Method not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind: participant blinded with
matched placebo injections no methods
given for blinding of personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind: no methods given for blind-
ing of personnel
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Numbers randomised to each group and
dropouts per group not stated
Selective reporting (reporting bias) Unclear risk All expected outcomes reported, primary
outcome data given but some secondary
data with no significant between group dif-
ferences were not fully reported
Study size High risk < 50 participants per treatment arm
AE: adverse event; BTX: botulinum toxin; BTX-A: botulinum toxin type A; CM: chronic migraine; EM: episodic migraine; F: female;
FU: follow-up; LOCF: last observation carried forward; HIT-6: Headache Impact Test - 6 question version; HRQoL: Health-
Related Quality-of-Life score; ICHD: International Classification of Headache Disorders; IHS: International Headache Society
ITT: intention-to-treat;M: male;MIDAS: Migraine Disability Assessment Score;MIGSEV: migraine severity scale;MIQ:Migraine
Impact Questionnaire; MOH: medication overuse headache; OL: open-label; QUALY: quality adjusted life years; SF-36: 36-Item
Short Form Health Survey; TENS: transcutaneous electrical nerve stimulation; VAS: visual analogue scale
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Cady 2012 No relevant comparison, BTX used in both arms
De Tommaso 2016 Clinical assessments carried out at baseline and after all participants had crossed over to receive BTX, no
precross-over recording of clinical outcomes took place
Evers 2004 Some included participants had tension-type headache and migraine; contact with trial author confirmed that
data for migraine-only participants were not available
Guyuron 2005 Surgical removal of trigger sites in addition to BTX treatment
Ondo 2004 Trial of people with chronic daily headache; contact with trial author confirmed that data for migraine-only
participants were not available
Ruggeri 2013 Health economics paper, data sourced from trial publications
Schwedt 2007 Report of placebo-treated participants only
BTX: botulinum toxin
Characteristics of studies awaiting assessment [ordered by study ID]
Brin 2000
Methods Randomised, double-blind, placebo-controlled, parallel-group, multi-site
Single treatment with 12-week FU
4 arms of injections of Botox vs placebo
Assessments carried out at baseline, 2, 4, 8, 12 and 16 weeks
Participants Inclusion criteria not stated
Exclusion criteria not stated
N = 48
CM/EM eligibility unclear, MOH eligibility unclear
Interventions Intervention (arm 1): injections of Botox (dose and number of injections unclear) into frontal and temporal sites
Intervention (arm 2): matched injections of Botox into frontal sites and injections of placebo into temporal sites
Intervention (arm 3): matched injections of placebo into frontal sites and injections of Botox into temporal sites
Control: matched injections of placebo into frontal and temporal sites
Outcomes Frequency of migraine
Duration of migraine
Severity of migraine
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Notes Abstract only
Funder: Allergan Inc
Diary period not stated
Ipsen 2006
Methods Randomised, double-blind, placebo-controlled, parallel-group, multi-site
Number of treatment sessions not stated, 3-month time frame
Injections of Dysport (fixed or follow the pain not stated) vs placebo
Assessment time points not stated
Participants Inclusion criteria: migraine without aura or with typical aura as defined by IHS criteria, migraine attacks persisting
for > 1 year; 2-6 migraine attacks/month of at least moderate severity over the 3 months preceding the pre-inclusion
visit; 2-6 migraine attacks of at least moderate severity during the screening period
Exclusion criteria: non-migraine headaches such as tension-type headaches; migraine with prolonged aura, familial
hemiplegic migraine, basilar migraine, migraine aura without headache, migraine with acute onset aura, ophthalmo-
plegic migraine, retinal migraine, complications of migraine; onset of migraine is after age of 50; overuse of acute
migraine medications (individuals who take medications for acute migraine > 10 d/month) or have a history of drug
or alcohol abuse
Target N = 150
CM/EM included, MOH excluded
Interventions Intervention: Dysport injections into pericranial muscles, number and dose not stated
Control: placebo
Outcomes Number of migraine attacks
Intensity of the migraine attacks
Duration of the migraine attacks
Use of rescue medication
Quality-of-life measure (instrument unspecified)
Notes Protocol (NCT00301665) only, enrolment completed 2005
Funder Ipsen
Diary period not stated
Kuper 2007
Methods Not stated if randomised but is stated as double-blind, placebo-controlled, parallel-group, number of sites unclear
2 treatment cycles, 90 days between treatments
Fixed injections of Botox vs placebo
Assessments carried out at 3 months after each treatment session
Participants Inclusion criteria: aged 18-65 years; 3-15 days migraine per month; suffered migraines for at least 1 year
Exclusion criteria not stated
Target N = 90
CM excluded, MOH eligibility unclear
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Interventions Intervention: Botox (25 U) in fixed muscle injection sites (temporalis, frontalis, procerus, corrugator)
Control: matched placebo injections
Outcomes Frequency of migraine (unit not stated)
Use of rescue medication
Quality-of-life measure (instrument unspecified)
Notes Trial design publication only
Funder: German Federal Ministry of Education and Research
Diary period not stated
Mathew 2005
Methods Randomised, double-blind, placebo-controlled, parallel-group, multi-site
3 treatment cycles, 90 days between treatments
Follow the pain injections of Botox vs placebo following a single-blind placebo run-in phase to classify participants
as placebo responders or nonresponders
Assessments carried out at baseline, and every 30 days out to day 270. An additional assessment for days -60 to -30
was carried out to make the placebo response classification
Participants Inclusion criteria: aged 18-65 years; headaches on > 15 days of the 30-day baseline period; any combination of mi-
graines, with/without aura, migrainous/probable migraine, and/or episodic/chronic tension-type headaches defined
by ICHD-I criteria; stable medical condition; chronic medication regimens, including prophylactic medications, had
to be stable for at least 3 months prior to baseline period; willing and able to stay on current medications during the
course of the trial
Exclusion criteria: any medical condition or used any agent that may have put them at risk with exposure to Botox;
infection or skin problem at any of the injection sites; known allergy or sensitivity to the trial medication or its
components; history of “complicated” migraine; Beck Depression inventory score > 24; previous therapy with BTX
of any serotype, an injection of anaesthetics or steroids into the trial-targeted muscles during the 30 days prior to
baseline period; overusing or abusing symptomatic medication, alcohol, or drugs; concurrent chronic use or chronic
use in the 3months prior to the screening period of muscle relaxants; women who were pregnant, nursing, or planning
a pregnancy during the trial, or who were unable or unwilling to use a reliable form of contraception during the trial
N = 355, mean age 43.5 years, M 55/F 300 (inclusive of all headache types)
Baseline characteristics for migraine-only participants not stated
Interventions Intervention: Botox 105-200 U, number of injections per site determined by treating physician (frontal/glabellar 25-
40 U, occipitalis 20 U, temporalis 20-50 U, masseter optional; 0-50 U, trapezius 20-60 U, semispinalis 10-20 U,
splenius capitis 10-20 U)
Control: matched placebo injections
Outcomes Number of headache-free days
Proportion of responders
Number of headache attacks
Use of rescue medication
MIDAS
Headache Pain-Specific Quality of life questionnaire
Adverse events
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Notes Data for migraine-only participants required for inclusion
Funder: Allergan Inc
Diary period 30 days
Silberstein 2005
Methods Randomised, double-blind, placebo-controlled, parallel-group, multi-site
3 treatment cycles, 90 days between treatments
Fixed injections of Botox (3 dosing arms) vs placebo following a single-blind placebo run-in phase to classify partic-
ipants as placebo responders or nonresponders
Assessments carried out at baseline, and every 30 days out to day 270. An additional assessment for days -60 to -30
was carried out to make the placebo response classification
Participants Inclusion criteria: aged 18-65 years; headaches on > 15 days during a 30-day baseline period; headaches could include
any combination of migraines: those with/without aura, migrainous headache, probable migraine, and/or episodic
or chronic tension-type headaches according to ICHD-I criteria; medically stable; long-term medication (including
long-term prophylactic headache medications) had to be stable for at least 3 months immediately before the baseline
period; acute headache pain medication could be taken as needed; willing to continue taking current medications
during the course of the trial
Exclusion criteria: any medical condition (e.g. neuromuscular disorders) or used any agent that might expose them
to risk if they received Botox; infection or skin problem at any of the injection sites, known allergy or sensitivity
to the trial medication or to its components; cluster headache or chronic paroxysmal hemicrania, analgesic rebound
headache, headache secondary to head trauma or whiplash injury, a history of “complicated”migraine (e.g.migrainous
infarction, hemiplegic migraine, ophthalmoplegic migraine, or basilar migraine), a Beck Depression Inventory score
> 24, previous therapy with BTX of any serotype, an injection of anaesthetics or corticosteroids into the trial-targeted
muscles during the 30 days immediately before the baseline period; abuse of symptomatic medication, alcohol,
or drugs; concurrent or long-term use of muscle relaxants (e.g. cyclobenzaprine, carisoprodol, or benzodiazepines)
during the 3 months before the screening period was prohibited; women who were pregnant or nursing or unable or
unwilling to use a reliable form of contraception during the trial
N = 702, mean age 43.4 years, M 120/F 582 (inclusive of all headache types)
Baseline characteristics for migraine-only participants not stated
Interventions Intervention (arm 1): Botox 255 U, 20 injections, frontalis 30 U, 4 sites; corrugator 15 U, 2 sites; temporalis 30 U,
4 sites; splenius capitis 30 U, 2 sites; trapezius 60 U, 4 sites; semispinalis capitis 30 U, 2 sites; suboccipital region 30
U, 2 sites
Intervention (arm 2): Botox 150 U, 20 injections, frontalis 20 U, 4 sites; corrugator 10 U, 2 sites; temporalis 20 U,
4 sites; splenius capitis 20 U, 2 sites; trapezius 40 U, 4 sites; semispinalis capitis 20 U, 2 sites; suboccipital region 20
U, 2 sites
Intervention (arm 3): Botox 75 U, 20 injections, frontalis 10 U, 4 sites; corrugator 5 U, 2 sites; temporalis 10 U, 4
sites; splenius capitis 10 U, 2 sites; trapezius 20 U, 4 sites; semispinalis capitis 10 U, 2 sites; suboccipital region 10
U, 2 sites
Control: matched placebo injections
Outcomes Number of headache-free days
Proportion of responders
Number of headache attacks
Number of moderate-severe migraines
Use of rescue medication
88Botulinum toxins for the prevention of migraine in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Silberstein 2005 (Continued)
MIDAS
Headache Pain-Specific Quality of life questionnaire
AE
Notes Data for migraine-only participants required for inclusion
Funder: Allergan Inc
Diary period 30 days
AE: adverse event; BTX: botulinum toxin; CM: chronic migraine; EM: episodic migraine; F: female; FU: follow-up; ICHD: Interna-
tional Classification ofHeadacheDisorders; IHS: International Headache SocietyM: male;MIDAS: Migraine Disability Assessment
Score;MOH: medication overuse headache
Characteristics of ongoing studies [ordered by study ID]
NCT02074163
Trial name or title ASIS for Botox in chronic migraine (ASISinCM)
Methods Randomised, double-blind, active control, parallel-group
Aim 2 only relevant to this review: guided delivery of Botox into subdermal bloodless space, between the skin
and muscle vs Botox injected intramuscularly
Participants Inclusion criteria: aged 18-65 years; history of chronic migraine (with/without aura) according to the criteria
proposed by the Headache Classification Committee of the IHS for at least 3 months prior to enrolment;
preventive medication, if taking, must be stable for at least 3 months
Exclusion criteria: headache disorders outside IHS-defined chronicmigraine definition; evidence of underlying
pathology contributing to their headaches; any pathology of the salivary glands such as sialadenitis or condition
or symptom that would alter the content of saliva; any medical condition that may increase their risk with
exposure to Botox including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral
sclerosis, or any other significant disease that might interfere with neuromuscular function; profound atrophy
or weakness of muscles in the target areas of injection
Target N = 60
Interventions Intervention: Botox injection guided by device to delivery into subdermal bloodless space between skin and
muscle at 6 muscle group sites (glabella, frontal, temporal, occipital, paraspinal, and trapezius)
Control: conventional intramuscular injections of Botox in same muscle groups (Gglabella, frontal, temporal,
occipital, paraspinal, and trapezius)
Outcomes Number of headache days
Total cumulative hours of headache on headache days
AE
Starting date January 2016
Contact information Li Nguyen, MD (714)-453-7857 dr.li.nguyen@asis-inc.com
Thanh Phung, MD 714-893-1915 thanhphung@idit-inc.com
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NCT02074163 (Continued)
Notes The recruitment status of this trial is unknown. The completion date has passed and the status has not been
verified in more than two years
Protocol: NCT:02074163
Funder: ASIS Corporation listed as sponsors and collaborators
NCT02291380
Trial name or title A study to evaluate botulinum toxin type A for injection HengLi for prophylactic treatment of chronic
migraine
Methods Randomised, double-blind, placebo-controlled, parallel-group
Hypothesis relating to this review: that Botox for injection (HengLi) for prophylactic treatment with chronic
migraine in adults is safe and efficacious
Participants Inclusion criteria: age ≥ 18 and ≤ 65, male or female; complying with the ICHD-3(β) diagnostic criteria
for chronic migraine
Exclusion criteria: pregnancy, nursing, or planning a pregnancy during the trial period, or women of child-
bearing potential, not using a reliable means of contraception; known allergy or sensitivity to trial medication
or its component; accepted prophylactic treatments of migraine within the 4 weeks before screening; cardiac
functional insufficiency; renal insufficiency (serum creatinine > 1.5 times upper limit of normal); hepatic
diseases (alanine aminotransferase or aspartate aminotransferase > twice upper limit of normal); systemic
myoneural junction diseases (e.g. myasthenia, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, etc.);
history of facial palsy; infection or dermatological condition at the injection sites;
other types of migraine that do not comply with the diagnostic criteria for chronic migraine; BTX therapy
in the past 6 months; used aminoglycoside antibiotics in the recent week or need to use aminoglycoside
antibiotics during conduct of the clinical trial; severe cognitive disorder or mental illness, alcohol or drug
abuse; involved in other clinical trials over the 3 months prior to this trial
Target N = 288
Interventions Intervention: Botox for injection in these trials, minimum intramuscular dose of 155 U of Botox (HengLi)
administered to 31 injection sites across 7 head and neck muscles using a fixed-site, fixed-dose injection
paradigm (each injection was 5 U in 0.1 mL). In addition, up to 40 U Botox, administered intramuscularly
to 8 additional injection sites across 3 head and neck muscles, was allowed, using a follow-the-pain approach.
Thus, the minimum dose was 155 U and the maximum dose was 195 U
Control: matched placebo injections
Outcomes Number of headache days
Number of headache attacks
Number of migraine attacks
Proportion of responders (≥ 50% reduction in migraine)
Use of rescue medications
Severity of migraine
Duration of migraine
MIDAS
HIT-6
Starting date September 2014
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NCT02291380 (Continued)
Contact information Lanzhou Institute of Biological Products Co., Ltd
Notes Protocol NCT02291380
Funder: Lanzhou Institute of Biological Products Co., Ltd listed as Sponsors and Collaborators
NTR3440
Trial name or title Chronification and reversibility of migraine (CHARM)
Methods Randomised, double-blind, placebo-controlled, parallel-group
Hypothesis relating to this review: treatment with BTX-A injections (at the start of the therapy) will increase
the success rate of withdrawal therapy or will improve quality of life during the withdrawal period
Participants Inclusion criteria: suffering from chronic migraine according to the ICHD-II criteria for chronic migraine
with medication overuse according to the ICHD-II criteria
Exclusion criteria: age under 18 years; other neurological conditions that may interfere with the trial; any
oncological or psychiatric disease, any cognitive disorders and/or behavioural problems which may interfere
with the trial; substance abuse; use of non-triptan or non-analgesic acute anti-headachemedication; pregnancy,
planned pregnancy, current nursing; specific risk factors for BTX and magnetic resonance imaging
Target N = 180
Interventions Intervention: withdrawal therapy with 1-time concomitant BTX-A injections in 31 locations according to
the injection protocol by Allergan (total 155U)
Placebo: withdrawal therapy with 1-time concomitant low-dose BTX-A injections in the facial region and
NaCl injections in the other regions according to the injection protocol by Allergan (Total 17.5U)
Withdrawal therapy is considered standard treatment for this group and takes 3 months. During this time,
participants will be guided by a trained headache-nurse
Outcomes Number of headache days
Number of migraine days
Number of migraine attacks
Proportion of responders (≥ 50% reduction in migraine)
HIT-6
Depression scales
SF-36 questionnaire
Starting date 1 September 2012
Contact information G.M.Terwindt@lumc.nl
Notes Full publication due in 2017
Protocol NTR3440
Funder: NWO (VIDI grant)
AE: adverse events;BTX: botulinum toxin; BTX-A: botulinum toxin type AHIT-6: Headache Impact Test-6 question version; ICHD:
International Classification of Headache Disorders; IHS: International Headache Society;MIDAS: Migraine Disability Assessment
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D A T A A N D A N A L Y S E S
Comparison 1. Botulinum toxin type A versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of migraine days 5 1915 Mean Difference (IV, Random, 95% CI) -2.39 [-4.02, -0.76]
1.1 Chronic migraine 4 1497 Mean Difference (IV, Random, 95% CI) -3.07 [-4.73, -1.41]
1.2 Episodic migraine 1 418 Mean Difference (IV, Random, 95% CI) -0.20 [-0.77, 0.37]
2 Number of headache days 2 1384 Mean Difference (IV, Random, 95% CI) -1.86 [-2.74, -0.98]
2.1 Chronic migraine 2 1384 Mean Difference (IV, Random, 95% CI) -1.86 [-2.74, -0.98]
3 Number of migraine attacks 6 2004 Mean Difference (IV, Random, 95% CI) -0.46 [-1.34, 0.41]
3.1 Chronic migraine 1 679 Mean Difference (IV, Random, 95% CI) 0.10 [-0.71, 0.91]
3.2 Episodic migraine 3 1096 Mean Difference (IV, Random, 95% CI) 0.13 [-0.17, 0.43]
3.3 Mixed 2 229 Mean Difference (IV, Random, 95% CI) -2.08 [-6.78, 2.63]
4 Severity of migraine (Visual
Analogue Score 0-10)
4 209 Mean Difference (IV, Random, 95% CI) -3.30 [-4.16, -2.45]
4.1 Chronic migraine 2 75 Mean Difference (IV, Random, 95% CI) -2.70 [-3.31, -2.09]
4.2 Episodic migraine 1 32 Mean Difference (IV, Random, 95% CI) -4.9 [-6.56, -3.24]
4.3 Mixed 1 102 Mean Difference (IV, Random, 95% CI) -3.5 [-4.52, -2.48]
5 Use of rescue medication 2 717 Mean Difference (IV, Random, 95% CI) -1.29 [-3.09, 0.52]
5.1 Chronic migraine 2 717 Mean Difference (IV, Random, 95% CI) -1.29 [-3.09, 0.52]
6 Total adverse events 13 3325 Risk Ratio (M-H, Random, 95% CI) 1.28 [1.12, 1.47]
6.1 Chronic migraine 5 1494 Risk Ratio (M-H, Random, 95% CI) 1.22 [1.07, 1.40]
6.2 Episodic migraine 6 1673 Risk Ratio (M-H, Random, 95% CI) 1.28 [1.02, 1.60]
6.3 Mixed 2 158 Risk Ratio (M-H, Random, 95% CI) 1.47 [0.57, 3.76]
7 Adverse event - blepharoptosis 7 1867 Risk Ratio (M-H, Random, 95% CI) 7.29 [3.18, 16.73]
7.1 Episodic migraine 5 1637 Risk Ratio (M-H, Random, 95% CI) 9.53 [3.87, 23.44]
7.2 Mixed 2 230 Risk Ratio (M-H, Random, 95% CI) 1.58 [0.18, 13.59]
8 Adverse event - muscle weakness 6 2602 Risk Ratio (M-H, Random, 95% CI) 13.67 [6.73, 27.75]
8.1 Chronic migraine 2 1379 Risk Ratio (M-H, Random, 95% CI) 12.68 [3.49, 46.05]
8.2 Episodic migraine 4 1223 Risk Ratio (M-H, Random, 95% CI) 14.12 [6.05, 32.94]
9 Adverse event - neck pain 6 2424 Risk Ratio (M-H, Random, 95% CI) 2.98 [2.06, 4.32]
9.1 Chronic migraine 3 1432 Risk Ratio (M-H, Random, 95% CI) 2.47 [1.48, 4.12]
9.2 Episodic migraine 2 864 Risk Ratio (M-H, Random, 95% CI) 3.93 [2.27, 6.79]
9.3 Mixed 1 128 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.09, 10.47]
10 Adverse event - injection site
pain
8 1332 Risk Ratio (M-H, Random, 95% CI) 2.10 [1.02, 4.33]
10.1 Chronic migraine 3 115 Risk Ratio (M-H, Random, 95% CI) 2.57 [0.81, 8.15]
10.2 Episodic migraine 3 987 Risk Ratio (M-H, Random, 95% CI) 3.23 [1.14, 9.13]
10.3 Mixed 2 230 Risk Ratio (M-H, Random, 95% CI) 0.20 [0.03, 1.58]
11 Total treatment related adverse
events
6 2893 Risk Ratio (M-H, Random, 95% CI) 2.18 [1.73, 2.75]
11.1 Chronic migraine 2 1379 Risk Ratio (M-H, Random, 95% CI) 2.32 [1.85, 2.91]
11.2 Episodic migraine 4 1514 Risk Ratio (M-H, Random, 95% CI) 2.06 [1.37, 3.08]
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12 Withdrawals due to adverse
events in trials with multiple
rounds of treatment.
4 2248 Risk Ratio (M-H, Random, 95% CI) 3.28 [1.52, 7.07]
12.1 Chronic migraine 2 1384 Risk Ratio (M-H, Random, 95% CI) 3.71 [1.38, 9.98]
12.2 Episodic migraine 2 864 Risk Ratio (M-H, Random, 95% CI) 2.73 [0.81, 9.19]
Comparison 2. Botulinum toxin type A versus other established prophylactic agent
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Migraine impact and disability
assessment scores
2 101 Mean Difference (IV, Random, 95% CI) 4.27 [-28.15, 36.69]
1.1 Chronic migraine 1 42 Mean Difference (IV, Random, 95% CI) 22.8 [-2.56, 48.16]
1.2 Mixed 1 59 Mean Difference (IV, Random, 95% CI) -10.50 [-23.23, 2.
23]
2 Total adverse events 2 114 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.37, 1.88]
2.1 Chronic migraine 1 55 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.94, 1.14]
2.2 Mixed 1 59 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.44, 1.00]
3 Total treatment related adverse
events
2 114 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.59, 0.98]
3.1 Chronic migraine 1 55 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.60, 1.08]
3.2 Mixed 1 59 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.38, 1.09]
4 Withdrawals due to adverse
events in trials with multiple
rounds of treatment.
2 119 Risk Ratio (M-H, Random, 95% CI) 0.28 [0.10, 0.79]
4.1 Chronic migraine 1 60 Risk Ratio (M-H, Random, 95% CI) 0.38 [0.11, 1.28]
4.2 Mixed 1 59 Risk Ratio (M-H, Random, 95% CI) 0.12 [0.02, 0.91]
Comparison 3. Dysport ≥ 150 U versus Dysport < 150 U
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total adverse events 2 150 Risk Ratio (M-H, Random, 95% CI) 1.59 [0.47, 5.32]
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Comparison 4. Botox dosing studies
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of migraine days 2 353 Mean Difference (IV, Random, 95% CI) 0.40 [-0.19, 0.99]
1.1 Episodic migraine Botox
≥ 50 U vs Botox < 50
2 353 Mean Difference (IV, Random, 95% CI) 0.40 [-0.19, 0.99]
2 Adverse event - muscle weakness 1 754 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.84, 1.39]
2.1 Botox ≥ 200 U versus
Botox < 200 U
1 377 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.73, 1.47]
2.2 Botox ≥ 150 U versus
Botox < 150 U
1 377 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.78, 1.64]
3 Adverse event - blepharoptosis 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 ≥ 50 U versus < 50 U in
frontalis and/or corrugator
1 377 Risk Ratio (M-H, Random, 95% CI) 2.31 [1.20, 4.43]
3.2 ≥ 30 U versus < 30 U in
frontalis and/or corrugator
2 459 Risk Ratio (M-H, Random, 95% CI) 2.36 [0.58, 9.65]
3.3 ≥ 10 U versus < 10 U in
frontalis and/or corrugator
2 406 Risk Ratio (M-H, Random, 95% CI) 2.42 [0.99, 5.94]
4 Adverse event - neck pain 1 754 Risk Ratio (M-H, Random, 95% CI) 1.22 [0.91, 1.65]
4.1 Botox ≥ 200 U versus
Botox < 200 U
1 377 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.83, 1.89]
4.2 Botox ≥ 150 U versus
Botox < 150 U
1 377 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.76, 1.86]
5 Adverse event - injection site
pain
2 959 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.52, 2.51]
5.1 Botox ≥ 200 U versus
Botox < 200 U
2 500 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.13, 11.97]
5.2 Botox ≥150 U versus
Botox <150 U
1 377 Risk Ratio (M-H, Random, 95% CI) 1.45 [0.48, 4.41]
5.3 Botox ≥ 50 U versus
Botox < 50 U
1 82 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.34, 4.12]
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Analysis 1.1. Comparison 1 Botulinum toxin type A versus placebo, Outcome 1 Number of migraine days.
Review: Botulinum toxins for the prevention of migraine in adults
Comparison: 1 Botulinum toxin type A versus placebo
Outcome: 1 Number of migraine days
Study or subgroup Botulinum toxin Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Chronic migraine
Aurora 2010 (PREEMPT 1) 341 -7.6 (6.5) 338 -6.1 (6.8) 24.3 % -1.50 [ -2.50, -0.50 ]
Cady 2014 9 -10.1 (5.9) 10 -5.2 (5.1) 7.6 % -4.90 [ -9.88, 0.08 ]
Diener 2010 (PREEMPT 2) 347 -8.7 (6.6) 358 -6.3 (6.7) 24.4 % -2.40 [ -3.38, -1.42 ]
Mazza 2016 63 9.4 (8.6) 31 15.1 (1.8) 17.9 % -5.70 [ -7.92, -3.48 ]
Subtotal (95% CI) 760 737 74.1 % -3.07 [ -4.73, -1.41 ]
Heterogeneity: Tau2 = 1.84; Chi2 = 12.56, df = 3 (P = 0.01); I2 =76%
Test for overall effect: Z = 3.62 (P = 0.00029)
2 Episodic migraine
Elkind I 2006 312 -1.4 (2.5) 106 -1.2 (2.6) 25.9 % -0.20 [ -0.77, 0.37 ]
Subtotal (95% CI) 312 106 25.9 % -0.20 [ -0.77, 0.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Total (95% CI) 1072 843 100.0 % -2.39 [ -4.02, -0.76 ]
Heterogeneity: Tau2 = 2.59; Chi2 = 35.80, df = 4 (P<0.00001); I2 =89%
Test for overall effect: Z = 2.88 (P = 0.0040)
Test for subgroup differences: Chi2 = 10.26, df = 1 (P = 0.00), I2 =90%
-20 -10 0 10 20
Favours botulinum toxin Favours placebo
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Analysis 1.2. Comparison 1 Botulinum toxin type A versus placebo, Outcome 2 Number of headache days.
Review: Botulinum toxins for the prevention of migraine in adults
Comparison: 1 Botulinum toxin type A versus placebo
Outcome: 2 Number of headache days
Study or subgroup Botulinum toxin Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Chronic migraine
Aurora 2010 (PREEMPT 1) 341 -7.8 (6.6) 338 -6.4 (6.7) 49.2 % -1.40 [ -2.40, -0.40 ]
Diener 2010 (PREEMPT 2) 347 -9 (6.5) 358 -6.7 (6.7) 50.8 % -2.30 [ -3.27, -1.33 ]
Total (95% CI) 688 696 100.0 % -1.86 [ -2.74, -0.98 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 1.60, df = 1 (P = 0.21); I2 =37%
Test for overall effect: Z = 4.13 (P = 0.000037)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours botulinum toxin Favours placebo
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Analysis 1.3. Comparison 1 Botulinum toxin type A versus placebo, Outcome 3 Number of migraine
attacks.
Review: Botulinum toxins for the prevention of migraine in adults
Comparison: 1 Botulinum toxin type A versus placebo
Outcome: 3 Number of migraine attacks
Study or subgroup Botulinum toxin Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Chronic migraine
Aurora 2010 (PREEMPT 1) 341 -4.8 (5.1) 338 -4.9 (5.7) 16.9 % 0.10 [ -0.71, 0.91 ]
Subtotal (95% CI) 341 338 16.9 % 0.10 [ -0.71, 0.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
2 Episodic migraine
Aurora 2007 187 -2.5 (2.9) 182 -2.9 (2.3) 18.4 % 0.40 [ -0.13, 0.93 ]
Relja 2007 377 -2.4 (2.1) 118 -2.4 (1.9) 19.0 % 0.0 [ -0.40, 0.40 ]
Saper 2007 187 -1.4 (2.2) 45 -1.4 (2.8) 16.5 % 0.0 [ -0.88, 0.88 ]
Subtotal (95% CI) 751 345 54.0 % 0.13 [ -0.17, 0.43 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.47, df = 2 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.83 (P = 0.41)
3 Mixed
Chankrachang 2011 86 -1.9 (2.8) 41 -2.2 (2.6) 15.8 % 0.30 [ -0.69, 1.29 ]
Hou 2015 83 2.7 (1.1) 19 7.2 (3) 13.3 % -4.50 [ -5.87, -3.13 ]
Subtotal (95% CI) 169 60 29.1 % -2.08 [ -6.78, 2.63 ]
Heterogeneity: Tau2 = 11.15; Chi2 = 30.96, df = 1 (P<0.00001); I2 =97%
Test for overall effect: Z = 0.86 (P = 0.39)
Total (95% CI) 1261 743 100.0 % -0.46 [ -1.34, 0.41 ]
Heterogeneity: Tau2 = 1.01; Chi2 = 43.97, df = 5 (P<0.00001); I2 =89%
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Chi2 = 0.84, df = 2 (P = 0.66), I2 =0.0%
-20 -10 0 10 20
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Analysis 1.4. Comparison 1 Botulinum toxin type A versus placebo, Outcome 4 Severity of migraine (Visual
Analogue Score 0-10).
Review: Botulinum toxins for the prevention of migraine in adults
Comparison: 1 Botulinum toxin type A versus placebo
Outcome: 4 Severity of migraine (Visual Analogue Score 0-10)
Study or subgroup Botulinum toxin Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Chronic migraine
Hollanda 2014 20 3.45 (2.39) 18 6.17 (2.5) 18.3 % -2.72 [ -4.28, -1.16 ]
Lauretti 2014 28 6.5 (1.3) 9 9.2 (0.7) 36.6 % -2.70 [ -3.36, -2.04 ]
Subtotal (95% CI) 48 27 54.9 % -2.70 [ -3.31, -2.09 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 8.67 (P < 0.00001)
2 Episodic migraine
Anand 2006 16 2.4 (3.2) 16 7.3 (1.1) 17.0 % -4.90 [ -6.56, -3.24 ]
Subtotal (95% CI) 16 16 17.0 % -4.90 [ -6.56, -3.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.79 (P < 0.00001)
3 Mixed
Hou 2015 83 2.8 (1.2) 19 6.3 (2.2) 28.1 % -3.50 [ -4.52, -2.48 ]
Subtotal (95% CI) 83 19 28.1 % -3.50 [ -4.52, -2.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.71 (P < 0.00001)
Total (95% CI) 147 62 100.0 % -3.30 [ -4.16, -2.45 ]
Heterogeneity: Tau2 = 0.40; Chi2 = 6.74, df = 3 (P = 0.08); I2 =55%
Test for overall effect: Z = 7.58 (P < 0.00001)
Test for subgroup differences: Chi2 = 6.74, df = 2 (P = 0.03), I2 =70%
-10 -5 0 5 10
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Analysis 1.5. Comparison 1 Botulinum toxin type A versus placebo, Outcome 5 Use of rescue medication.
Review: Botulinum toxins for the prevention of migraine in adults
Comparison: 1 Botulinum toxin type A versus placebo
Outcome: 5 Use of rescue medication
Study or subgroup Botulinum toxin Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Chronic migraine
Aurora 2010 (PREEMPT 1) 341 -10.3 (18.7) 338 -10.4 (18.5) 30.6 % 0.10 [ -2.70, 2.90 ]
Hollanda 2014 20 -3.5 (2.1) 18 -1.6 (2.2) 69.4 % -1.90 [ -3.27, -0.53 ]
Total (95% CI) 361 356 100.0 % -1.29 [ -3.09, 0.52 ]
Heterogeneity: Tau2 = 0.74; Chi2 = 1.58, df = 1 (P = 0.21); I2 =37%
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours botulinum toxin Favours placebo
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Analysis 1.6. Comparison 1 Botulinum toxin type A versus placebo, Outcome 6 Total adverse events.
Review: Botulinum toxins for the prevention of migraine in adults
Comparison: 1 Botulinum toxin type A versus placebo
Outcome: 6 Total adverse events
Study or subgroup Botulinum toxin Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Chronic migraine
Allergan 2015 9/25 2/27 0.9 % 4.86 [ 1.16, 20.36 ]
Aurora 2010 (PREEMPT 1) 203/340 156/334 17.0 % 1.28 [ 1.11, 1.48 ]
Diener 2010 (PREEMPT 2) 226/347 202/358 18.1 % 1.15 [ 1.02, 1.30 ]
Hollanda 2014 9/20 7/18 2.8 % 1.16 [ 0.54, 2.46 ]
Jabbari 2014 1/13 0/12 0.2 % 2.79 [ 0.12, 62.48 ]
Subtotal (95% CI) 745 749 38.9 % 1.22 [ 1.07, 1.40 ]
Total events: 448 (Botulinum toxin), 367 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 5.18, df = 4 (P = 0.27); I2 =23%
Test for overall effect: Z = 2.98 (P = 0.0028)
2 Episodic migraine
Anand 2006 0/16 0/16 Not estimable
Aurora 2007 152/187 109/182 17.3 % 1.36 [ 1.18, 1.56 ]
Elkind I 2006 159/312 50/106 13.1 % 1.08 [ 0.86, 1.36 ]
Petri 2009 16/64 11/63 3.3 % 1.43 [ 0.72, 2.84 ]
Relja 2007 355/377 64/118 15.9 % 1.74 [ 1.47, 2.05 ]
Saper 2007 86/187 23/45 9.5 % 0.90 [ 0.65, 1.25 ]
Subtotal (95% CI) 1143 530 59.2 % 1.28 [ 1.02, 1.60 ]
Total events: 768 (Botulinum toxin), 257 (Placebo)
Heterogeneity: Tau2 = 0.05; Chi2 = 18.26, df = 4 (P = 0.001); I2 =78%
Test for overall effect: Z = 2.13 (P = 0.033)
3 Mixed
Blumenkron 2006 0/16 0/14 Not estimable
Chankrachang 2011 15/86 5/42 1.9 % 1.47 [ 0.57, 3.76 ]
Subtotal (95% CI) 102 56 1.9 % 1.47 [ 0.57, 3.76 ]
Total events: 15 (Botulinum toxin), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
Total (95% CI) 1990 1335 100.0 % 1.28 [ 1.12, 1.47 ]
Total events: 1231 (Botulinum toxin), 629 (Placebo)
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(. . . Continued)
Study or subgroup Botulinum toxin Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.02; Chi2 = 26.74, df = 10 (P = 0.003); I2 =63%
Test for overall effect: Z = 3.58 (P = 0.00035)
Test for subgroup differences: Chi2 = 0.23, df = 2 (P = 0.89), I2 =0.0%
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Analysis 1.7. Comparison 1 Botulinum toxin type A versus placebo, Outcome 7 Adverse event -
blepharoptosis.
Review: Botulinum toxins for the prevention of migraine in adults
Comparison: 1 Botulinum toxin type A versus placebo
Outcome: 7 Adverse event - blepharoptosis
Study or subgroup Botulinum toxin Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Episodic migraine
Aurora 2007 29/187 3/182 50.3 % 9.41 [ 2.92, 30.34 ]
Elkind I 2006 15/312 0/106 8.8 % 10.60 [ 0.64, 175.60 ]
Relja 2007 33/377 0/118 8.9 % 21.09 [ 1.30, 341.63 ]
Saper 2007 5/187 0/45 8.3 % 2.69 [ 0.15, 47.81 ]
Silberstein 2000 13/82 0/41 8.8 % 13.66 [ 0.83, 224.27 ]
Subtotal (95% CI) 1145 492 85.1 % 9.53 [ 3.87, 23.44 ]
Total events: 95 (Botulinum toxin), 3 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.18, df = 4 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 4.91 (P < 0.00001)
2 Mixed
Chankrachang 2011 1/86 0/42 6.8 % 1.48 [ 0.06, 35.64 ]
Hou 2015 3/83 0/19 8.1 % 1.67 [ 0.09, 30.99 ]
Subtotal (95% CI) 169 61 14.9 % 1.58 [ 0.18, 13.59 ]
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(. . . Continued)
Study or subgroup Botulinum toxin Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 4 (Botulinum toxin), 0 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.68)
Total (95% CI) 1314 553 100.0 % 7.29 [ 3.18, 16.73 ]
Total events: 99 (Botulinum toxin), 3 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.61, df = 6 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 4.69 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.28, df = 1 (P = 0.13), I2 =56%
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Analysis 1.8. Comparison 1 Botulinum toxin type A versus placebo, Outcome 8 Adverse event - muscle
weakness.
Review: Botulinum toxins for the prevention of migraine in adults
Comparison: 1 Botulinum toxin type A versus placebo
Outcome: 8 Adverse event - muscle weakness
Study or subgroup Botulinum toxin Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Chronic migraine
Aurora 2010 (PREEMPT 1) 20/340 0/334 6.4 % 40.28 [ 2.45, 663.26 ]
Diener 2010 (PREEMPT 2) 18/347 2/358 23.7 % 9.29 [ 2.17, 39.72 ]
Subtotal (95% CI) 687 692 30.1 % 12.68 [ 3.49, 46.05 ]
Total events: 38 (Botulinum toxin), 2 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.93, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 3.86 (P = 0.00011)
2 Episodic migraine
Aurora 2007 49/187 2/182 25.6 % 23.84 [ 5.89, 96.61 ]
Petri 2009 8/64 1/63 11.9 % 7.88 [ 1.01, 61.14 ]
Relja 2007 100/377 2/118 26.2 % 15.65 [ 3.92, 62.48 ]
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(. . . Continued)
Study or subgroup Botulinum toxin Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Saper 2007 6/187 0/45 6.1 % 3.18 [ 0.18, 55.45 ]
Subtotal (95% CI) 815 408 69.9 % 14.12 [ 6.05, 32.94 ]
Total events: 163 (Botulinum toxin), 5 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.96, df = 3 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 6.12 (P < 0.00001)
Total (95% CI) 1502 1100 100.0 % 13.67 [ 6.73, 27.75 ]
Total events: 201 (Botulinum toxin), 7 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.89, df = 5 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 7.24 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.89), I2 =0.0%
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Analysis 1.9. Comparison 1 Botulinum toxin type A versus placebo, Outcome 9 Adverse event - neck pain.
Review: Botulinum toxins for the prevention of migraine in adults
Comparison: 1 Botulinum toxin type A versus placebo
Outcome: 9 Adverse event - neck pain
Study or subgroup Botulinum toxin Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Chronic migraine
Allergan 2015 4/25 1/27 3.0 % 4.32 [ 0.52, 36.09 ]
Aurora 2010 (PREEMPT 1) 20/341 11/334 26.4 % 1.78 [ 0.87, 3.66 ]
Diener 2010 (PREEMPT 2) 26/347 8/358 22.6 % 3.35 [ 1.54, 7.30 ]
Subtotal (95% CI) 713 719 52.0 % 2.47 [ 1.48, 4.12 ]
Total events: 50 (Botulinum toxin), 20 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.66, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 3.45 (P = 0.00056)
2 Episodic migraine
Aurora 2007 32/187 8/182 24.5 % 3.89 [ 1.84, 8.22 ]
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(. . . Continued)
Study or subgroup Botulinum toxin Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Relja 2007 76/377 6/118 21.1 % 3.96 [ 1.77, 8.87 ]
Subtotal (95% CI) 564 300 45.6 % 3.93 [ 2.27, 6.79 ]
Total events: 108 (Botulinum toxin), 14 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 4.89 (P < 0.00001)
3 Mixed
Chankrachang 2011 2/86 1/42 2.4 % 0.98 [ 0.09, 10.47 ]
Subtotal (95% CI) 86 42 2.4 % 0.98 [ 0.09, 10.47 ]
Total events: 2 (Botulinum toxin), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
Total (95% CI) 1363 1061 100.0 % 2.98 [ 2.06, 4.32 ]
Total events: 160 (Botulinum toxin), 35 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.04, df = 5 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 5.79 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.34, df = 2 (P = 0.31), I2 =15%
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Analysis 1.10. Comparison 1 Botulinum toxin type A versus placebo, Outcome 10 Adverse event - injection
site pain.
Review: Botulinum toxins for the prevention of migraine in adults
Comparison: 1 Botulinum toxin type A versus placebo
Outcome: 10 Adverse event - injection site pain
Study or subgroup Botulinum toxin Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Chronic migraine
Allergan 2015 2/25 1/27 9.6 % 2.16 [ 0.21, 22.38 ]
Hollanda 2014 6/20 2/18 24.3 % 2.70 [ 0.62, 11.72 ]
Jabbari 2014 1/13 0/12 5.4 % 2.79 [ 0.12, 62.48 ]
Subtotal (95% CI) 58 57 39.3 % 2.57 [ 0.81, 8.15 ]
Total events: 9 (Botulinum toxin), 3 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 2 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.60 (P = 0.11)
2 Episodic migraine
Aurora 2007 4/187 1/182 11.0 % 3.89 [ 0.44, 34.50 ]
Relja 2007 16/377 2/118 24.7 % 2.50 [ 0.58, 10.73 ]
Silberstein 2000 9/82 1/41 12.7 % 4.50 [ 0.59, 34.32 ]
Subtotal (95% CI) 646 341 48.4 % 3.23 [ 1.14, 9.13 ]
Total events: 29 (Botulinum toxin), 4 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.25, df = 2 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 2.21 (P = 0.027)
3 Mixed
Chankrachang 2011 0/86 1/42 5.2 % 0.16 [ 0.01, 3.96 ]
Hou 2015 1/83 1/19 7.0 % 0.23 [ 0.01, 3.50 ]
Subtotal (95% CI) 169 61 12.2 % 0.20 [ 0.03, 1.58 ]
Total events: 1 (Botulinum toxin), 2 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.53 (P = 0.13)
Total (95% CI) 873 459 100.0 % 2.10 [ 1.02, 4.33 ]
Total events: 39 (Botulinum toxin), 9 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.06, df = 7 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 2.01 (P = 0.045)
Test for subgroup differences: Chi2 = 5.75, df = 2 (P = 0.06), I2 =65%
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Analysis 1.11. Comparison 1 Botulinum toxin type A versus placebo, Outcome 11 Total treatment related
adverse events.
Review: Botulinum toxins for the prevention of migraine in adults
Comparison: 1 Botulinum toxin type A versus placebo
Outcome: 11 Total treatment related adverse events
Study or subgroup Botulinum toxin Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Chronic migraine
Aurora 2010 (PREEMPT 1) 86/340 39/334 18.6 % 2.17 [ 1.53, 3.06 ]
Diener 2010 (PREEMPT 2) 116/347 49/358 20.8 % 2.44 [ 1.81, 3.30 ]
Subtotal (95% CI) 687 692 39.3 % 2.32 [ 1.85, 2.91 ]
Total events: 202 (Botulinum toxin), 88 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 7.28 (P < 0.00001)
2 Episodic migraine
Aurora 2007 113/187 39/182 20.7 % 2.82 [ 2.09, 3.81 ]
Elkind I 2006 61/312 7/106 7.3 % 2.96 [ 1.40, 6.27 ]
Relja 2007 243/377 37/118 21.9 % 2.06 [ 1.56, 2.71 ]
Saper 2007 45/187 11/45 10.8 % 0.98 [ 0.55, 1.75 ]
Subtotal (95% CI) 1063 451 60.7 % 2.06 [ 1.37, 3.08 ]
Total events: 462 (Botulinum toxin), 94 (Placebo)
Heterogeneity: Tau2 = 0.11; Chi2 = 11.01, df = 3 (P = 0.01); I2 =73%
Test for overall effect: Z = 3.50 (P = 0.00046)
Total (95% CI) 1750 1143 100.0 % 2.18 [ 1.73, 2.75 ]
Total events: 664 (Botulinum toxin), 182 (Placebo)
Heterogeneity: Tau2 = 0.04; Chi2 = 11.41, df = 5 (P = 0.04); I2 =56%
Test for overall effect: Z = 6.59 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.26, df = 1 (P = 0.61), I2 =0.0%
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Analysis 1.12. Comparison 1 Botulinum toxin type A versus placebo, Outcome 12 Withdrawals due to
adverse events in trials with multiple rounds of treatment..
Review: Botulinum toxins for the prevention of migraine in adults
Comparison: 1 Botulinum toxin type A versus placebo
Outcome: 12 Withdrawals due to adverse events in trials with multiple rounds of treatment.
Study or subgroup Botulinum toxin Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Chronic migraine
Aurora 2010 (PREEMPT 1) 11/341 2/338 26.2 % 5.45 [ 1.22, 24.41 ]
Diener 2010 (PREEMPT 2) 8/347 3/358 33.8 % 2.75 [ 0.74, 10.29 ]
Subtotal (95% CI) 688 696 60.0 % 3.71 [ 1.38, 9.98 ]
Total events: 19 (Botulinum toxin), 5 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.46, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 2.59 (P = 0.0095)
2 Episodic migraine
Aurora 2007 6/187 1/182 13.2 % 5.84 [ 0.71, 48.03 ]
Relja 2007 12/377 2/118 26.8 % 1.88 [ 0.43, 8.27 ]
Subtotal (95% CI) 564 300 40.0 % 2.73 [ 0.81, 9.19 ]
Total events: 18 (Botulinum toxin), 3 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.75, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 1.63 (P = 0.10)
Total (95% CI) 1252 996 100.0 % 3.28 [ 1.52, 7.07 ]
Total events: 37 (Botulinum toxin), 8 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.35, df = 3 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 3.04 (P = 0.0024)
Test for subgroup differences: Chi2 = 0.15, df = 1 (P = 0.70), I2 =0.0%
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Analysis 2.1. Comparison 2 Botulinum toxin type A versus other established prophylactic agent, Outcome 1
Migraine impact and disability assessment scores.
Review: Botulinum toxins for the prevention of migraine in adults
Comparison: 2 Botulinum toxin type A versus other established prophylactic agent
Outcome: 1 Migraine impact and disability assessment scores
Study or subgroup Botulinum toxin Active control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Chronic migraine
Mathew 2009 22 -10.5 (24.1) 20 -33.3 (53.1) 44.4 % 22.80 [ -2.56, 48.16 ]
Subtotal (95% CI) 22 20 44.4 % 22.80 [ -2.56, 48.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.76 (P = 0.078)
2 Mixed
Blumenfeld 2008 30 -23.1 (29.8) 29 -12.6 (19.1) 55.6 % -10.50 [ -23.23, 2.23 ]
Subtotal (95% CI) 30 29 55.6 % -10.50 [ -23.23, 2.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.62 (P = 0.11)
Total (95% CI) 52 49 100.0 % 4.27 [ -28.15, 36.69 ]
Heterogeneity: Tau2 = 449.66; Chi2 = 5.29, df = 1 (P = 0.02); I2 =81%
Test for overall effect: Z = 0.26 (P = 0.80)
Test for subgroup differences: Chi2 = 5.29, df = 1 (P = 0.02), I2 =81%
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Analysis 2.2. Comparison 2 Botulinum toxin type A versus other established prophylactic agent, Outcome 2
Total adverse events.
Review: Botulinum toxins for the prevention of migraine in adults
Comparison: 2 Botulinum toxin type A versus other established prophylactic agent
Outcome: 2 Total adverse events
Study or subgroup Botulinum toxin Active control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Chronic migraine
Mathew 2009 26/26 28/29 53.0 % 1.03 [ 0.94, 1.14 ]
Subtotal (95% CI) 26 29 53.0 % 1.03 [ 0.94, 1.14 ]
Total events: 26 (Botulinum toxin), 28 (Active control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
2 Mixed
Blumenfeld 2008 15/30 22/29 47.0 % 0.66 [ 0.44, 1.00 ]
Subtotal (95% CI) 30 29 47.0 % 0.66 [ 0.44, 1.00 ]
Total events: 15 (Botulinum toxin), 22 (Active control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.98 (P = 0.048)
Total (95% CI) 56 58 100.0 % 0.84 [ 0.37, 1.88 ]
Total events: 41 (Botulinum toxin), 50 (Active control)
Heterogeneity: Tau2 = 0.32; Chi2 = 14.74, df = 1 (P = 0.00012); I2 =93%
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Chi2 = 4.32, df = 1 (P = 0.04), I2 =77%
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Analysis 2.3. Comparison 2 Botulinum toxin type A versus other established prophylactic agent, Outcome 3
Total treatment related adverse events.
Review: Botulinum toxins for the prevention of migraine in adults
Comparison: 2 Botulinum toxin type A versus other established prophylactic agent
Outcome: 3 Total treatment related adverse events
Study or subgroup Botulinum toxin Active control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Chronic migraine
Mathew 2009 18/26 25/29 75.9 % 0.80 [ 0.60, 1.08 ]
Subtotal (95% CI) 26 29 75.9 % 0.80 [ 0.60, 1.08 ]
Total events: 18 (Botulinum toxin), 25 (Active control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.46 (P = 0.14)
2 Mixed
Blumenfeld 2008 12/30 18/29 24.1 % 0.64 [ 0.38, 1.09 ]
Subtotal (95% CI) 30 29 24.1 % 0.64 [ 0.38, 1.09 ]
Total events: 12 (Botulinum toxin), 18 (Active control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.099)
Total (95% CI) 56 58 100.0 % 0.76 [ 0.59, 0.98 ]
Total events: 30 (Botulinum toxin), 43 (Active control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.60, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 2.08 (P = 0.038)
Test for subgroup differences: Chi2 = 0.52, df = 1 (P = 0.47), I2 =0.0%
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Analysis 2.4. Comparison 2 Botulinum toxin type A versus other established prophylactic agent, Outcome 4
Withdrawals due to adverse events in trials with multiple rounds of treatment..
Review: Botulinum toxins for the prevention of migraine in adults
Comparison: 2 Botulinum toxin type A versus other established prophylactic agent
Outcome: 4 Withdrawals due to adverse events in trials with multiple rounds of treatment.
Study or subgroup Botulinum toxin Active control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Chronic migraine
Mathew 2009 3/30 8/30 73.0 % 0.38 [ 0.11, 1.28 ]
Subtotal (95% CI) 30 30 73.0 % 0.38 [ 0.11, 1.28 ]
Total events: 3 (Botulinum toxin), 8 (Active control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.57 (P = 0.12)
2 Mixed
Blumenfeld 2008 1/30 8/29 27.0 % 0.12 [ 0.02, 0.91 ]
Subtotal (95% CI) 30 29 27.0 % 0.12 [ 0.02, 0.91 ]
Total events: 1 (Botulinum toxin), 8 (Active control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.06 (P = 0.040)
Total (95% CI) 60 59 100.0 % 0.28 [ 0.10, 0.79 ]
Total events: 4 (Botulinum toxin), 16 (Active control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.93, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 2.41 (P = 0.016)
Test for subgroup differences: Chi2 = 0.89, df = 1 (P = 0.35), I2 =0.0%
0.01 0.1 1 10 100
Favours botulinum toxin Favours active control
111Botulinum toxins for the prevention of migraine in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.1. Comparison 3 Dysport ≥ 150 U versus Dysport < 150 U, Outcome 1 Total adverse events.
Review: Botulinum toxins for the prevention of migraine in adults
Comparison: 3 Dysport≥ 150 U versus Dysport < 150 U
Outcome: 1 Total adverse events
Study or subgroup High dose Low dose Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Chankrachang 2011 12/32 4/32 48.4 % 3.00 [ 1.08, 8.32 ]
Petri 2009 7/43 8/43 51.6 % 0.88 [ 0.35, 2.20 ]
Total (95% CI) 75 75 100.0 % 1.59 [ 0.47, 5.32 ]
Total events: 19 (High dose), 12 (Low dose)
Heterogeneity: Tau2 = 0.52; Chi2 = 3.10, df = 1 (P = 0.08); I2 =68%
Test for overall effect: Z = 0.75 (P = 0.45)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Botox dosing studies, Outcome 1 Number of migraine days.
Review: Botulinum toxins for the prevention of migraine in adults
Comparison: 4 Botox dosing studies
Outcome: 1 Number of migraine days
Study or subgroup Dose≥50 U Dose <50 U
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Episodic migraine Botox≥ 50 U vs Botox < 50
Elkind I 2006 89 -1.5 (2.7) 81 -2 (2.8) 50.7 % 0.50 [ -0.33, 1.33 ]
Elkind II 2006 91 -1.8 (2.9) 92 -2.1 (2.9) 49.3 % 0.30 [ -0.54, 1.14 ]
Total (95% CI) 180 173 100.0 % 0.40 [ -0.19, 0.99 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 1.33 (P = 0.18)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours≥50 U Favours <50 U
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Analysis 4.2. Comparison 4 Botox dosing studies, Outcome 2 Adverse event - muscle weakness.
Review: Botulinum toxins for the prevention of migraine in adults
Comparison: 4 Botox dosing studies
Outcome: 2 Adverse event - muscle weakness
Study or subgroup High dose Low dose Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Botox≥ 200 U versus Botox < 200 U
Relja 2007 35/129 65/248 52.5 % 1.04 [ 0.73, 1.47 ]
Subtotal (95% CI) 129 248 52.5 % 1.04 [ 0.73, 1.47 ]
Total events: 35 (High dose), 65 (Low dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
2 Botox≥ 150 U versus Botox < 150 U
Relja 2007 70/254 30/123 47.5 % 1.13 [ 0.78, 1.64 ]
Subtotal (95% CI) 254 123 47.5 % 1.13 [ 0.78, 1.64 ]
Total events: 70 (High dose), 30 (Low dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
Total (95% CI) 383 371 100.0 % 1.08 [ 0.84, 1.39 ]
Total events: 105 (High dose), 95 (Low dose)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.56)
Test for subgroup differences: Chi2 = 0.11, df = 1 (P = 0.74), I2 =0.0%
0.01 0.1 1 10 100
Favours Botox high dose Favours Botox low dose
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Analysis 4.3. Comparison 4 Botox dosing studies, Outcome 3 Adverse event - blepharoptosis.
Review: Botulinum toxins for the prevention of migraine in adults
Comparison: 4 Botox dosing studies
Outcome: 3 Adverse event - blepharoptosis
Study or subgroup High dose Low dose Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1≥ 50 U versus < 50 U in frontalis and/or corrugator
Relja 2007 18/129 15/248 100.0 % 2.31 [ 1.20, 4.43 ]
Subtotal (95% CI) 129 248 100.0 % 2.31 [ 1.20, 4.43 ]
Total events: 18 (High dose), 15 (Low dose)
Heterogeneity: not applicable
Test for overall effect: Z = 2.52 (P = 0.012)
2≥ 30 U versus < 30 U in frontalis and/or corrugator
Relja 2007 30/254 3/123 47.7 % 4.84 [ 1.51, 15.56 ]
Silberstein 2000 7/40 6/42 52.3 % 1.23 [ 0.45, 3.33 ]
Subtotal (95% CI) 294 165 100.0 % 2.36 [ 0.58, 9.65 ]
Total events: 37 (High dose), 9 (Low dose)
Heterogeneity: Tau2 = 0.73; Chi2 = 3.36, df = 1 (P = 0.07); I2 =70%
Test for overall effect: Z = 1.20 (P = 0.23)
3≥ 10 U versus < 10 U in frontalis and/or corrugator
Elkind I 2006 8/106 7/206 82.6 % 2.22 [ 0.83, 5.96 ]
Saper 2007 4/49 1/45 17.4 % 3.67 [ 0.43, 31.65 ]
Subtotal (95% CI) 155 251 100.0 % 2.42 [ 0.99, 5.94 ]
Total events: 12 (High dose), 8 (Low dose)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 1.93 (P = 0.053)
Test for subgroup differences: Chi2 = 0.01, df = 2 (P = 1.00), I2 =0.0%
0.01 0.1 1 10 100
Favours Botox high dose Favours Botox low dose
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Analysis 4.4. Comparison 4 Botox dosing studies, Outcome 4 Adverse event - neck pain.
Review: Botulinum toxins for the prevention of migraine in adults
Comparison: 4 Botox dosing studies
Outcome: 4 Adverse event - neck pain
Study or subgroup High dose Low dose Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Botox≥ 200 U versus Botox < 200 U
Relja 2007 30/129 46/248 54.5 % 1.25 [ 0.83, 1.89 ]
Subtotal (95% CI) 129 248 54.5 % 1.25 [ 0.83, 1.89 ]
Total events: 30 (High dose), 46 (Low dose)
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
2 Botox≥ 150 U versus Botox < 150 U
Relja 2007 54/254 22/123 45.5 % 1.19 [ 0.76, 1.86 ]
Subtotal (95% CI) 254 123 45.5 % 1.19 [ 0.76, 1.86 ]
Total events: 54 (High dose), 22 (Low dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
Total (95% CI) 383 371 100.0 % 1.22 [ 0.91, 1.65 ]
Total events: 84 (High dose), 68 (Low dose)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.86), I2 =0.0%
0.01 0.1 1 10 100
Favours Botox high dose Favours Botox low dose
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Analysis 4.5. Comparison 4 Botox dosing studies, Outcome 5 Adverse event - injection site pain.
Review: Botulinum toxins for the prevention of migraine in adults
Comparison: 4 Botox dosing studies
Outcome: 5 Adverse event - injection site pain
Study or subgroup High dose Low dose Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Botox≥ 200 U versus Botox < 200 U
Relja 2007 3/129 13/248 27.7 % 0.44 [ 0.13, 1.53 ]
Silberstein 2000 9/82 1/41 12.8 % 4.50 [ 0.59, 34.32 ]
Subtotal (95% CI) 211 289 40.5 % 1.23 [ 0.13, 11.97 ]
Total events: 12 (High dose), 14 (Low dose)
Heterogeneity: Tau2 = 2.01; Chi2 = 3.73, df = 1 (P = 0.05); I2 =73%
Test for overall effect: Z = 0.17 (P = 0.86)
2 Botox≥150 U versus Botox <150 U
Relja 2007 12/254 4/123 31.9 % 1.45 [ 0.48, 4.41 ]
Subtotal (95% CI) 254 123 31.9 % 1.45 [ 0.48, 4.41 ]
Total events: 12 (High dose), 4 (Low dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
3 Botox≥ 50 U versus Botox < 50 U
Silberstein 2000 5/42 4/40 27.6 % 1.19 [ 0.34, 4.12 ]
Subtotal (95% CI) 42 40 27.6 % 1.19 [ 0.34, 4.12 ]
Total events: 5 (High dose), 4 (Low dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
Total (95% CI) 507 452 100.0 % 1.14 [ 0.52, 2.51 ]
Total events: 29 (High dose), 22 (Low dose)
Heterogeneity: Tau2 = 0.18; Chi2 = 4.18, df = 3 (P = 0.24); I2 =28%
Test for overall effect: Z = 0.34 (P = 0.74)
Test for subgroup differences: Chi2 = 0.06, df = 2 (P = 0.97), I2 =0.0%
0.01 0.1 1 10 100
Favours Botox high dose Favours Botox low dose
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A D D I T I O N A L T A B L E S
Table 1. Glossary of terms
Term Definition
Chronic migraine (IHS 1988) Not defined
Chronic migraine (IHS 2004) Description: migraine headache occurring on ≥ 15 days per month for > 3 months in
the absence of medication overuse
Diagnostic criteria
A. Headache fulfilling criteria C and D for 1.1 migraine without aura on 15 days/month
for more than 3 months
B. Not attributed to another disorder
Chronic migraine (IHS 2013) Description: headache occurring on ≥ 15 days per month for > 3 months, which has
the features of migraine headache on at least 8 days per month
Diagnostic criteria
A.Headache (tension-type-like and/ormigraine-like on≥ 15days/month for > 3months
and fulfilling criteria B and C
B.Occurring in a patient who has had at least 5 attacks fulfilling criteria B-D formigraine
without aura and/or criteria B and C for migraine with aura
C. On 8 days per month for > 3 months, fulfilling any of the following:
• criteria C and D for migraine without aura;
• criteria B and C for migraine with aura;
• believed by the patient to be migraine at onset and relieved by a triptan or ergot
derivative.
D. Not better accounted for by another ICHD-III diagnosis
Medication overuse headache (IHS 1988) Not defined
Medication overuse headache (IHS 2004) Diagnostic criteria
A. Headache present on ≥ 15 days/month fulfilling criteria C and D
B. Regular overuse for > 3 months of one or more drugs that can be taken for acute and/
or symptomatic treatment of headache
C. Headache has developed or markedly worsened during medication overuse
D. Headache resolves or reverts to its previous pattern within 2 months after discontin-
uation of overused medication
Medication overuse headache (IHS 2013) Description: headache occurring on ≥ 15 days/month developing as a consequence of
regular overuse of acute or symptomatic headache medication (on ≥ 10, or ≥ 15 days/
month, depending on the medication) for > 3 months. It usually, but not invariably,
resolves after the overuse is stopped
Diagnostic criteria
A. Headache occurring on 15 days/month in a patient with a pre-existing headache
disorder
B. Regular overuse for more than 3 months of ≥ 1 drugs that can be taken for acute
and/or symptomatic treatment of headache
C. Not better accounted for by another ICHD-III diagnosis
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Table 1. Glossary of terms (Continued)
Migraine (IHS 2013) Migraine has 2 major subtypes.
Migraine without aura is a clinical syndrome characterised by headache with specific
features and associated symptoms
Migraine with aura is primarily characterised by the transient focal neurological symp-
toms that usually precede or sometimes accompany the headache
Migraine with aura (IHS 2013) Description: recurrent attacks, lasting minutes, of unilateral fully reversible visual, sen-
sory or other central nervous system symptoms that usually develop gradually and are
usually followed by headache and associated migraine symptoms
Diagnostic criteria
A. At least 2 attacks fulfilling criteria B and C
B. One or more of the following fully reversible aura symptoms: 1. visual, 2. sensory, 3.
speech and/or language, 4. motor, 5. brainstem, 6. retinal
C. At least 2 of the following 4 characteristics:
• at least 1 aura symptom spreads gradually over 5 minutes, and/or ≥ 2 symptoms
occur in succession;
• each individual aura symptom lasts 5-60 minutes;
• at least one aura symptom is unilateral;
• the aura is accompanied, or followed within 60 minutes, by headache.
D. Not better accounted for by another ICHD-3 diagnosis, and transient ischaemic
attack has been excluded
Migraine without aura (IHS 2013) Description: recurrent headache disorder manifesting in attacks lasting 4-72 h. Typical
characteristics of the headache are unilateral location, pulsating quality, moderate or
severe intensity, aggravation by routine physical activity and association with nausea and/
or photophobia and phonophobia
Diagnostic criteria
A. At least 5 attacks1 fulfilling criteria B-D
B. Headache attacks lasting 4-72 h (untreated or unsuccessfully treated)
C. Headache has at least 2 of the following 4 characteristics:
• unilateral location;
• pulsating quality;
• moderate or severe pain intensity;
• aggravation by or causing avoidance of routine physical activity (e.g. walking or
climbing stairs).
D. During headache at least one of the following: 1. nausea and/or vomiting, 2. photo-
phobia and phonophobia
E. Not better accounted for by another ICHD-III diagnosis.
SNARE complex (Goodsell 2013) Soluble NSF-attachment protein receptor (NSF: N-ethylmaleimide-sensitive factor)
SNAP-25 (Goodsell 2013) Synaptosomal-associated protein-25
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Table 2. FDA-issued names for botulinum toxin products
Trade name Manufacturer FDA-issued name Sero-type
Botox Allergan OnabotulinumtoxinA Botulinum toxin type A
Botox cosmetic Allergan OnabotulinumtoxinA Botulinum toxin type A
Dysport Ipsen AbobotulinumtoxinA Botulinum toxin type A
HengLi Lanzhou Institute of biological prod-
ucts
Not issued Botulinum toxin type A
Myobloc Solstice RimabotulinumtoxinB Botulinum toxin type B
Prosigne Lanzhou Institute of biological prod-
ucts
Not issued Botulinum toxin type A
Xeomin Merz IncobotulinumtoxinA Botulinum toxin type A
Allergan, Ipsen and Galderma all responded but were unable to provide additional eligible data. Merz, Solstice, and Lanzhou Institute
of biological products were contacted without response.
A P P E N D I C E S
Appendix 1. Search strategies
CENTRAL (via CRSO)
#1 MESH DESCRIPTOR headache disorders EXPLODE ALL TREES
#2 MESH DESCRIPTOR headache EXPLODE ALL TREES
#3 ((headache* or migrain* or cephalgi* or cephalalgi* or hemicrani*)):TI,AB,KY
#4 #1 OR #2 OR #3
#5 MESH DESCRIPTOR botulinum toxins EXPLODE ALL TREES
#6 ((botulin* adj toxin*)):TI,AB,KY
#7 ((botulinum* or oculinu* or boto* or onabotulinum*)):TI,AB,KY
#8 MESH DESCRIPTOR Botulinum Toxins, Type A EXPLODE ALL TREES
#9 (clostridium botulinum):TI,AB,KY
#10 (clostridium botulin*):TI,AB,KY
#11 #5 OR #6 OR #7 OR #8 OR #9 OR #10
#12 #4 AND #11
MEDLINE (via OVID)
#1 Exp headache disorders/
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#2 headache/
#3 (headache* or migrain* or cephalgi* or cephalalgi* or hemicrani*).mp.
#4 or/1-3
#5 exp botulinum toxins/
#6 (botulin* adj toxin*).tw
#7 (botulinum* or oculinu* or boto* or onabotulinum*).tw.
#8 exp botulinum toxin type A/
#9 Exp clostridium botulinum/
#10 clostridium botulin*.tw.
#11 or/5-10
12 randomized controlled trial.pt.
13 controlled clinical trial.pt.
14 randomized.ab.
15 placebo.ab.
16 drug therapy.fs.
17 randomly.ab.
18 trial.ab.
19 groups.ab.
20 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19
21 exp animals/ not humans.sh.
22 20 not 21
23 4 and 11 and 22
Embase (via OVID)
1 exp headache disorders/
2 headache/
3 (headache* or migrain* or cephalgi* or cephalalgi* or hemicrani*).tw.
4 or/1-3
5 exp botulinum toxins/
6 (botulin* adj toxin*).tw.
7 (botulinum* or oculinu* or boto* or onabotulinum*).tw.
8 exp botulinum toxin type A/
9 exp clostridium botulinum/
10 clostridium botulin*.tw.
11 or/5-10
12 random$.tw.
13 factorial$.tw.
14 crossover$.tw.
15 cross over$.tw.
16 cross-over$.tw.
17 placebo$.tw.
18 (doubl$ adj blind$).tw.
19 (singl$ adj blind$).tw.
20 assign$.tw.
21 allocat$.tw.
22 volunteer$.tw.
23 Crossover Procedure/
24 double-blind procedure.tw.
25 Randomized Controlled Trial/
26 Single Blind Procedure/
27 or/12-26
28 (animal/ or nonhuman/) not human/
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29 27 not 28
30 4 and 11 and 29
Appendix 2. Botulinum toxin versus non-established agents summary
Botulinum toxin versus other agent: histamine
One trial (Millán-Guerrero 2009) with 100 participants compared a single round of injections of Botox (50 U) into the head and neck
muscles with injections of histamine (1 to 10 µg) injected into upper arm twice a week for 12 weeks. The trial publication reports that
there were no significant between-group differences in number of migraine attacks per month (P = 0.52), duration of migraine (P =
0.21), headache intensity (P = 0.32), use of rescue medications (P = 0.12) and patient’s global impression of disease (MIDAS score, P
= 0.12) at the four week time point. Statistical analyses for between group comparisons are not reported for any outcome measures at
the 12-week time point. Number of migraine days, number of headache days, quality-of-life measures, adverse events data and cost-
effectiveness outcomes were not recorded for this trial.
Appendix 3. Dosing studies summary
Botulinum toxin versus clinically relevant different dose of botulinum toxin: Botox
Comparisons between different doses of Botox were studied in five trials and 1049 participants (Elkind I 2006; Elkind II 2006; Relja
2007; Saper 2007; Silberstein 2000). All but one (Elkind II 2006) also included a placebo arm and we discussed the results of the
pooled treatment arms compared with placebo earlier. We attempted to organise data into four clinically relevant dose comparisons: ≥
200 U and < 200 U; ≥ 150 U and < 150 U; ≥ 100 U and < 100 U; ≥ 50 U and < 50 U.
Primary outcome: number of migraine days per month
Two trials run in sequence (Elkind I 2006; Elkind II 2006) reported migraine days data for 353 participants comparing 50 U Botox
versus 25 U Botox, we excluded the lower-dose arm (7.5 U Botox) in Elkind I 2006 from this comparison to prevent double counting,
as participants from that arm were re-randomised into Elkind II 2006. No statistically significant between-group difference (0.4 days,
95% CI -0.2 to 1.0, P = 0.18) resulted from aggregation of these data (Analysis 4.1). One additional trial (Relja 2007) recorded this
outcome but did not report the results in a usable format.
Secondary outcomes
Efficacy outcomes
Two trials reported number of migraine attacks but only one of those provided meta-analysable data (Relja 2007) for 377 participants.
This trial’s results did not show a statistically significant between-group difference for arms treated with≥ 200 U compared with pooled
lower doses, or for treatment with ≥ 150 compared with < 150 U (P = 0.21 and P = 0.65 respectively). Silberstein 2000 randomised
82 participants into two dosing arms comparing treatment with 75 U of Botox and treatment with 25 U, they reported a reduction
in favour of the group treated with 75 U Botox of 1.1 attacks (P ≤ 0.046). None of the trials included in this comparison reported
meta-analysable data for duration of migraine, proportion of responders or use of rescue medication. All trials recorded a measure of
migraine severity, but none of the trials reported data for analysis or gave a clear description of the results for the dosing arms. All trials
recorded a global impression scale, but no data were available for analysis. Two trials did not report their results in enough detail to draw
comparisons between their dosing arms (Elkind I 2006; Relja 2007) and one trial failed to provide any statistical analysis comparing
the two Botox-treated arms. Elkind II 2006 reported only that no consistent statistically significant differences between groups were
identified for the patient global assessment score.
Quality-of-life measures were recorded by three trials (Elkind I 2006; Elkind II 2006; Relja 2007). Two of these failed to provide
enough detail to allow between-group comparisons to be made for the dosing arms. Elkind II 2006 recorded data for the Migraine-
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Specific Measure of Quality of Life questionnaire, the Migraine Impact Questionnaire, and the Headache Pain Specific Quality of Life
questionnaire and reported that there were no consistent statistically significant differences between groups on any measure. No cost
effectiveness analyses were identified for this comparison.
Safety outcomes
Doses administered in the two trials reporting data for treatment-related adverse events were not comparable within our chosen
categories. The ≥ 200 U versus < 200 U and ≥ 150 U versus < 150 U comparisons data from Relja 2007 did not show a statistically
significant between-group difference in risk of treatment-related adverse events (P = 0.37 and P = 0.61 respectively). Elkind I 2006
compared two low dose arms (50 U versus 25 U) and found an increased risk of a treatment-related adverse event for participants
treated with the higher of these two doses, with a RR of 2.1 (95% CI 1.4 to 3.3).
There were no between-group differences in the risk ratio (RR) of muscle weakness (200 U: RR 1.04, 95% CI 0.73 to 1.47, P = 0.85,
N = 377; 150 U: RR 1.13, 95 % CI 0.78 to 1.64, P = 0.52, N = 377; Analysis 4.2), neck pain (200 U: RR 1.25, 95% CI 0.83 to 1.89,
P = 0.28, N = 377; 150 U: RR 1.19, 95% CI 0.76 to 1.86, P = 0.45, N = 377; Analysis 4.4), or injection site pain (200 U: RR 1.23,
95% CI 0.13 to 11.97, P = 0.86, N = 500; 150 U: RR 1.45, 95% CI 0.48 to 4.41, P = 0.51, N = 377; 50 U: RR 1.19, 95% CI 0.34
to 4.12, P = 0.78, N = 82; Analysis 4.5) for any of the above and below dose comparisons analysed).
For the analysis of blepharoptosis-related adverse events, we considered only doses administered into the frontalis and/or corrugator
muscles, so the comparisons were: ≥ 50 U and < 50 U; ≥ 30 U and < 30 U; and ≥ 10 U and < 10 U of Botox (Analysis 4.3). The RR
of blepharoptosis for higher doses of Botox was around 2 times that for lower doses in all cases but the result was statistically significant
for the highest dose comparison only (50 U: RR 2.31, 95% CI 1.58 to 4.43, N = 377; 30 U: RR 2.36, 95% CI 0.58 to 9.65, P = 0.23,
N = 459; 10 U: RR 2.42, 95% CI 0.99 to 5.94, P = 0.051, N = 406).
Botulinum toxin versus clinically relevant different dose of botulinum toxin: other botulinum toxin preparations
Two trials with 150 participants compared different dosing arms of Dysport (Chankrachang 2011; Petri 2009). Both included a placebo
arm and were also involved in the relevant section earlier in this review. A further trial compared two different doses (33 U and 25
U), in 30 participants, of a further botulinum toxin agent, Prosigne, with a Botox arm (dose 25 U) and a placebo arm to attempt to
establish dose equivalency (Lauretti 2014).
Primary outcome: number of migraine days per month
None of the trials reporting dose comparisons of other botulinum toxins recorded the primary outcome for this review.
Secondary outcomes
Efficacy outcomes
The number of headache days was recorded by Petri 2009 only and they did not report any data, but stated that the between-
group differences were not statistically significant. Two trials recorded number of migraine attacks (Chankrachang 2011; Petri 2009).
Chankrachang 2011, N = 86, stated that there was no significant difference between the treated groups, for which the dose comparison
was 240 U Dysport vs 120 U Dysport (P = 0.87). Petri 2009, N = 60, provided no statistical analysis comparing the groups treated
with 210 U Dysport vs 80 U Dysport and no data to allow the analysis to be carried out by the review authors. Only Petri 2009
recorded the mean duration of migraine and frequency of use of rescue medications and again, the trial authors reported just that the
difference between the groups was not statistically significant. None of the trials recorded proportion of responders. All trials recorded
a measure of headache intensity. The trials studying Dysport both reported that there were no significant between-group differences
in migraine severity. The trial studying dose equivalency of Botox compared with Prosigne (Lauretti 2014) reported that there was
no statistically significant between-group difference for the 33 U Prosigne group. Chankrachang 2011 reported that there were no
statistically significant between-group differences in patient or investigator global assessment scores or MIDAS scores for the regular
diary period of four weeks. No between-group comparison was reported for patient global assessment scores by Petri 2009 and clinical
global assessment scores were reported as showing no statistically significant between-group difference. Only Chankrachang 2011
recorded a quality-of-life measure. They used the SF-36 questionnaire and reported that there were no statistically significant between-
group differences. No cost-effectiveness analyses were identified for this comparison.
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Safety outcomes
The numbers of participants experiencing any adverse event were reported by both trials of Dysport. Meta-analysis of these data,
grouping arms treating with ≥ 150 U and < 150 U, showed no significant between group difference in the RR of experiencing an
adverse event (RR 1.59, 95% CI 0.47 to 5.32, P = 0.45; Analysis 3.1). The specific adverse event types of interest for this review were
not reported in the correct format for analysis, with the single exception that Petri 2009 stated that ptosis was experienced by one
participant in each treated group (N = 32 per arm).
C O N T R I B U T I O N S O F A U T H O R S
CEC and AS conceived the review. CH ran searches not covered by the review group’s information specialist. CH, CLT, CR and AS
screened the search results. CH, CLT, CR,WS, CEC and AS assessed the quality of trials and extracted data. CH contacted trial authors,
managed data and entered it into Review Manager 5 (RevMan 2014), and carried out data analysis. NI provided statistical advice. CH,
CLT, CR, NI, CEC and AS were involved in interpretation of the results. All review authors read and edited the final version of the
review.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We updated the clinical trials registry search strategy to reflect changes in database coverage and availability. We removed the following:
CentreWatch Clinical Trials listing service; metaRegister of Controlled Trials ( mRCT), as they are no longer in existence. The latter
is covered by The World Health Organization’s International Clinical Trials Registry Platform ( ICTRP) ( www.who.int/ictrp/en/),
which we added to the strategy.
We changed age of included participants from ’over 18 years of age’ to ’18 years of age and over’; the former appeared in the protocol
erroneously.
We added text to search strategies to clarify that no date restrictions were used.
Section ’Types of outcome measures’ extended in places to make it clearer.
Outcomes measure ’duration of migraine’ replaces headache duration as it is clearer in meaning; the actual outcome measure reporting
covered is the same for the two terms.
Headache index added to list of outcome measures, this measure is a combination of frequency and severity information and as such
we felt it had to be assessed based on our original criteria but that we needed to add it to our outcome list to make its eligibility explicit.
For trial selection we changed text to show that trials without sufficient information were not excluded but put into the trials awaiting
classification section as suggested by the Cochrane editorial group.
We extended ’Risk of bias’ categories to include a separate section for performance bias and reporting bias, which should have appeared
in the protocol. We removed the domain ’other’.
We activated the section ’Assessment of reporting biases’ and described reasons for not carrying out funnel plots as per Cochrane editors’
recommendations.
We decided to use a random-effects model for our data analysis, as the data extraction stage of the review process showed a great deal
of clinical heterogeneity in the populations studied and dose and injection paradigms used for treating with botulinum toxin.
We updated our GRADE methods wording to align with current standards.
We carried out an additional sensitivity analysis to assess the effect of small trials on the pooled estimate for our primary outcome due
to concerns about the robustness of the overall estimate.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Botulinum Toxins, Type A [∗therapeutic use]; Chronic Disease; Migraine Disorders [∗prevention & control]; Randomized Controlled
Trials as Topic
MeSH check words
Adult; Female; Humans; Male
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